WO2024059808A1 - Wee1 inhibitors and methods for treating cancer - Google Patents
Wee1 inhibitors and methods for treating cancer Download PDFInfo
- Publication number
- WO2024059808A1 WO2024059808A1 PCT/US2023/074329 US2023074329W WO2024059808A1 WO 2024059808 A1 WO2024059808 A1 WO 2024059808A1 US 2023074329 W US2023074329 W US 2023074329W WO 2024059808 A1 WO2024059808 A1 WO 2024059808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- acceptable salt
- substituted
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims description 112
- 206010028980 Neoplasm Diseases 0.000 title claims description 100
- 238000000034 method Methods 0.000 title description 76
- 239000003112 inhibitor Substances 0.000 title description 17
- 101150040313 Wee1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 287
- 150000003839 salts Chemical class 0.000 claims abstract description 136
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 183
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 57
- 125000003118 aryl group Chemical group 0.000 claims description 53
- 125000000623 heterocyclic group Chemical group 0.000 claims description 52
- 230000002401 inhibitory effect Effects 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 125000002947 alkylene group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000000649 small cell carcinoma Diseases 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010000830 Acute leukaemia Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 7
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 7
- 208000017604 Hodgkin disease Diseases 0.000 claims description 7
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 7
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 7
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 7
- 210000000232 gallbladder Anatomy 0.000 claims description 7
- 210000000244 kidney pelvis Anatomy 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 201000008968 osteosarcoma Diseases 0.000 claims description 7
- 208000037244 polycythemia vera Diseases 0.000 claims description 7
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 210000004291 uterus Anatomy 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010034299 Penile cancer Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 206010046392 Ureteric cancer Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 201000010175 gallbladder cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 201000011294 ureter cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 210
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 description 272
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 236
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 174
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 171
- -1 nitro, sulfenyl Chemical group 0.000 description 168
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 162
- 238000006243 chemical reaction Methods 0.000 description 154
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 150
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- 239000000047 product Substances 0.000 description 109
- 239000000243 solution Substances 0.000 description 107
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 76
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 75
- 230000002829 reductive effect Effects 0.000 description 72
- 239000012043 crude product Substances 0.000 description 69
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 67
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 64
- 230000000694 effects Effects 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- 239000007787 solid Substances 0.000 description 57
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 40
- 125000000753 cycloalkyl group Chemical group 0.000 description 38
- 239000012044 organic layer Substances 0.000 description 38
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 37
- 125000004429 atom Chemical group 0.000 description 37
- 239000000706 filtrate Substances 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 34
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 33
- 239000012267 brine Substances 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000007858 starting material Substances 0.000 description 29
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 238000002953 preparative HPLC Methods 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 125000005842 heteroatom Chemical group 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000004440 column chromatography Methods 0.000 description 19
- 125000000392 cycloalkenyl group Chemical group 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 14
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 102100036816 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Human genes 0.000 description 8
- 101000851788 Homo sapiens Eukaryotic peptide chain release factor GTP-binding subunit ERF3A Proteins 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000001064 degrader Substances 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- NSQYMQABPXEHOY-UHFFFAOYSA-N pyrazolo[3,4-d]pyrimidin-3-one Chemical compound C1=NC=C2C(=O)N=NC2=N1 NSQYMQABPXEHOY-UHFFFAOYSA-N 0.000 description 8
- 125000003003 spiro group Chemical group 0.000 description 8
- RYSICGXZRVMXDP-UHFFFAOYSA-N 3-bromopiperidine-2,6-dione Chemical compound BrC1CCC(=O)NC1=O RYSICGXZRVMXDP-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- HRVXPXCISZSDCC-UHFFFAOYSA-N piperidine-4-carbaldehyde Chemical compound O=CC1CCNCC1 HRVXPXCISZSDCC-UHFFFAOYSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- BKWJAKQVGHWELA-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)-2-pyridinyl]-6-[4-(4-methyl-1-piperazinyl)anilino]-2-prop-2-enyl-3-pyrazolo[3,4-d]pyrimidinone Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C2C(=O)N(CC=C)N(C=3N=C(C=CC=3)C(C)(C)O)C2=N1 BKWJAKQVGHWELA-UHFFFAOYSA-N 0.000 description 6
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 6
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000003277 amino group Chemical class 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 5
- 229950009557 adavosertib Drugs 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 229940127204 compound 29 Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 4
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 4
- CHXUEVQRXAXREA-UHFFFAOYSA-N N1(CCNCC1)C1=CC=C(NC2C(NC(CC2)=O)=O)C=C1 Chemical compound N1(CCNCC1)C1=CC=C(NC2C(NC(CC2)=O)=O)C=C1 CHXUEVQRXAXREA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 4
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940126142 compound 16 Drugs 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 4
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- JVJPHIBFEJRVNE-UHFFFAOYSA-N 3-(4-aminophenyl)piperidine-2,6-dione Chemical compound C1=CC(N)=CC=C1C1C(=O)NC(=O)CC1 JVJPHIBFEJRVNE-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 3
- 108010034798 CDC2 Protein Kinase Proteins 0.000 description 3
- 102000009728 CDC2 Protein Kinase Human genes 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- CMHZNWBDBAYTQZ-UHFFFAOYSA-N [4-[2,6-bis(phenylmethoxy)pyridin-3-yl]phenyl]boronic acid Chemical compound OB(C(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1)O CMHZNWBDBAYTQZ-UHFFFAOYSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 230000012820 cell cycle checkpoint Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SVQVBAUJEKSBEC-UHFFFAOYSA-N tert-butyl n-(4-formylphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(C=O)C=C1 SVQVBAUJEKSBEC-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 2
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- ROXSMYHOLGAUDT-UHFFFAOYSA-N 2-azaspiro[3.3]heptan-6-ylmethanol Chemical compound C1C(CO)CC11CNC1 ROXSMYHOLGAUDT-UHFFFAOYSA-N 0.000 description 2
- WOULORBKOHBDKE-UHFFFAOYSA-N 3-(4-piperazin-1-ylphenyl)piperidine-2,6-dione Chemical compound N1(CCNCC1)C1=CC=C(C=C1)C1C(NC(CC1)=O)=O WOULORBKOHBDKE-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- YNQYVYYDXFGYDR-UHFFFAOYSA-N 3-[4-(4-aminobutoxy)phenyl]piperidine-2,6-dione Chemical compound NCCCCOC1=CC=C(C(CCC(N2)=O)C2=O)C=C1 YNQYVYYDXFGYDR-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- SNIAVEPVHCNSOA-UHFFFAOYSA-N 4-(4-bromophenyl)piperidine-2,6-dione Chemical compound C1=CC(Br)=CC=C1C1CC(=O)NC(=O)C1 SNIAVEPVHCNSOA-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- KRNSYSYRLQDHDK-UHFFFAOYSA-N 6,7-dihydro-5h-cyclopenta[b]pyridine Chemical compound C1=CN=C2CCCC2=C1 KRNSYSYRLQDHDK-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- YUXOGVJBGYTVJO-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=NC(=CC=C1C1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)OCC1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC1=NC(=CC=C1C1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)OCC1=CC=CC=C1 YUXOGVJBGYTVJO-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- XPYNRJGWSHHKNP-UHFFFAOYSA-N NC(CC1)CCN1C1=CC=C(C(CCC(N2)=O)C2=O)C=C1 Chemical compound NC(CC1)CCN1C1=CC=C(C(CCC(N2)=O)C2=O)C=C1 XPYNRJGWSHHKNP-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 125000005631 S-sulfonamido group Chemical group 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- JVBSERFNLCHCRI-UHFFFAOYSA-N [1-(3-aminophenyl)piperidin-4-yl]methanol Chemical compound NC1=CC=CC(N2CCC(CO)CC2)=C1 JVBSERFNLCHCRI-UHFFFAOYSA-N 0.000 description 2
- QFAUWIRKROYCPI-UHFFFAOYSA-N [1-(3-nitrophenyl)piperidin-4-yl]methanol Chemical compound C1CC(CO)CCN1C1=CC=CC([N+]([O-])=O)=C1 QFAUWIRKROYCPI-UHFFFAOYSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 125000006309 butyl amino group Chemical group 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- MZJMHHWOOZFMPV-UHFFFAOYSA-N tert-butyl 4-[4-(2,6-dioxopiperidin-3-yl)phenyl]piperazine-1-carboxylate Chemical compound O=C1NC(CCC1C1=CC=C(C=C1)N1CCN(CC1)C(=O)OC(C)(C)C)=O MZJMHHWOOZFMPV-UHFFFAOYSA-N 0.000 description 2
- SOVDTDAAHYTEJE-UHFFFAOYSA-N tert-butyl N-[4-[4-(2,6-dioxopiperidin-3-yl)phenoxy]butyl]carbamate Chemical compound CC(C)(C)OC(NCCCCOC1=CC=C(C(CCC(N2)=O)C2=O)C=C1)=O SOVDTDAAHYTEJE-UHFFFAOYSA-N 0.000 description 2
- LAWNSYWKHNZIBE-UHFFFAOYSA-N tert-butyl n-[4-(2-oxoethyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(CC=O)C=C1 LAWNSYWKHNZIBE-UHFFFAOYSA-N 0.000 description 2
- MEGFWFYATPUBOI-UHFFFAOYSA-N tert-butyl n-[[1-(4-nitrophenyl)piperidin-4-yl]methyl]carbamate Chemical compound C1CC(CNC(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)C=C1 MEGFWFYATPUBOI-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- BODYVHJTUHHINQ-UHFFFAOYSA-N (4-boronophenyl)boronic acid Chemical compound OB(O)C1=CC=C(B(O)O)C=C1 BODYVHJTUHHINQ-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- LKLLNYWECKEQIB-UHFFFAOYSA-N 1,3,5-triazinane Chemical compound C1NCNCN1 LKLLNYWECKEQIB-UHFFFAOYSA-N 0.000 description 1
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- IVJFXSLMUSQZMC-UHFFFAOYSA-N 1,3-dithiole Chemical compound C1SC=CS1 IVJFXSLMUSQZMC-UHFFFAOYSA-N 0.000 description 1
- QVFHFKPGBODJJB-UHFFFAOYSA-N 1,3-oxathiane Chemical compound C1COCSC1 QVFHFKPGBODJJB-UHFFFAOYSA-N 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical compound C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 1
- CPRVXMQHLPTWLY-UHFFFAOYSA-N 1,4-oxathiine Chemical compound O1C=CSC=C1 CPRVXMQHLPTWLY-UHFFFAOYSA-N 0.000 description 1
- TVOBVNNUECNRHY-UHFFFAOYSA-N 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-(4-morpholin-4-ylanilino)-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one Chemical compound CC(C)(O)c1cccc(n1)-n1n(CC=C)c(=O)c2cnc(Nc3ccc(cc3)N3CCOCC3)nc12 TVOBVNNUECNRHY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- CUCJJMLDIUSNPU-UHFFFAOYSA-N 1-oxidopiperidin-1-ium Chemical compound [O-][NH+]1CCCCC1 CUCJJMLDIUSNPU-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- QXHDYMUPPXAMPQ-UHFFFAOYSA-N 2-(4-aminophenyl)ethanol Chemical compound NC1=CC=C(CCO)C=C1 QXHDYMUPPXAMPQ-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical group C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- PSNDWZOXFDKLLH-UHFFFAOYSA-N 2-azaspiro[3.4]octane Chemical compound C1NCC11CCCC1 PSNDWZOXFDKLLH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- SUSDYISRJSLTST-UHFFFAOYSA-N 2-oxaspiro[3.3]heptane Chemical compound C1CCC21COC2 SUSDYISRJSLTST-UHFFFAOYSA-N 0.000 description 1
- NTMUDPWGPGZGQW-UHFFFAOYSA-N 2-oxaspiro[3.4]octane Chemical compound C1OCC11CCCC1 NTMUDPWGPGZGQW-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZSYRDSTUBZGDKI-UHFFFAOYSA-N 3-(4-bromophenyl)pentanedioic acid Chemical compound OC(=O)CC(CC(O)=O)C1=CC=C(Br)C=C1 ZSYRDSTUBZGDKI-UHFFFAOYSA-N 0.000 description 1
- WODKXGCVVOOEIJ-UHFFFAOYSA-N 3-(4-bromophenyl)propan-1-ol Chemical compound OCCCC1=CC=C(Br)C=C1 WODKXGCVVOOEIJ-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- BHPOOUUMRGOCIR-UHFFFAOYSA-N 3-bromo-2,6-bis(phenylmethoxy)pyridine Chemical compound N1=C(OCC=2C=CC=CC=2)C(Br)=CC=C1OCC1=CC=CC=C1 BHPOOUUMRGOCIR-UHFFFAOYSA-N 0.000 description 1
- SJGNPEZYXVEDED-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=C=N[CH]1 SJGNPEZYXVEDED-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- XKLMZPIKSUMFTO-UHFFFAOYSA-N 4-(3-bromophenyl)piperidine-2,6-dione Chemical compound BrC1=CC=CC(C2CC(=O)NC(=O)C2)=C1 XKLMZPIKSUMFTO-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- MRUWJENAYHTDQG-UHFFFAOYSA-N 4H-pyran Chemical compound C1C=COC=C1 MRUWJENAYHTDQG-UHFFFAOYSA-N 0.000 description 1
- UCZQXJKDCHCTAI-UHFFFAOYSA-N 4h-1,3-dioxine Chemical compound C1OCC=CO1 UCZQXJKDCHCTAI-UHFFFAOYSA-N 0.000 description 1
- YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 description 1
- BYVSMDBDTBXASR-UHFFFAOYSA-N 5,6-dihydro-4h-oxazine Chemical compound C1CON=CC1 BYVSMDBDTBXASR-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YGWCOOARKLKAGW-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1(C1)CN1C(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(C1)CC1(C1)CN1C(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1)=O YGWCOOARKLKAGW-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FHOZJVPWMWLZMR-UHFFFAOYSA-N NC(CC1)CCN1C(C=C1)=CC=C1NC(CCC(N1)=O)C1=O Chemical compound NC(CC1)CCN1C(C=C1)=CC=C1NC(CCC(N1)=O)C1=O FHOZJVPWMWLZMR-UHFFFAOYSA-N 0.000 description 1
- 229910017906 NH3H2O Inorganic materials 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- FTUQDOHAUBZCGT-UHFFFAOYSA-N OC(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1 Chemical compound OC(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1 FTUQDOHAUBZCGT-UHFFFAOYSA-N 0.000 description 1
- YNBKVCRGCPPLIE-UHFFFAOYSA-N OCC(CC1)CCN1C1=CC=C(C(CCC(N2)=O)C2=O)C=C1 Chemical compound OCC(CC1)CCN1C1=CC=C(C(CCC(N2)=O)C2=O)C=C1 YNBKVCRGCPPLIE-UHFFFAOYSA-N 0.000 description 1
- CJBHFNDKVKFHIW-UHFFFAOYSA-N OCCC(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1 Chemical compound OCCC(C=C1)=CC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1 CJBHFNDKVKFHIW-UHFFFAOYSA-N 0.000 description 1
- TYKAMJNGHVMWDX-UHFFFAOYSA-N OCCC1=CC=C(C(CCC(N2)=O)C2=O)C=C1 Chemical compound OCCC1=CC=C(C(CCC(N2)=O)C2=O)C=C1 TYKAMJNGHVMWDX-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229940126117 ZN-c3 Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- NGYBOKVDHWTDRR-UHFFFAOYSA-N diethyl 2,4-diacetyl-3-(4-bromophenyl)pentanedioate Chemical compound CCOC(=O)C(C(C)=O)C(C(C(C)=O)C(=O)OCC)C1=CC=C(Br)C=C1 NGYBOKVDHWTDRR-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SNQXJPARXFUULZ-UHFFFAOYSA-N dioxolane Chemical compound C1COOC1 SNQXJPARXFUULZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229940125974 heterobifunctional degrader Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- QHJOWSXZDCTNQX-UHFFFAOYSA-N methyl 2-(4-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=C1 QHJOWSXZDCTNQX-UHFFFAOYSA-N 0.000 description 1
- MTXVQNKHYCPIOF-UHFFFAOYSA-N methyl 2-[4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]phenyl]acetate Chemical compound COC(=O)CC1=CC=C(OCCNC(=O)OC(C)(C)C)C=C1 MTXVQNKHYCPIOF-UHFFFAOYSA-N 0.000 description 1
- BFDUUHJUZGYBIM-UHFFFAOYSA-N methyl 2-[4-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]acetate Chemical compound COC(=O)CC1=CC=C(CO[Si](C)(C)C(C)(C)C)C=C1 BFDUUHJUZGYBIM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000006618 mitotic catastrophe Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001326 naphthylalkyl group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003538 neomorphic effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical compound O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical group C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- KVOUHLVOTMOJBS-UHFFFAOYSA-N tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CNC1 KVOUHLVOTMOJBS-UHFFFAOYSA-N 0.000 description 1
- RXFHRKPNLPBDGE-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)C=C1 RXFHRKPNLPBDGE-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- IRTFUXIFKUEQRA-UHFFFAOYSA-N tert-butyl 6-[4-(2,6-dioxopiperidin-3-yl)phenyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1(C1)CN1C1=CC=C(C(CCC(N2)=O)C2=O)C=C1)=O IRTFUXIFKUEQRA-UHFFFAOYSA-N 0.000 description 1
- FSVLLSRKSDMUDC-UHFFFAOYSA-N tert-butyl n-(1-oxaspiro[2.5]octan-6-yl)carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCC11OC1 FSVLLSRKSDMUDC-UHFFFAOYSA-N 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- LIYMTLVBAVHPBU-UHFFFAOYSA-N tert-butyl n-(4-hydroxybutyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCO LIYMTLVBAVHPBU-UHFFFAOYSA-N 0.000 description 1
- WYVFPGFWUKBXPZ-UHFFFAOYSA-N tert-butyl n-(4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(=O)CC1 WYVFPGFWUKBXPZ-UHFFFAOYSA-N 0.000 description 1
- VHYXAWLOJGIJPC-UHFFFAOYSA-N tert-butyl n-(piperidin-4-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCNCC1 VHYXAWLOJGIJPC-UHFFFAOYSA-N 0.000 description 1
- KMLYSSLRVSHVQR-UHFFFAOYSA-N tert-butyl n-[1-(3-nitrophenyl)piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C1=CC=CC([N+]([O-])=O)=C1 KMLYSSLRVSHVQR-UHFFFAOYSA-N 0.000 description 1
- LPSBMWGYPPYZDB-UHFFFAOYSA-N tert-butyl n-[4-(3-oxopropyl)phenyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(CCC=O)C=C1 LPSBMWGYPPYZDB-UHFFFAOYSA-N 0.000 description 1
- OIUOZTIQFGXPKH-UHFFFAOYSA-N tert-butyl n-[4-(4-formylpiperidin-1-yl)phenyl]carbamate Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1N1CCC(C=O)CC1 OIUOZTIQFGXPKH-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Compounds of general Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.
Description
WEE1 INHIBITORS AND METHODS FOR TREATING CANCER
INCORPORATION BY REFERENCE TO PRIORITY APPLICATIONS
[0001] Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby expressly incorporated by reference under 37 CFR 1.57, and Rules 4.18 and 20.6, including U.S. Provisional Application No. 63/376,024, filed September 16, 2022, which is hereby incorporated by reference in its entirety.
BACKGROUND
Field
[0002] The present application relates generally to compounds that are WEE1 inhibitors and/or degraders thereof, and methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer.
Description
[0003] DNA is constantly damaged from the environment. Light, chemicals, stress, and cellular replication lead to single- or double- stranded breakage along DNA’s backbone. Typically, organisms defend against DNA damage by repair proteins that either reconnect, or re-synthesize damaged DNA. The correct functioning of these proteins are essential for life. The incorrect replacement of nucleotides into DNA can cause mutations (and other genetic alterations including but not limited to insertions, deletions, and frameshifts), genetic disease, and loss of protein function. The altogether loss of DNA repair can cause cell death, tumor progression, and cancer.
[0004] Cell cycle checkpoints are important for proper DNA repair, ensuring that cells do not progress with cellular- replication until their genomic integrity is restored. WEE1 is a nuclear kinase involved in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry. Normal cells repair damaged DNA during G1 arrest. Cancer cells often have a deficient Gl-S checkpoint and depend on a functional G2-M checkpoint for DNA repair. WEE1 is overexpressed in various cancer types.
[0005] Various inhibitors and/or degraders of WEE 1 are known to those skilled in the art. Sec, c.g., WO 2019/173082 and WO 2020/069105. However, there remains an urgent need for inhibitors and/or degraders of WEE1 that are useful for the treatment of conditions characterized by excessive cellular proliferation, such as cancer.
SUMMARY
[0006] Various embodiments provide a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
R1 can be absent, a substituted or an unsubstituted 6 to 10 membered aryl, -NH-(a substituted or an unsubstituted 6 to 10 membered aryl)-, a substituted or an unsubstituted 5 to 10 membered heteroaryl, -NH-(a substituted or an unsubstituted 5 to 10 membered heteroaryl)- or -NH-(a substituted or an unsubstituted 6 to 10 membered cycloalkyl)-;
R2 can be absent, a substituted or an unsubstituted 4 to 10 membered heterocyclyl or -O-(a substituted or an unsubstituted 4 to 10 membered heterocyclyl)-;
R3 can be absent, a substituted or an unsubstituted Ci-Ce alkylene, -NH-, -NH-(a substituted or an unsubstituted Ci-Ce alkylene)-, -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH- or -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH-(a substituted or an unsubstituted Ci-Ce alkylene)-;
R4 can be absent or a substituted or an unsubstituted 4 to 10 membered heterocyclyl; with the proviso that at least two of R1, R2, R3 and R4 are present;
RD can be a substituted or an unsubstituted Ci-Cb alkyl; and
Y is -CH or N (nitrogen).
[0007] Another embodiment provides a compound, or a pharmaceutically acceptable salt thereof, wherein the compound can have a structure selected from those of Compound Nos. 1 to 18 as described herein.
[0008] Another embodiment provides a pharmaceutical composition that can include an effective amount of a compound of the Formula (I) as described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
[0009] Another embodiment provides a use of an effective amount of a compound of the Formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that can include such a compound as described herein, in the manufacture of a medicament for ameliorating or treating a cancer, wherein the cancer can be selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non- small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft pail sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’ s lymphoma.
[0010] Another embodiment provides a use of an effective amount of a compound of the Formula (I) as described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that can include such a compound as described above, in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or tumor can be due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a nonsmall cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer,
Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’s lymphoma.
[0011] Another embodiment provides a use of an effective amount of a compound of the Formula (I) as described herein, or a pharmaceutical composition that can include such a compound as described above, in the manufacture of a medicament for ameliorating or treating a malignant growth or tumor, wherein the malignant growth or tumor can be due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-small cell cancer, a breast cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’s lymphoma.
[0012] These and other embodiments are described in greater detail below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 illustrates a general synthetic scheme for preparing compounds of the Formula (I).
[0014] FIG. 2 illustrates a general synthetic scheme for preparing embodiments of compounds of the Formula (I).
[0015] FIG. 3 illustrates a general synthetic scheme for preparing embodiments of compounds of the Formula (I).
[0016] FIG. 4 illustrates a synthetic scheme for preparing Intermediate 1.
[0017] FIG. 5 illustrates a synthetic scheme for preparing Intermediate 2.
[0018] FIG. 6 illustrates a synthetic scheme for preparing Intermediate 3.
[0019] FIG. 7 illustrates a synthetic scheme for preparing Intermediate 4.
[0020] FIG. 8 illustrates a synthetic scheme for preparing Intermediate 5.
[0021] FIG. 9 dlustrates a synthetic scheme for preparing Intermediate 6.
[0022] FIG. 10 illustrates a synthetic schcmc for preparing Intermediate 7.
[0023] FIG. 11 illustrates a synthetic scheme for preparing Intermediate 8.
[0024] FIG. 12 illustrates a synthetic scheme for preparing Intermediate 9.
[0025] FIG. 13 illustrates a synthetic scheme for preparing Intermediate 10.
[0026] FIG. 14 illustrates a synthetic scheme for preparing Intermediate 12.
[0027] FIG. 15 illustrates a synthetic scheme for preparing Intermediate 13.
[0028] FIG. 16 illustrates a synthetic scheme for preparing Intermediate 14.
[0029] FIG. 17 illustrates a synthetic scheme for preparing Intermediate 15.
[0030] FIG. 18 illustrates a synthetic scheme for preparing Intermediate 16.
[0031] FIG. 19 illustrates a synthetic scheme for preparing Intermediate 17.
[0032] FIG. 20 illustrates a synthetic scheme for preparing Intermediate 18.
[0033] FIG. 21 illustrates a synthetic scheme for preparing Intermediate 19.
[0034] FIG. 22 illustrates a synthetic scheme for preparing Intermediate 21.
[0035] FIG. 23 illustrates a synthetic scheme for preparing Intermediate 22.
[0036] FIG. 24 illustrates a synthetic scheme for preparing Intermediate 23.
[0037] FIG. 25 illustrates a synthetic scheme for preparing Intermediate 24.
[0038] FIG. 26 illustrates a synthetic scheme for preparing Intermediate 25.
[0039] FIG. 27 illustrates a synthetic scheme for preparing Intermediate 26.
[0040] FIG. 28 illustrates a synthetic scheme for preparing Intermediate 27.
[0041] FIG. 29 illustrates a synthetic scheme for preparing Intermediate 28.
[0042] FIG. 30 illustrates a synthetic scheme for preparing Intermediate 29.
[0043] FIG. 31 illustrates a synthetic scheme for preparing Intermediate 30.
[0044] FIG. 32 illustrates a synthetic scheme for preparing Intermediate 31.
[0045] FIG. 33 illustrates a synthetic scheme for preparing Intermediate 33.
[0046] FIG. 34 illustrates a synthetic scheme for preparing Intermediate 34.
[0047] FIG. 35 illustrates a synthetic scheme for preparing Intermediate 35.
[0048] FIG. 36 illustrates a synthetic scheme for preparing Intermediate 36.
[0049] FIG. 37 illustrates a synthetic scheme for preparing Intermediate 37.
[0050] FIG. 38 illustrates a synthetic scheme for preparing Intermediate 38.
[0051] FIG. 39 illustrates a synthetic scheme for preparing Intermediate 40.
[0052] FIG. 40 illustrates a synthetic scheme for preparing Intermediate 43.
[0053] FIG. 41 illustrates a synthetic scheme for preparing Intermediate 44.
[0054] FIG. 42 illustrates a synthetic scheme for preparing Intermediate 47 and Intermediate 48.
[0055] FIG. 43 illustrates a synthetic scheme for preparing Intermediate 50.
[0056] FIG. 44 illustrates a synthetic scheme for preparing Intermediate 51.
[0057] FIG. 45 illustrates a synthetic scheme for preparing Intermediate 52.
[0058] FIG. 46 illustrates a synthetic scheme for preparing Intermediate 53.
[0059] FIG. 47 illustrates a synthetic scheme for preparing Intermediate 54.
[0060] FIG. 48 illustrates a synthetic scheme for preparing Intermediate 55.
[0061] FIG. 49 illustrates a synthetic scheme for preparing Intermediate 56.
[0062] FIG. 50 illustrates a synthetic scheme for preparing Intermediate 57.
[0063] FIG. 51 illustrates a synthetic scheme for preparing Intermediate 58.
[0064] FIG. 52 illustrates a synthetic scheme for preparing Intermediate 60.
DETAILED DESCRIPTION
[0065] WEE1 is a tyrosine kinase that is a critical component of the ATR- mediated G2 cell cycle checkpoint control that prevents entry into mitosis in response to cellular DNA damage. ATR phosphorylates and activates CHK1, which in turn activates WEE1, leading to the selective phosphorylation of cyclin-dependent kinase 1 (CDK1) at Tyrl5, thereby stabilizing the CDKl-cyclin B complex and halting cell-cycle progression. This process confers a survival advantage by allowing tumor cells time to repair damaged DNA prior to entering mitosis. Inhibition of WEE 1 abrogates the G2 checkpoint, promoting cancer cells with DNA damage to enter into unscheduled mitosis and undergo cell death via mitotic catastrophe. Therefore, WEE1 inhibition and/or degradation has the potential to sensitize tumors to DNA-damaging agents, such as cisplatin, and to induce tumor cell death.
Definitions
[0066] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are
incorporated by reference in their entirety unless stated otherwise. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
[0067] Whenever a group is described as being “optionally substituted” that group may be unsubstituted or substituted with one or more of the indicated substituents. Likewise, when a group is described as being “unsubstituted or substituted” if substituted, the substituent(s) may be selected from one or more the indicated substituents. If no substituents are indicated, it is meant that the indicated “optionally substituted” or “substituted” group may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), cycloalkyl(alkyl), heteroaryl(alkyl), heterocyclyl(alkyl), hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S- sulfonamide, N-sulfonamido, C-carboxy, O-carboxy, nitro, sulfenyl, sulfinyl, sulfonyl, haloalkyl, hydroxyalkyl, haloalkoxy, an amino, a mono-substituted amine group, a di-substituted amine group and an amine(Ci-C6 alkyl).
[0068] As used herein, “Ca to Cb” in which “a” and “b” are integers refer to the number of carbon atoms in a group. The indicated group can contain from “a” to “b”, inclusive, carbon atoms. Thus, for example, a “Ci to C4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2CH2-. CH3CH2CH(CH3)- and (CH3)3C-. If no “a” and “b” are designated, the broadest range described in these definitions is to be assumed.
[0069] If two “R” groups are described as being “taken together” the R groups and the atoms they are attached to can form a cycloalkyl, cycloalkenyl, aryl, heteroaryl or heterocycle. For example, without limitation, if Ra and Rb of an NRaRb group are indicated to be “taken together,” it means that they are covalently bonded to one another to form a ring:
.Ra
— N ' Rb
[0070] As used herein, the term “alkyl” refers to a fully saturated aliphatic hydrocarbon group. The alkyl moiety may be branched or straight chain. Examples of branched alkyl groups include, but are not limited to, iso-propyl, sec-butyl, t-butyl and the like. Examples of straight chain alkyl groups include, but are not limited to, methyl, ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl and the like. The alkyl group may have 1 to 30
carbon atoms (whenever it appears herein, a numerical range such as “1 to 30” refers to each integer in the given range; e.g., “1 to 30 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 30 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 12 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 6 carbon atoms. An alkyl group may be substituted or unsubstituted.
[0071] The term “alkenyl” used herein refers to a monovalent straight or branched chain radical of from two to twenty carbon atoms containing a carbon double bond(s) including, but not limited to, 1 -propenyl, 2-propenyl, 2-methyl-l -propenyl, 1-butenyl, 2- butenyl and the like. An alkenyl group may be unsubstituted or substituted.
[0072] The term “alkynyl” used herein refers to a monovalent straight or branched chain radical of from two to twenty carbon atoms containing a carbon triple bond(s) including, but not limited to, 1-propynyl, 1-butynyl, 2-butynyl and the like. An alkynyl group may be unsubstituted or substituted.
[0073] As used herein, “cycloalkyl” refers to a completely saturated (no double or triple bonds) mono- or multi- cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion. As used herein, the term “fused” refers to two rings which have two atoms and one bond in common. As used herein, the term “bridged cycloalkyl” refers to compounds wherein the cycloalkyl contains a linkage of one or more atoms connecting non-adjacent atoms. As used herein, the term “spiro” refers to two rings which have one atom in common and the two rings are not linked by a bridge. Cycloalkyl groups can contain 3 to 30 atoms in the ring(s), 3 to 20 atoms in the ring(s), 3 to 10 atoms in the ring(s), 3 to 8 atoms in the ring(s) or 3 to 6 atoms in the ring(s). A cycloalkyl group may be unsubstituted or substituted. Examples of monocycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Examples of fused cycloalkyl groups are decahydronaphthalenyl, dodecahydro- IH-phenalenyl and tetradecahydroanthracenyl; examples of bridged cycloalkyl groups are bicyclo[l.l.l]pentyl, adamantanyl and norbornanyl; and examples of spiro cycloalkyl groups include spiro[3.3]heptane and spiro[4.5]decane.
[0074] As used herein, “cycloalkenyl” refers to a mono- or multi- cyclic hydrocarbon ring system that contains one or more double bonds in at least one ring; although, if there is more than one, the double bonds cannot form a fully delocalized pi-electron system throughout all the rings (otherwise the group would be “aryl,” as defined herein). Cycloalkenyl groups can contain 3 to 10 atoms in the ring(s), 3 to 8 atoms in the ring(s) or 3 to 6 atoms in the ring(s). When composed of two or more rings, the rings may be connected together in a fused, bridged or spiro fashion. A cycloalkenyl group may be unsubstituted or substituted.
[0075] As used herein, “carbocyclyl” refers to a non-aromatic a mono- or multi- cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion, as described herein. Carbocyclyl groups can contain 3 to 30 atoms in the ring(s), 3 to 20 atoms in the ring(s), 3 to 10 atoms in the ring(s), 3 to 8 atoms in the ring(s) or 3 to 6 atoms in the ring(s). A carbocyclyl group may be unsubstituted or substituted. Examples of carbocyclyl groups include, but are in no way limited to, cycloalkyl groups and cycloalkenyl groups, as defined herein, and the non-aromatic portions of 1,2,3 ,4-tetrahydronaphthalene, 2,3-dihydro-lH-indene, 5, 6,7,8- tetrahydroquinoline and 6,7-dihydro-5H-cyclopenta[b]pyridine.
[0076] As used herein, “aryl” refers to a carbocyclic (all carbon) monocyclic or multicyclic aromatic ring system (including fused ring systems where two carbocyclic rings share a chemical bond) that has a fully delocalized pi-electron system throughout all the rings. The number of carbon atoms in an aryl group can vary. For example, the aryl group can be a Ce-Cu aryl group, a Ce-Cio aryl group or a Ce aryl group. Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene. An aryl group may be substituted or unsubstituted.
[0077] As used herein, “heteroaryl” refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system) that contain(s) one or more heteroatoms (for example, 1, 2 or 3 heteroatoms), that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur. The number of atoms in the ring(s) of a heteroaryl group can vary. For example, the heteroaryl group can contain 4 to 14 atoms in the ring(s), 5 to 10 atoms in the ring(s) or 5 to 6 atoms in the ring(s), such as nine carbon atoms and one heteroatom; eight carbon atoms and two heteroatoms; seven carbon atoms and
three heteroatoms; eight carhon atoms and one heteroatom; seven carhon atoms and two hctcroatoms; six carbon atoms and three hctcroatoms; five carbon atoms and four heteroatoms; five carbon atoms and one heteroatom; four carbon atoms and two heteroatoms; three carbon atoms and three heteroatoms; four carbon atoms and one heteroatom; three carbon atoms and two heteroatoms; or two carbon atoms and three heteroatoms. Furthermore, the term “heteroaryl” includes fused ring systems where two rings, such as at least one aryl ring and at least one heteroaryl ring or at least two heteroaryl rings, share at least one chemical bond. Examples of heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2,3-oxadiazole, 1,2,4- oxadiazole, thiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzoisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, purine, pteridine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline and triazine. A heteroaryl group may be substituted or unsubstituted.
[0078] As used herein, “heterocyclyl” or “heteroalicyclyl” refers to three-, four-, five-, six-, seven-, eight-, nine-, ten-, up to 18-membered monocyclic, bicyclic and tricyclic ring system wherein carbon atoms together with from 1 to 5 heteroatoms constitute said ring system. A heterocycle may optionally contain one or more unsaturated bonds situated in such a way, however, that a fully delocalized pi-electron system does not occur throughout all the rings. The heteroatom(s) is an element other than carbon including, but not limited to, oxygen, sulfur and nitrogen. A heterocycle may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio-systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused, bridged or spiro fashion. As used herein, the term “fused” refers to two rings which have two atoms and one bond in common. As used herein, the term “bridged heterocyclyl” or “bridged heteroalicyclyl” refers to compounds wherein the heterocyclyl or heteroalicyclyl contains a linkage of one or more atoms connecting non-adjacent atoms. As used herein, the term “spiro” refers to two rings which have one atom in common and the two rings are not linked by a bridge. Heterocyclyl and heteroalicyclyl groups can contain 3 to 30 atoms in the ring(s), 3 to 20 atoms in the ring(s), 3 to 10 atoms in the ring(s), 3 to 8 atoms in the ring(s) or 3 to 6 atoms in the ring(s). For
example, five carbon atoms and one heteroatom; four carbon atoms and two heteroatoms; three carbon atoms and three hctcroatoms; four carbon atoms and one hctcroatom; three carbon atoms and two heteroatoms; two carbon atoms and three heteroatoms; one carbon atom and four heteroatoms; three carbon atoms and one heteroatom; or two carbon atoms and one heteroatom. Additionally, any nitrogens in a heteroalicyclic may be quaternized. Heterocyclyl or heteroalicyclic groups may be unsubstituted or substituted. Examples of such “heterocyclyl” or “heteroalicyclyl” groups include but are not limited to, 1,3-dioxin, 1,3- dioxane, 1,4-dioxane, 1,2-dioxolane, 1,3-dioxolane, 1,4-dioxolane, 1,3-oxathiane, 1,4- oxathiin, 1,3 -oxathiolane, 1,3-dithiole, 1,3-dithiolane, 1,4-oxathiane, tetrahydro- 1,4-thiazine, 2H-l,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-1, 3, 5-triazine, imidazoline, imidazolidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, morpholine, oxirane, piperidine N-Oxide, piperidine, piperazine, pyrrolidine, azepane, pyrrolidone, pyrrolidione, 4-piperidone, pyrazoline, pyrazolidine, 2-oxopyrrolidine, tetrahydropyran, 4H-pyran, tetrahydrothiopyran, thiamorpholine, thiamorpholine sulfoxide, thiamorpholine sulfone and their benzo-fused analogs (e.g., benzimidazolidinone, tetrahydroquinoline and/or 3,4-methylenedioxyphenyl). Examples of spiro heterocyclyl groups include 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 2-oxa-6- azaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2-oxaspiro[3.4]octane and 2- azaspiro[3.4]octane.
[0079] As used herein, “aralkyl” and “aryl(alkyl)” refer to an aryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and aryl group of an aralkyl may be substituted or unsubstituted. Examples include but are not limited to benzyl, 2-phenylalkyl, 3 -phenylalkyl and naphthylalkyl.
[0080] As used herein, “heteroaralkyl” and “heteroaryl(alkyl)” refer to a heteroaryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and heteroaryl group of heteroaralkyl may be substituted or unsubstituted. Examples include but are not limited to 2-thienylalkyl, 3-thienylalkyl, furylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl and imidazolylalkyl and their benzo-fused analogs.
[0081] A “heteroalicyclyl(alkyl)” and “heterocyclyl(alkyl)” refer to a heterocyclic or a heteroalicyclic group connected, as a substituent, via a lower alkylene group. The lower
alkylene and heterocyclyl of a (heteroalicyclyl)alkyl may be substituted or unsubstituted. Examples include but arc not limited tctrahydro-2H-pyran-4-yl(mcthyl), pipcridin-4- yl(ethyl), piperidin-4-yl(propyl), tetrahydro-2H-thiopyran-4-yl(methyl) and l,3-thiazinan-4- yl(methyl).
[0082] As used herein, “alkylene groups” are straight-chained alkyl groups that are -CH2- tethering, forming bonds to connect molecular fragments via their terminal carbon atoms. Embodiments of alkylene groups may be represented herein by -(CH2)n- where n is an integer in the range of 1 to 30. “Lower” alkylene groups are alkylene groups that contain 1 to 6 carbon atoms. Examples of lower alkylene groups include but are not limited to methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-) and butylene (- CH2CH2CH2CH2-). An alkylene group can be substituted by replacing one or more hydrogen of the alkylene group and/or by substituting both hydrogens on the same carbon with a
cycloalkyl group (e.g., -C- ).
[0083] As used herein, the term “hydroxy” refers to a -OH group.
[0084] As used herein, “alkoxy” refers to the Formula -OR wherein R is an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl) is defined herein. A non-limiting list of alkoxys are methoxy, ethoxy, n-propoxy, 1 -methylethoxy (iso-propoxy), n-butoxy, iso-butoxy, sec -butoxy, tert-butoxy, phenoxy and benzoxy. An alkoxy may be substituted or unsubstituted.
[0085] As used herein, “acyl” refers to a hydrogen, alkyl, alkenyl, alkynyl, aryl, hctcroaryl, heterocyclyl, aryl(alkyl), hctcroaryl(alkyl) and hctcrocyclyl(alkyl) connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl and acryl. An acyl may be substituted or unsubstituted.
[0086] A “cyano” group refers to a “-CN” group.
[0087] The term “halogen atom” or “halogen” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, such as, fluorine, chlorine, bromine and iodine.
[0088] A “thiocarbonyl” group refers to a “-C(=S)R” group in which R can be the same as defined with respect to O-carboxy. A thiocarbonyl may be substituted or unsubstituted.
[0089] An “O-carbamyl” group refers to a “-0C(=0)N(RARB)” group in which RA and RB can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An O-carbamyl may be substituted or unsubstituted.
[0090] An “N-carbamyl” group refers to an “R0C(=0)N(RA)-” group in which R and RA can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An N-carbamyl may be substituted or unsubstituted.
[0091] An “O-thiocarbamyl” group refers to a “-OC(=S)-N(RARB)” group in which RA and RB can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An O-thiocarbamyl may be substituted or unsubstituted.
[0092] An “N-thiocarbamyl” group refers to an “ROC(=S)N(RA)-” group in which R and RA can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An N-thiocarbamyl may be substituted or unsubstituted.
[0093] A “C-amido” group refers to a “-C(=0)N(RARB)” group in which RA and RB can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalky l(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). A C-amido may be substituted or unsubstituted.
[0094] An “N-amido” group refers to a “RC(=O)N(RA)-” group in which R and RA can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An N-amido may be substituted or unsubstituted.
[0095] An “S-sulfonamido” group refers to a “-SO2N(RARB)” group in which RA and RB can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a
cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or hctcrocyclyl(alkyl). An S-sulfonamido may be substituted or unsubstituted.
[0096] An “N-sulfonamido” group refers to a “RSO2N(RA)-” group in which R and RA can be independently hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). An N-sulfonamido may be substituted or unsubstituted.
[0097] An “O-carboxy” group refers to a “RC(=O)O-” group in which R can be hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl), as defined herein. An O-carboxy may be substituted or unsubstituted.
[0098] The terms “ester” and “C-carboxy” refer to a “-C(=O)OR” group in which R can be the same as defined with respect to O-carboxy. An ester and C-carboxy may be substituted or unsubstituted.
[0099] A “nitro” group refers to an “-NO2” group.
[0100] A “sulfenyl” group refers to an “-SR” group in which R can be hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl). A sulfenyl may be substituted or unsubstituted.
[0101] A “sulfinyl” group refers to an “-S(=O)-R” group in which R can be the same as defined with respect to sulfenyl. A sulfinyl may be substituted or unsubstituted.
[0102] A “sulfonyl” group refers to an “SO2R” group in which R can be the same as defined with respect to sulfenyl. A sulfonyl may be substituted or unsubstituted.
[0103] As used herein, “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkyl, di-haloalkyl, tri- haloalkyl and polyhaloalkyl). Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, l-chloro-2-fluoromethyl, 2-fluoroisobutyl and pentafluoroethyl. A haloalkyl may be substituted or unsubstituted.
[0104] As used herein, “haloalkoxy” refers to an alkoxy group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkoxy, di- haloalkoxy and tri- haloalkoxy). Such groups include but are not limited to, chloromethoxy,
fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1 -chloro-2-fluoromethoxy and 2- fluoroisobutoxy. A haloalkoxy may be substituted or unsubstituted.
[0105] The term “amino” as used herein refers to a -NH2 group.
[0106] A “mono-substituted amine” group refers to a “-NHRA” group in which RA can be an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl), as defined herein. The RA may be substituted or unsubstituted. Examples of mono-substituted amino groups include, but are not limited to, -NH(methyl), -NH(phenyl) and the like.
[0107] A “di- substituted amine” group refers to a “-NRARB” group in which RA and RB can be independently an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl, aryl, heteroaryl, heterocyclyl, cycloalkyl(alkyl), aryl(alkyl), heteroaryl(alkyl) or heterocyclyl(alkyl), as defined herein. RA and RB can independently be substituted or unsubstituted. Examples of di-substituted amino groups include, but are not limited to, -N(methyl)2, -N(phenyl)(methyl), -N(ethyl)(methyl) and the like.
[0108] As used herein, “amine(alkyl)” group refers to an -(alkylene)-NR’R” radical where R’ and R” are independently hydrogen or alkyl as defined herein. An amine(alkyl) may be substituted or unsubstituted. Examples of amine(alkyl) groups include, but are not limited to, -CH2NH(methyl), -CH2NH(phenyl), -CH2CH2NH(methyl), -CH2CH2NH(phenyl), -CH2N(methyl)2, -CH2N(phenyl)(methyl), -NCH2(ethyl)(methyl), -CH2CH2N(methyl)2, -CH2CH2N(phenyl)(methyl), -NCH2CH2(ethyl)(methyl) and the like.
[0109] Where the number of substituents is not specified (e.g. haloalkyl), there may be one or more substituents present. For example, “haloalkyl” may include one or more of the same or different halogens. As another example, “C1-C3 alkoxyphenyl” may include one or more of the same or different alkoxy groups containing one, two or three atoms.
[0110] As used herein, a radical indicates species with a single, unpaired electron such that the species containing the radical can be covalently bonded to another species. Hence, in this context, a radical is not necessarily a free radical. Rather, a radical indicates a specific portion of a larger molecule. The term “radical” can be used interchangeably with the term “group.”
[0111] The term “pharmaceutically acceptable salt” refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does
not abrogate the biological activity and properties of the compound. Tn some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), a sulfuric acid, a nitric acid and a phosphoric acid (such as 2,3- dihydroxypropyl dihydrogen phosphate). Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, trifluoroacetic, benzoic, salicylic, 2- oxopentanedioic or naphthalenesulfonic acid. Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium, a potassium or a lithium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of a carbonate, a salt of a bicarbonate, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine and salts with amino acids such as arginine and lysine. For compounds of Formula (I), those skilled in the art understand that when a salt is formed by protonation of a nitrogen-based group (for example, NH2), the nitrogen-based group can be associated with a positive charge (for example, NH2 can become NH3 +) and the positive charge can be balanced by a negatively charged counterion (such as CF).
[0112] The terms “WEE1 inhibition”, “WEE1 inhibitor” and similar terms as used herein refer to inhibiting the activity or function of a WEE 1 tyrosine kinase, e.g., by degrading WEE1 tyrosine kinase and/or by reducing the activity of WEE 1 tyrosine kinase with regard to mediating phosphorylation of CDK1. A WEE1 inhibitor that functions by degrading WEE1 tyrosine kinase may be referred to herein as a WEE1 degrader.
[0113] It is understood that, in any compound described herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S -configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched or a stereoisomeric mixture. In addition, it is understood that, in any compound described herein having one or more double bond(s) generating geometrical isomers that can be defined as E or Z, each
double bond may independently be E or Z a mixture thereof. Likewise, it is understood that, in any compound described, all tautomeric forms arc also intended to be included.
[0114] It is to be understood that where compounds disclosed herein have unfilled valencies, then the valencies are to be filled with hydrogens or isotopes thereof, e.g., hydrogen- 1 (protium) and hydrogen-2 (deuterium). Compounds described herein can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
[0115] It is understood that the compounds described herein can be labeled isotopically. Substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound structure a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position of the compound that a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen- 1 (protium), hydrogen-2 (deuterium) and hydrogen-3 (tritium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
[0116] It is understood that the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates and hydrates. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol or the like. In other embodiments, the compounds described herein exist in unsolvated form. Solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol or the like. Hydrates are formed when the solvent is water or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
[0117] Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.
[0118] Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; and use of terms like ‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words of similar- meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment. In addition, the term “comprising” is to be interpreted synonymously with the phrases “having at least” or “including at least”. When used in the context of a compound, composition or device, the term “comprising” means that the compound, composition or device includes at least the recited features or components, but may also include additional features or components.
[0119] With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.
Compounds
[0120] Some embodiments disclosed herein relate to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein R1, R2, R3, R4, Rc and RD are as described below.
[0121] In various embodiments, R1 in Formula (I) can be absent, a substituted or an unsubstituted 6 to 10 membered aryl, -NH-(a substituted or an unsubstituted 6 to 10 membered aryl)-, a substituted or an unsubstituted 5 to 10 membered heteroaryl, -NH-(a substituted or an unsubstituted 5 to 10 membered heteroaryl)- or -NH-(a substituted or an unsubstituted 6 to 10 membered cycloalkyl)-. In an embodiment, R1 can be absent. In another embodiment, R1 can be a substituted or an unsubstituted 6 to 10 membered aryl. For example, in such an embodiment R1 can be an unsubstituted phenyl. In another embodiment, R1 can be -NH-(a substituted or an unsubstituted 6 to 10 membered aryl)-. For example, in such an embodiment R1 can
substituted or an unsubstituted 5 to 10 membered hctcroaryl. In another embodiment, R1 can be -NH-(a substituted or an unsubstituted 5 to 10 membered heteroaryl)-. In another embodiment, R1 can be a -NH-(a substituted or an unsubstituted 6 to 10 membered cycloalkyl)-. For example, in such an embodiment R1 can be
[0122] In various embodiments, R2 in Formula (I) can be absent, a substituted or an unsubstituted 4 to 10 membered heterocyclyl or -O-(a substituted or an unsubstituted 4 to 10 membered heterocyclyl)-. In an embodiment, R2 can be absent. In another embodiment, R2 can be a substituted or an unsubstituted 4 to 10 membered heterocyclyl. For example, in
another embodiment, R2 can be
In another embodiment, R2 can be a -0-(a substituted or an unsubstituted 4 to 10 membered heterocyclyl)-. For example, in such an embodiment R can
[0123] In various embodiments, R3 in Formula (I) can be absent, a substituted or an unsubstituted Ci-Ce alkylene, -NH-, -NH-(a substituted or an unsubstituted Ci-Ce alkylene)-, -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH- or -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH-(a substituted or an unsubstituted Ci-Ce alkylene)-. In an embodiment, R3 can be absent. In another embodiment, R3 can be a substituted or an unsubstituted Ci-Ce alkylene. For example, in such an embodiment R3 can be -(CH2)-, - (CH2CH2)- or -(CH2CH2CH2)-. In another embodiment, R3 can be -(CH2CHOH)-. In another embodiment, R3 is -NH-. In another embodiment, R3 can be -NH-(a substituted or an unsubstituted Ci-Ce alkylene)-. For example, in such an embodiment R3 can be -NH- (CH2)-. In another embodiment, R3 can be -NH-(CH2CH2)-, -NH-(CH2CH2CH2)- or -NH- (CH2CH2 CH2CH2)-. In another embodiment, R3 can be a -O-(a substituted or an unsubstituted Ci-Ce alkylcnc)-NH-. In another embodiment, R3 can be -O-(CH2)4-NH- In another embodiment, R3 can be a -O-(a substituted or an unsubstituted C1-C6 alkylene)-NH- (a substituted or an unsubstituted Ci-Ce alkylene)-. For example, in such an embodiment R3 can be -O-(CH2)2-NH-(CH2)-.
[0124] In various embodiments, R4 in Formula (I) can be absent or a substituted or an unsubstituted 4 to 10 membered heterocyclyl. In an embodiment, R4 can be absent. In another embodiment, R4 can be an unsubstituted 4 to 10 membered heterocyclyl. For example, in such an embodiment R4 can be
[0125] In various embodiments, at least two of R1, R2, R3 and R4 in Formula (I) are present. In some embodiments, at least three of R1, R2, R3 and R4 are present. In some embodiments, all four of R1, R2, R3 and R4 are present.
[0126] In various embodiments, Rc in Formula (I) can be
, wherein Y is -CH or N (nitrogen). In some embodiments Rc in Formula (I) can be
and Y is -CH. In some embodiments Rc in Formula (I) can be
and Y is N (nitrogen). In some embodiments Rc in Formula (I) can
[0127] In various embodiments, RD can be a substituted or an unsubstituted C1-C6 alkyl. In various embodiments, RD can be a substituted Ci-Ce alkyl. In various embodiments, RD can be an unsubstituted Ci-Ce alkyl. In various embodiments, RD can be a halogensubstituted Ci-C6 alkyl. In various embodiments, RD can be an ethyl. In various embodiments, RD can be a methyl. In various embodiments, RD can be a halogen-substituted ethyl. In various embodiments, RD can be a halogen-substituted methyl.
[0128] Various embodiments provide a compound (e.g., a compound of Formula (I)), or a pharmaceutically acceptable salt thereof, wherein the compound has a structure selected from those of Compound Nos. 1 to 42 as listed in the following Table A:
[0129] Compounds of the Formula (I), or pharmaceutically acceptable salts thereof, can be made in various ways by those skilled using known techniques as guided by the detailed teachings provided herein, including the Examples provided below. For example, in an embodiment, compounds of the Formula (I) are prepared in accordance with the general schemes illustrated in FIGS. 1-52. Any preliminary reaction steps required to form starting compounds or other precursors, can be carried out by those skilled in the art, for example by appropriate adjustment of the reagents and conditions described in the Examples. In FIGS. 1-52, the variables including R1, R2, R3, R4, Rc and RD can be as described elsewhere herein, taking into consideration the synthetic conversions involved as understood by those of skill in the art. R5, R6, R7 and R8 are understood by those of skill in the art to be synthetic precursors of R3 and R4, as further illustrated in the Examples below.
Pharmaceutical Compositions
[0130] Some embodiments described herein relate to a pharmaceutical composition, which can include an effective amount of one or more compounds described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
[0131] The term “pharmaceutical composition” refers to a mixture of one or more compounds and/or salts disclosed herein with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Pharmaceutical compositions will generally be tailored to the specific intended route of administration.
[0132] The term “physiologically acceptable” defines a carrier, diluent or excipient that does not abrogate the biological activity and properties of the compound nor cause appreciable damage or injury to an animal to which delivery of the composition is intended.
[0133] As used herein, a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, without limitation, dimethyl sulfoxide (DMSO) is a commonly utilized carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject.
[0134] As used herein, a “diluent” refers to an ingredient in a pharmaceutical composition that lacks appreciable pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the pH and isotonicity of human blood.
[0135] As used herein, an “excipient” refers to an essentially inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition. For example, stabilizers such as anti-oxidants and metal-chelating agents are excipients. In an embodiment, the pharmaceutical composition comprises an anti-oxidant and/or a metalchelating agent. A “diluent” is a type of excipient.
[0136] The pharmaceutical compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or carriers, diluents, excipients or combinations thereof. Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art.
[0137] The pharmaceutical compositions disclosed herein may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes. Additionally, the active ingredients are contained in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein may be provided as salts with pharmaceutically compatible counterions.
[0138] Multiple techniques of administering a compound, salt and/or composition exist in the art including, but not limited to, oral, rectal, pulmonary, topical, aerosol, injection,
infusion and parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intranasal and intraocular injections. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered orally.
[0139] One may also administer the compound, salt and/or composition in a local rather than systemic manner, for example, via injection or implantation of the compound directly into the affected area, often in a depot or sustained release formulation. Furthermore, one may administer the compound in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the organ. For example, intranasal or pulmonary delivery to target a respiratory disease or condition may be desirable.
[0140] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions that can include a compound and/or salt described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
Uses and Methods of Treatment
[0141] Some embodiments described herein relate to a method for ameliorating and/or treating a cancer described herein that can include administering an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) to a subject having a cancer described herein.
Other embodiments described herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for ameliorating and/or treating a cancer described herein. Still other embodiments described herein relate to an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for ameliorating and/or treating a cancer described herein.
[0142] Some embodiments described herein relate to a method for inhibiting replication of a malignant growth or a tumor that can include contacting the growth or the tumor with an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof), wherein the malignant growth or tumor is due to a cancer described herein. Other embodiments described herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer described herein. Still other embodiments described herein relate to an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer described herein.
[0143] Some embodiments described herein relate to a method for ameliorating or treating a cancer described herein that can include contacting a malignant growth or a tumor
with an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) to a subject having a cancer described herein. Other embodiments described herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for ameliorating or treating a cancer that can include contacting a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer described herein. Still other embodiments described herein relate to an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for ameliorating or treating a cancer that can include contacting a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer described herein.
[0144] Some embodiments described herein relate to a method for inhibiting the activity of WEE1 (for example, inhibiting the activity of WEE1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53- deficient cells and/or decreasing the overexpression of WEE1 in cells) that can include providing an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) to a cancer cell from a cancer described herein. Other embodiments described herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for inhibiting the activity of WEE1 (for example, inhibiting the activity of WEE1 in TP53-
mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-dcficicnt cells and/or decreasing the overexpression of WEE1 in cells). Still other embodiments described herein relate to an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for inhibiting the activity of WEE 1 (for example, inhibiting the activity of WEE 1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE 1 in cells). Some embodiments described herein relate to a method for inhibiting the activity of WEE 1 (for example, inhibiting the activity of WEE 1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE1 in cells) that can include providing an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) to a cancer cell from a cancer described herein. Other embodiments described herein relate to a method for inhibiting the activity of WEE 1 (for example, inhibiting the activity of WEE 1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE1 in cells) that can include contacting a cancer cell from a cancer described herein with an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof), and thereby inhibiting the activity of WEE E
[0145] Some embodiments described herein relate to a method for ameliorating or treating a cancer described herein that can include inhibiting the activity of WEE1 (for example, inhibiting the activity of WEE 1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE1 in cells) using an effective amount of a compound
described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof). Other embodiments described herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for ameliorating or treating a cancer described herein by inhibiting the activity of WEE1 (for example, inhibiting the activity of WEE1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE 1 in cells). Still other embodiments described herein relate to an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for ameliorating or treating a cancer described herein by inhibiting the activity of WEE1 (for example, inhibiting the activity of WEE1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53- deficient cells and/or decreasing the overexpression of WEE 1 in cells). Some embodiments described herein relate to a method for ameliorating or treating a cancer described herein that can include contacting a cancer cell with an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof), wherein the compound inhibits the activity of WEE1 (for example, inhibiting the activity of WEE1 in TP53-mutated cells, inhibiting the activity of WEE1 in TP53 wild-type cells, inhibiting the activity in WEE1 p53-deficient cells and/or decreasing the overexpression of WEE 1 in cells).
[0146] Some embodiments disclosed herein relate to a method for inhibiting the activity of WEE1 that can include providing an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt
thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) to a subject having a cancer described herein or a cancer cell from a cancer described herein. Other embodiments disclosed herein relate to the use of an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for inhibiting the activity of WEE1. Still other embodiments disclosed herein relate to a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) for inhibiting the activity of WEE 1.
[0147] Examples of suitable cancers include, but are not limited to: brain cancers, cervicocerebral cancers, esophageal cancers, thyroid cancers, small cell cancers, non-small cell cancers, breast cancers, lung cancers (for example non-small cell lung cancer and small cell lung cancer), stomach cancers, gallbladder/bile duct cancers, liver cancers, pancreatic cancers, colon cancers, rectal cancers, ovarian cancers, choriocarcinomas, uterus body cancers, uterocervical cancers, renal pelvis/ureter cancers, bladder cancers, prostate cancers, penis cancers, testicular cancers, fetal cancers, Wilms’ cancer, skin cancers, malignant melanoma, neuroblastomas, osteosarcomas, Ewing's tumors, soft part sarcomas, acute leukemia, chronic lymphatic leukemias, chronic myelocytic leukemias, polycythemia vera, malignant lymphomas, multiple myeloma, Hodgkin's lymphomas and non-Hodgkin’s lymphomas.
[0148] As described herein, a cancer can become resistant to one or more anticancer agents. In some embodiments, a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition that includes an effective amount of a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) can be used to treat and/or ameliorate a cancer that has become resistant to one or more anti-cancer agents (such as one or more WEE1 inhibitors). Examples of anti-cancer agents that a subject may have
developed resistance to include, but are not limited to, WEE1 inhibitors (such as AZDI 775). In some embodiments, the cancer that has become resistant to one or more anti-canccr agents can be a cancer described herein.
[0149] Several known WEE1 inhibitors can cause one or more undesirable side effects in the subject being treated. Examples of undesirable side effects include, but are not limited to, thrombocytopenia, neutropenia, anemia, diarrhea, vomiting, nausea, abdominal pain, and constipation. In some embodiments, a compound described herein (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof) can decrease the number and/or severity of one or more side effects associated with a known WEE1 inhibitor. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can result in a severity of a side effect (such as one of those described herein) that is 25% less than compared to the severity of the same side effect experienced by a subject receiving a known WEE1 inhibitor (such as AZD1775, formally known as MK1775 (CAS No.: 955365-80-7, 2-allyl-l-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4- methylpiperazin-l-yl)phenylamino)-l,2-dihydropyrazolo[3,4-d]pyrimidin-3-one)). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a number of side effects that is 25% less than compared to the number of side effects experienced by a subject receiving a known WEE1 inhibitor (for example, AZD1775). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a severity of a side effect (such as one of those described herein) that is less in the range of about 10% to about 30% compared to the severity of the same side effect experienced by a subject receiving a known WEE1 inhibitor (such as AZD1775). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a number of side effects that is in the range of about 10% to about 30% less than compared to the number of side effects experienced by a subject receiving a known WEE1 inhibitor (for example, AZD1775).
[0150] The one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that can be used to treat, ameliorate and/or inhibit the growth of a cancer wherein inhibiting the activity of WEE1 is beneficial is provided in any of the embodiments described under the heading titled “Compounds” above.
[0151] As used herein, a “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees, and apes, and, in particular, humans. In some embodiments, the subject can be human. In some embodiments, the subject can be a child and/or an infant, for example, a child or infant with a fever. In other embodiments, the subject can be an adult.
[0152] As used herein, the terms “treat,” “treating,” “treatment,” “therapeutic,” and “therapy” do not necessarily mean total cure or abolition of the disease or condition. Any alleviation of any undesired signs or symptoms of the disease or condition, to any extent can be considered treatment and/or therapy. Furthermore, treatment may include acts that may worsen the subject’s overall feeling of well-being or appearance.
[0153] The terms “therapeutically effective amount” and “effective amount” are used to indicate an amount of an active compound, or pharmaceutical agent, which elicits the biological or medicinal response indicated. For example, a therapeutically effective amount of compound, salt or composition can be the amount needed to prevent, alleviate or ameliorate symptoms of the disease or condition, or prolong the survival of the subject being treated. This response may occur in a tissue, system, animal or human and includes alleviation of the signs or symptoms of the disease or condition being treated. Determination of an effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein. The therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical ai ts will recognize.
[0154] For example, an effective amount of a compound, or radiation, is the amount that results in: (a) the reduction, alleviation or disappearance of one or more symptoms caused by the cancer, (b) the reduction of tumor size, (c) the elimination of the tumor, and/or (d) long-term disease stabilization (growth arrest) of the tumor. In the treatment of lung
cancer (such as non-small cell lung cancer) a therapeutically effective amount is that amount that alleviates or eliminates cough, shortness of breath and/or pain. As another example, an effective amount, or a therapeutically effective amount of an WEE1 inhibitor and/or degrader is the amount which results in the reduction in WEE1 activity and/or phosphorylation (such as phosphorylation of CDC2). The reduction in WEE1 activity is known to those skilled in the art and can be determined by the analysis of WEE1 intrinsic kinase activity and downstream substrate phosphorylation.
[0155] The amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature and/or symptoms of the disease or condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician. In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. As will be understood by those of skill in the ail, in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the dosage ranges described herein in order to effectively and aggressively treat particularly aggressive diseases or conditions.
[0156] In general, however, a suitable dose will often be in the range of from about 0.05 mg/kg to about 10 mg/kg. For example, a suitable dose may be in the range from about 0.10 mg/kg to about 7.5 mg/kg of body weight per day, such as about 0.15 mg/kg to about 5.0 mg/kg of body weight of the recipient per day, about 0.2 mg/kg to 4.0 mg/kg of body weight of the recipient per day, or any amount in between. The compound may be administered in unit dosage form; for example, containing 1 to 500 mg, 10 to 100 mg, 5 to 50 mg or any amount in between, of active ingredient per unit dosage form.
[0157] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations.
[0158] As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, the mammalian species treated, the particular
compounds employed and the specific use for which these compounds are employed. The determination of effective dosage levels, which is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine methods, for example, human clinical trials, in vivo studies and in vitro studies. For example, useful dosages of a compound of Formula (I), or pharmaceutically acceptable salts thereof, can be determined by comparing their in vitro activity, and in vivo activity in animal models. Such comparison can be done by comparison against an established drug, such as cisplatin and/or gemcitabine)
[0159] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vivo and/or in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.
[0160] It should be noted that the attending physician would know how to and when to terminate, interrupt or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the disease or condition to be treated and to the route of administration. The severity of the disease or condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
[0161] Compounds, salts and compositions disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be
established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies arc often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, dogs or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the ait to choose an appropriate model, dose, route of administration and/or regime.
EXAMPLES
[0162] Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.
Intermediate 1
[0163] Step 1: To a mixture of 3-(4-piperazin-l-ylanilino)piperidine-2, 6-dione (Reference: WO 2021/083949) (0.200 g, 497 pmol, TFA salt) in DCM (2 mL) were added tert-butyl (4-formylphenyl) carbamate (132 mg, 596 pmol), NaBH(OAc)3 (211mg, 994 pmol) and DIEA (321 mg, 2.49 mmol) at 0 °C. The mixture was stirred at 20 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into H2O (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (10 mL), dried over anhydrous Na S04, filtrated, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by prep-TLC (MeOH:EA = 1: 10, Rf = 0.5) to afford tert-butyl A-[4-[[4-[4-[(2,6-dioxo-3-piperidyl)amino] phenyl]piperazin- l-yl]methyl]phenyl] carbamate (Boc protected Intermediate 1) (0.120 g, 48% yield, 98% purity). LCMS (ESI+) m/z 494.2
[M+H]+, RT: 0.481 min.
NMR (400 MHz, DMSO-d6) 5 10.75 (br s, 1 H, NH), 9.29 (s, 1 H, NH), 7.39 (br d, J = 8.4 Hz, 2H), 7.18 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 8.9 Hz. 2H), 5.36 (br d, J = 7.1 Hz, 1H, NH), 4.23 - 4.14 (m, 1H). 3.41 (s, 2H), 2.90 - 2.97 (m, 4H), 2.75 - 2.65 (m, 1H), 2.63 - 2.53 (m, 1H), 2.50 - 2.43 (m, 4H), 2.16 - 2.04 (m, 1H), 1.80 - 1.65 (m, 1H), 1.47 (s, 9H).
[0164] Step 2: A mixture of Boc protected Intermediate 1 (0.120 g, 238 pmol, 98% purity) in TFA (0.2 mL) and DCM (2 mL) was stirred at 20 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into NaHCCh solution (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (10 mL), dried over anhydrous Na SCL and filtrated. The filtrate was concentrated under reduced pressure to give Intermediate 1, 3-[4-[4-[(4- aminophenyl)methyl]piperazin-l-yl]anilino]piperidine-2, 6-dione (80 mg, 71% yield, 84% purity). LCMS (ESI+) m/z 394.2 [M+H]+, RT: 0.688 min.
Intermediate 2 3-((4-(4-(4-aminophenethyl)piperazin- 1 -yl)phenyl)amino)piperidine-2, 6-dione (FIG. 5)
[0165] Step 1: Boc protected Intermediate 2 was prepared following the procedure described in Step 1 for Intermediate 1 using tert-butyl (4-(2- oxoethyl)phenyl)carbamate in place of tert-butyl (4-formylphenyl)carbamate in yield 57% with purity 95%. LCMS (ESI+) m/z 508.3 [M+H]+, RT: 0.554 min. ’ H NMR (400 MHz, DMSO-d6) 5 10.75 (s, 1H, NH), 9.21 (s, 1H, NH). 7.34 (br d. J= 8.4 Hz, 2H), 7.10 (d, J= 8.4 Hz, 2H), 6.75 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 5.37 (d, J = 7.3 Hz, 1H, NH), 4.19 (ddd, J= 11.2, 6.7, 4.9 Hz, 1H), 2.98 - 2.89 (m, 4H), 2.78 - 2.71 (m, 1H), 2.70 - 2.64 (m, 2H), 2.62 - 2.57 (m, 1H), 2.57 - 2.53 (m. 4H). 2.54 - 2.50 (m, 2H), 2.15 - 2.06 (m, 1H), 1.88 - 1.77 (m, 1H), 1.46 (s, 9H).
[0166] Step 2: Intermediate 2 was prepared following the procedure described in Step 2 for Intermediate 1. The isolated yield 73% with 95% purity was obtained. LCMS (ESI+) m/z 408.2 [M-H]+. RT: 0.149 min. ’ H NMR (400 MHz, DMSO-d6) 8 10.74 (s, 1H, NH), 6.87 (d, J = 8.3 Hz, 2H), 6.75 (d, J= 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 6.48 (d, J = 8.3 Hz, 2H), 5.36 (d, J = 7.3 Hz, 1H), 4.80 (br s, 2H), 4.19 (ddd, J =11.3, 7.0, 4.8 Hz, 1H), 2.99 - 2.88 (m. 4H), 2.78 - 2.68 (m. 1H). 2.62 - 2.52 (m, 8H), 2.47 - 2.44 (m, 1H), 2.15 - 2.07 (m, 1H), 1.89 - 1.77 (m, 1H).
[0167] Step 1: To a solution of 3-(4-piperazin-l-ylanilino)piperidine-2, 6-dione (300 mg, 1.04 mmol) in DMF (6 mL) were added l-fluoro-4-nitrobenzene (117 mg, 832 pmol) and DIEA (672 mg, 5.20 mmol) at 20 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (EA) (3 x 10 mL). The organic combined organic layers were washed with brine (3 x 10 mL) and dried over NaiSCU. After filtered, the filtrate was concentrated under reduced pressure to give 3-[4-[4- (4-nitrophenyl)piperazin-l-yl]anilino]piperidine-2, 6-dione (140 mg, 31% yield, 95% purity). LCMS (ESI+) m/z 410.1 [M+H]+, RT: 0.483 min. 1 H NMR (400 MHz, DMSO-d6) 8 10.76 (s, 1H, NH). 8.07 (d, 7= 9.4 Hz. 2H), 7.09 (d, 7 = 9.4 Hz, 2H), 6.82 (d. 7 = 8.8 Hz, 2H), 6.64 (d, 7 = 8.8 Hz, 2H), 5.45 (d, 7 = 7.3 Hz, 1H, NH), 4.21 (ddd, 7 = 11.2, 6.8, 4.8 Hz, 1H), 3.64 - 3.55 (m, 4H), 3.10 - 3.02 (m, 4H), 2.73 (ddd, 7 = 17.4, 11.8, 5.6 Hz, 1H), 2.57 (ddd, 7 = 17.6, 4.4, 4.0 Hz, 1H), 2.11 (ddd, 7 = 12.9, 8.8, 4.4 Hz, 1H), 1.85 (ddd, 7 = 24.1, 11.5, 4.3 Hz, 1H).
[0168] Step 2: To a solution of 3-[4-[4-(4-nitrophenyl)piperazin-l- yl]anilino]piperidine-2, 6-dione (from Step 1) (140 mg, 324 pmol, 95% purity) in TFE (3 mL) was added Pd/C (40.2 mg, 10% on carbon) at 25 °C. The reaction was stirred at 25 °C under
Hi atmosphere (15 psi) for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was filtered and the filter cake was washed with TFE (20 mL). The collected filtrate was concentrated to give Intermediate 3, 3-[4-[4-(4- aminophenyl) piperazin-l-yl]anilino]piperidine-2, 6-dione (70.0 mg, 54% yield, 94.91% purity). LCMS (ESI+) ni/z 380.2 [M+H]+, RT: 0.559 min.
NMR (400 MHz, DMSO-d6) 8 = 10.76 (br s, 1H, NH). 6.80 (br d. J = 8.8 Hz, 2H), 6.73 (d. J = 8.8 Hz, 2H), 6.63 (br d, J = 8.8 Hz, 2H), 6.51 (d, J - 8.8 Hz, 2H), 5.40 (d, J - 7.3 Hz, 1H, NH), 4.58 (br s, 2H, NH2), 4.20 (ddd, J = 11.2, 6.8, 5.0 Hz, 1H), 3.10 - 3.00 (m, 8H). 2.73 (ddd. J = 17.4, 11.8, 5.6 Hz, 1H), 2.58 (ddd, J = 17.4, 4.4, 4.4 Hz, 1H), 2.11 (ddd, J = 12.9, 8.8 Hz, 1H), 1.84 (ddd, J = 24.1, 12.0, 4.5 Hz, 1H).
Intermediate 4 3-((4-(4-(3-(4-aminophenyl)propyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione (FIG. 7)
[0169] Step 1 : Boc protected Intermediate 4 was prepared following the procedure described in Step 1 for Intermediate 1 using tert-butyl (4-(3- oxopropyl)phenyl)carbamate (Reference: WO 2012/177061, CN 103649199 A) in place of tert-butyl (4-formylphenyl)carbamate. The reaction was directly purified by prep-TLC (EA: MeOH = 10:1, Rf = 0.4) to give Boc-protected Intermediate 4 (0.18 g, 60% yield, 95% purity). LCMS (ESI+) m/z 522.3 [M+H]+. RT: 0.578 min. 1 H NMR (400 MHz, DMSO-d6) 8 10.75 (s, 1H, NH), 9.22 (br s, 1H, NH), 7.35 (br d, J - 8.1 Hz, 2H), 7.09 (br d, J - 8.1 Hz, 2H), 6.76 (br d, J = 8.6 Hz. 2H), 6.61 (br d. J = 8.6 Hz, 2H), 5.41 (br s, 1H), 4.19 (ddd, J = 10.2, 6.8, 4.8 Hz, 1H), 3.04 - 2.82 (m, 4H), 2.79 - 2.65 (m, 3H), 2.63 - 2.57 (m, 1H), 2.57 - 2.48 (m, 6H), 2.15 - 2.05 (m, 1H), 1.89 - 1.64 (m, 3H), 1.46 (s, 9H).
[0170] Step 2: Intermediate 4 was prepared following the procedure described in Step 2 for Intermediate 1. The mixture was concentrated under reduced pressure at 40 °C to give a product. The product was used to next step without further purification. Intermediate
4, 3-((4-(4-(3-(4-aminophenyl)propyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione, was obtained (81.0 mg, 192 pmol, 56% yield, 95% purity). LCMS (ESI+) m/z 422.2 [M+H]+, RT: 0.152 min. ’ H NMR (400 MHz, DMSO-d6) 8 10.75 (s, 1H. NH), 6.84 (d. J = 8.2 Hz, 2H), 6.74 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 6.47 (d, J = 8.2 Hz, 2H), 5.36 (d, J = 7.2 Hz, 1H), 4.79 (br s, 2H, NH2), 4.18 (ddd, J = 11.3, 6.9, 4.9 Hz, 1H), 3.00 - 2.86 (m, 4H), 2.72 (ddd, J = 17.5, 11.8. 5.6 Hz, 1H). 2.57 (ddd. J = 17.5, 4.2, 4.2 Hz. 1H). 2.47 (br s. 4H). 2.42 (br t, J - 7.6 Hz, 2H), 2.35 - 2.24 (m, 2H), 2.10 (ddd, J = 13.3, 8.7, 4.4 Hz, 1H), 1.83 (ddd, J = 24.2, 11.5, 4.4 Hz, 1H), 1.66 (ddd, J = 14.5, 7.4, 7.4 Hz, 2H).
[0171] Step 1: To a mixture of l-bromo-3-nitrobenzene (0.500 g, 2.48 mmol) in toluene (8 mL) were added tert-butyl /V-(4-pipcrazin- l-ylphcnyl)carbamatc (Reference: WO 2001/97810, page 41, 824 mg, 2.97 mmol), BINAP (154 mg, 248 pmol), Pd(OAc)2 (55.6 mg, 248 pmol) and Cs2COs (1.61 g, 4.95 mmol) at 20 °C. The reaction was stirred at 100 °C for 12 h under N2. LCMS showed that the starting material was consumed and the desired product was detected. The mixture was poured into H2O (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (5 x 10 mL), dried over anhydrous Na2SO4 and filtrated. The filtrate was concentrated under reduced pressure to give crude product. The crude product was purified by prep-TLC (PE: EA = 0: 1, Rf = 0.5) to give tert-butyl A-[4-[4-(3-nitrophenyl)piperazin-l-yl]phenyl]carbamate, the precursor of Intermediate 5 (0.700 g. 54% yield, 76% purity). LCMS (ESI+) m/z 399.2 [M+H]+, RT: 0.672 min. ’H NMR (400 MHz, DMSO-d6) 8 9.07 (br s, 1H, NH), 7.73 - 7.68 (m, 1H), 7.61 (ddd, J = 7.2, 2.0, 2.0 Hz. 1H), 7.54 - 7.43 (m, 2H), 7.32 (br d, J = 8.8 Hz. 2H), 6.92 (d, J = 8.8 Hz, 2H), 3.45 - 3.38 (m, 4H), 3.23 - 3.16 (m, 4H), 1.46 (s, 9H).
[0172] Step 2: To a solution of the product of Step 1 (0.700 g, 1.34 mmol 76% purity) in THF (10 mL) was added Pd/C (285 mg, 268 pmol, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 25 °C for 12 h. LCMS showed the reaction was completed the starting material consumed and the desired product was detected. The mixture was filtered and the filtrate was concentrated to give Intermediate 5, tert-butyl A-[4-[4-(3- aminophenyl)piperazin-l-yl] phenyl]carbamate (0.500 g, 91% yield, 90.15% purity). LCMS (ESI+) m/z 369.3 [M+H]+, RT: 0.863 min.
[0173] Step 1: To a mixture of Intermediate 5 (0.500 g, 1.36 mmol, 90.15% purity) in dioxane (6 mL) were added 3-bromopiperidine-2, 6-dione (313 mg, 1.63 mmol), DIEA (351 mg, 2.71 mmol) and Nal (40.7 mg, 271 pmol). The mixture was stirred at 100 °C for 12 h under N2. LCMS showed the reaction was completed the starting material consumed and the desired product was detected. The mixture was poured into H2O (30 mL). The mixture was extracted with DCM (3 x 30 mL). The organic phase was washed with brine (3 x 30 mL), dried over anhydrous Na2SO4 and filtrated. The filtrate was concentrated under reduced pressure to give Boc-protected Intermediate 6 (0.30 g, 43.54% yield, 85.15% purity). LCMS (ESI+) m/z 480.3 [M+H]+, RT: 0.853 min.
[0174] Step 2: A mixture of Boc-protected Intermediate 6 (0.500 g, 888 pmol, 85.15% purity) in DCM (10 mL) and TFA (1 mL) was stirred at 20 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into NaHCCL solution (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (5 x 10 mL), dried over anhydrous IShrtSCL and filtrated. The filtrate was concentrated under reduced pressure to give Intermediate 6,
3-((3-(4-(4-aminophenyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione (0.25 g, 37% yield, 50.47% purity) and used for next step reaction without further purification. LCMS (ESI+) m/z 380.2 [M+H]+, RT: 0.685 min.
[0175] Step 1: To a solution of [l-(4-aminophenyl)-4-piperidyl]methanol (Reference: WO 2021/127561, 1.00 g, 4.65 mmol, 95.97% purity) and 3-bromopiperidine- 2, 6-dione (893 mg, 4.65 mmol) in DMF (15.0 mL) was added NaHCOs (782 mg, 9.30 mmol) at 25 °C. The reaction was stirred at 60 °C under N2 for 2 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 3: 1 to 0: 1) to give 3-[4-[4- (hydroxymethyl)-l-piperidyl]anilino]piperidine-2, 6-dione (0.978 g, 3.02 mmol, 65% yield, 98.16% purity). LCMS (ESI+) m/z 318.2 [M+H]+, RT: 0.617 min.
NMR (400 MHz, DMSO-d6) 5 10.75 (s, 1H, NH), 6.75 (d, J = 8.9 Hz, 2H), 6.59 (d, J = 8.9 Hz, 2H), 5.35 (d, J = 7.2 Hz, 1H), 4.44 (t, J = 5.3 Hz, 1H), 4.18 (ddd, J = 11.3, 7.0, 4.8 Hz, 1H), 3.38 (br d, J = 11.9 Hz, 2H), 3.28 (t, J = 5.8 Hz, 2H), 2.79 - 2.66 (m, 1H), 2.62 - 2.53 (m, 1H), 2.48 - 2.40 (m, 2H), 2.15 - 2.05 (m, 1H), 1.89 - 1.77 (m, 1H), 1.72 (br d, J = 10.8 Hz, 2H), 1.48 - 1.34 (m, 1H), 1.23 (dq, J = 12.0, 4.1 Hz, 2H).
[0176] Step 2: To a mixture of 3-[4-[4-(hydroxymethyl)-l- piperidyl]anilino]piperidine-2, 6-dione (0.700 g, 2.16 mmol, 98.16% purity) in DCM (12.0 mL) were added TEA (2.19 g, 21.65 mmol,), pyridine; sulfur trioxide (2.21 g, 13.9 mmol) and DMSO (1.69 g, 21.7 mmol). The reaction was stirred at 25 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The reaction was extracted with DCM (3 x 60 mL). The organic layer was dried over NaiSCL. After filtered, the filtrate was concentrated under reduced pressure to give Intermediate 7, l-(4-((2,6-
dioxopiperidin-3-yl)amino)phenyl)piperidine-4-carbaldehyde (0.35 g, 31 % yield, 60.12% purity). LCMS (ESI+) m/z 316.2 [M+H]+, RT: 0.677 min.
Intermediate 8
(7?)-2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5/7-cyclopenta[Z>]pyridin-2-yl)-6-((4-
[0177] Step 1: In a 125 mL round bottom flask, (R)-2-allyl-l-(7-ethyl-7 -hydroxy - 6,7-dihydro-5H-cyclopenta[Z>]pyridin-2-yl)-6-(methylthio)-l/7-pyrazolo[3,4-d]pyrimidin- 3(2H)-one (Reference: WO 2019/173082 Al) and cooled to 0 °C. m-CPBA (616 mg, 2.75 mmol) was slowly added to the flask. The reaction was continued at room temperature (rt) for 1 h, then cooled back to 0 °C. tert-Butyl 4-(4-aminophenyl)piperazine-l -carboxylate (832 mg, 3.00 mmol) and DIEA (2.183 mL, 12.50 mmol) were added to the mixture. The reaction was continued at rt for 16 h. Water (30 mL) was added to the mixture and extracted with EtOAc (2 x 50 mL). The combined organic layer washed with saturated aq. NaHCCh solution and brine, dried over sodium sulfate and evaporated to obtain a black residue, which was then purified by silica gel column chromatography using Combi-Flash eluting with DCM-MeOH (0-10%). Pure product fractions combined and evaporated to give (R)-tert-butyl 4-(4-((2- allyl-l-(7-cthyl-7 -hydroxy-6, 7-dihydro-5//-cyclopcnta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro- l/7-pyrazolo[3,4-<7]pyrimidin-6yl) amino )phenyl)piperazine-l -carboxylate (1.15 g, 1.88 mmol, 75 % yield). LC/MS (ESI+) mA 613.4 [M+H]+.
[0178] Step 2: In a 25 mL round bottom flask, the product of Step 1 (225 mg, 0.367 mmol) was dissolved in dichloromethane (3 mL) and cooled to 0 °C. 2N HC1 in ether ( 1 mL) was added to the mixture and the reaction was continued at this temperature for 3 h. The reaction was quenched with cold sat. NaHCO aqueous solution and extracted with dichloromethane (3 15 mL). The combined organic layer was washed with brine, dried over sodium sulfate and evaporated. The resulting residue was purified on silica gel column
chromatography using dichloromethane-MeOH (0-100%). The product fractions were combined and evaporated to give Intermediate 8, (R)-2-allyl-l-(7-cthyl-7-hydroxy-6,7- dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(piperazin-l-yl)phenyl)amino)-lH- pyrazolo[3,4-d]pyrimidin-3(2H)-one, (150 mg, 0.293 mmol, 80 % yield). LC/MS (ESI+) m/z 513.41 [M+H]+.
[0179] Step 1: To a stirred solution of tert-butyl 4-aminopiperidine-l -carboxylate (1.09 g, 5.45 mmol) and l-(4-nitrophenyl)piperidin-4-one (1.00 g, 4.54 mmol) in 1,2- Dichloroethane (10 mL) at 0 °C, acetic acid (2.5 mL) was added dropwise, and the reaction was stirred at rt for 2 h. To this mixture at 0 °C, sodium triacetoxyborohydride (2.41 g, 11.4 mmol) was added portionwise and the mixture was allowed to stir at rt for an additional 16 h. After completion, the mixture was diluted with DCM (100 mL) and washed with water (2 x 50 mL) and brine (50 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to get the crude compound. The crude was purified by combi-flash chromatography (silica gel) using 0 to 5% methanol in DCM as eluting solvent to get tertbutyl 4-((l-(4-nitrophenyl)-2V-piperidin-4-yl)amino)piperidine-l -carboxylate (1.05 g, 57%). LC/MS (ESI+) m/z 405.42 [M+H]+. }H NMR (400 MHz. CDCL) 5 8.11 (d. J = 9.5, Hz. 2H), 6.82 (d, J = 9.5 Hz, 2H), 5.65 (br s, 1H), 4.14 (br s, 2H), 3.98 (br d, J = 13.2 Hz, 2H), 3.18 - 3.08 (m, 1H), 3.07 - 2.94 (m, 3H), 2.84 - 2.70 (m, 2H), 2.20 - 2.09 (m, 2H). 2.07 - 1.94 (m, 2H), 1.82 - 1.68 (m, 2H), 1.67 - 1.50 (m, 2H), 1.45 (s, 9H).
[0180] Step 2 : To a stirred solution of tert-butyl 4-((l-(4-nitrophenyl)-2V- piperidin-4-yl)amino)piperidine-l -carboxylate (1.30 g, 3.21 mmol) in DCM (13 mL) at 0 °C, trifluoroacetic acid (5 mL) was added drop wise and the mixture was stirred at rt for 2 h. After completion, the mixture was concentrated under vacuum to get the residue, which was washed with diethyl ether (10 mL). The resulting product was dissolved in 20% MeOH
in DCM (100 mL) and washed with saturated NaHCCh solution (2 x 100 mL) and brine solution (100 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to get l-(4-nitrophenyl)-N-(piperidin-4-yl)piperidin-4-amine (0.900 g, 92%). LC/MS (ESI+) m/z 305.15 [M+H]+. ’ H NMR (400 MHz, CDC13) 5 ’ H NMR (400 MHz, CDCI3) 88.10 (d, J = 9.6 Hz, 2H), 6.81 (d, J = 9.6 Hz, 2H), 3.92 (br d, J = 13.2 Hz, 2H), 3.16 (br d, J = 12.8 Hz. 2H). 3.09 - 2.97 (m, 2H), 2.97 - 2.86 (m. 1H), 2.79 - 2.62 (m, 3H). 2.02 - 1.86 (m, 4H), 1.48 - 1.35 (m, 2H), 1.35 - 1.22 (m, 2H).
Intermediate 10
[0181] Step 1: To a stirred solution of Intermediate 9 (800 mg, 2.63 mmol), methyl 2-(4-bromophenyl)acetate (783 mg, 3.42 mmol) in 1,4-Dioxane (10 mL) at rt, tripotassium phosphate (1.67 g, 7.87 mmol) was added and the mixture degassed with nitrogen gas for 15 minutes. To this mixture, tris(dibenzylideneacetone)dipalladium(0) (241 mg, 0.263 mmol) and X-Phos (125 mg, 0.263 mmol) were added. The mixture was stirred at 120 °C for 16 h. After completion, the mixture was diluted with ice cold 10% aq. AcOH (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over sodium sulphate, filtered and concentrated under reduced pressure to get the crude product . The crude was purified by combi-flash chromatography (silica gel, column 40 g) using 0 to 7% MeOH in DCM as an eluent to get methyl 2-(4-(4-((l-(4-nitrophenyl)piperidin-4- yl)amino)piperidin-l-yl)phenyl)acetate (705 mg, 59%). LC/MS (ESI+) m/z 453.67 [M+H]+. 1 H NMR (400 MHz, CDCh) 8 8.11 (d, J - 9.2 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H), 6.88 (d, J - 8.4 Hz, 2H), 6.81 (d, J = 9.6 Hz, 2H), 3.67 (s, 3H), 3.66 (d. J = 13.2 Hz, 2H), 3.54 (s, 2H), 3.07-2.88 (m, 5H), 2.77-2.70 (m, 2H), 2.10-2.04 (m, 4H), 1.67-1.62 (m, 4H).
[0182] Step 2: To a stirred solution of methyl 2-(4-(4-((l-(4- nitrophcnyl)pipcridin-4-yl)amino)pipcridin-l-yl)phcnyl)acctatc from Step 1 (0.6 g, 1.326 mmol) in DMF (6 mL) at -10 °C, acrylamide (0.104 g, 1.46 mmol) and Potassium tert- butoxide (IM solution in THF, 1.46 mL, 1.46 mmol) were added. The mixture was mixture at -10 °C to 0 °C for 2 h. The progress of reaction was monitored by TLC. After completion, the reaction was quenched with water (100 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 5% MeOH in DCM as eluent to get 3-(4-(4-((l-(4-nitrophenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2,6- dione (0.355 g, 54%). LC/MS (ESI+) m/z 492.75 [M+H]+.
[0183] Step 3: To a stirred solution of 3-(4-(4-((l-(4-nitrophenyl)piperidin-4- yl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione from Step 2 (0.250 g, 0.509 mmol) in MeOH (3 mL) under nitrogen atmosphere in a 100 mL round bottom flask, 10% Palladium on activated carbon (50% wet, 0.250 g) was added and the mixture was hydrogenated at rt for 16 h using hydrogen balloon. Upon completion, the reaction mixture was filtered through Celite pad and the filtrate was concentrated under reduced pressure to give Intermediate 10, 3-(4-(4-((l-(4-aminophenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2,6- dione (0.160 g, 68%). LC/MS (ESI+) m/z 462.33
8 10.77 (s, 1H), 8.82 (br s, 2H), 7.06 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H), 6.58 (d, J = 8.4 Hz, 2H), 5.59 (br s, 1H), 3.85 - 3.70 (m, 3H), 3.69 - 3.55 (m, 1H), 3.44 (br d, J = 11.6 Hz, 2H), 3.19 - 3.09 (m, 1H). 2.76 (t, J = 12.0 Hz, 2H), 2.70 - 2.55 (m, 3H), 2.19 - 1.95 (m, 5H), 1.79 - 1.60 (m, 4H), 1.30 - 1.18 (m, 2H).
Intermediate 11 N02
[0184] To a stirred solution of tert-butyl 4-((l-(4-nitrophenyl)piperidin-4- yl)mcthyl)pipcrazinc- 1 -carboxylate (Reference: US 2018/0099940, 3.10 g, 7.66 mmol) in DCM (30 mL) at 0 °C, trifluoroacetic acid (6 mL) was added dropwise and stirred the mixture at rt for 2 h. After completion, the mixture was concentrated under vacuum to get the crude product, which was washed with diethyl ether (25 mL). The resulting product was redissolved in 20% MeOH in DCM (200 mL) and washed with saturated NaHCCL solution (2 x 100 mL) and brine solution (100 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to get Intermediate 11, l-((l-(4-nitrophenyl)piperidin-4- yl)methyl)piperazine (2.05 g, 87%). LCMS (ESI+) m z 305.31 [M+H]+. 'H NMR (400 MHz, CDC13) 88.17 (d, J = 9.4 Hz, 2H), 6.86 (d, J = 9.4 Hz, 2H), 4.02 (br d, J = 12.8 Hz, 2H), 3.06 - 2.96 (m, 6H). 2.47 (br s. 4H), 2.26 (d, J = 6.8 Hz. 2H), 2.03 - 1.93 (m, 3H), 1.38 - 1.27 (m, 2H).
Intermediate 12 3-(4-(4-((l-(4-aminophenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)piperidine-2,6- dione (FIG. 14)
[0185] Intermediate 12 was prepared by following the similar- procedure described in Intermediate 10 using Intermediate 11 (1.000 g, 3.285 mmol) in place of Intermediate 9, afforded Intermediate 12, 3-(4-(4-((l-(4-aminophenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)piperidine-2,6-dione (51%, 46% and 53% for three steps). LCMS (ESI+) m/z 462.57 [M+H]+.
Intermediate 13
[0186] Intermediate 13 was prepared by following the similar procedure described in Intermediate 12 Step 2 using methyl 2-(4-(4-((terr- butoxycarbonyl)amino)piperidin-l-yl)phenyl)acetate (Reference: US 2016/0068512, 1.00 g, 2.87 mmol) to afford the Boc-protcctcd Intermediate 13. The Boc group was removed by standard TFA/DCM procedure to give Intermediate 13, TFA salt of 3-(4-(4-aminopiperidin- l-yl)phenyl)piperidine-2, 6-dione (49% and 99% for two steps). LCMS (ESI+) mJz 288.47 [M+H]+.
Intermediate 14
3-(4-(4-(((l-(4-aminophenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine- 2,6-dione (FIG. 16)
[0187] Step 1: To a stirred solution of Intermediate 13 TFA salt (540 mg, 1.40 mmol) and l-(4-nitrophenyl)piperidine-4-carbaldehyde (Reference: US 2021/0087170 P54 for similar procedure, 328 mg, 1.40 mmol) in DCE (10 mL) at rt, acetic acid (0.1 mL) was added. The mixture was stirred at rt for 1 h. To this mixture at 0 °C, NaBH(OAc)3 (595 mg, 2.80 mmol) was added and the resulting mixture was stirred at rt for 16 h. The reaction was quenched with water (35 mL) and extracted with dichloromethane (2 x 50 mL). The organic
layer was washed with water (20 mL) and saturated sodium bicarbonate solution (20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel flash chromatography using 0 to 60% MeOH in DCM as eluent to get 3-(4-(4-(((l-(4-nitrophenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl) piperidine-2, 6-dione (460 mg, 65%). LCMS (ESI+) m z 506.59 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 5 10.77 (s. 1H, NH), 8.32 (br s. 1H, NH), 8.05 (d. J = 9.6 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 7.04 (d, 7 - 9.6 Hz, 2H), 6.92 (d, J= 8.8 Hz, 2H), 4.08 (br d, 7 - 10.6 Hz, 2H), 3.81 (br d, J = 12.0 Hz. 2H), 3.75 - 3.60 (m, 1H), 3.30 - 3.15 (m, 1H), 3.00 (t, J = 11.6 Hz, 2H), 2.89 (br s, 2H), 2.74 (t, 7= 12.0 Hz, 2H), 2.70 - 2.58 (m, 1H), 2.54 - 2.45 (m, 1H), 2.20 - 2.05 (m, 1H), 2.05 - 1.88 (m, 4H), 1.84 (br d, 7 = 13.2 Hz, 2H), 1.67 - 1.50 (m, 2H), 1.30 - 1.20 (m, 2H).
[0188] Step 2: To a stirred solution of 3-(4-(4-(((l-(4-nitrophenyl)piperidin-4- yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (0.202 g, 0.4 mmol) in MeOH (10.1 mL) under nitrogen atmosphere, 10% palladium on carbon (50% wet, 0.170 g) was added at rt and the mixture was hydrogenated using hydrogen balloon at rt for 2 h. Progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was filtered through a celite bed and washed with MeOH (10 mL). The filtrate was concentrated under reduced pressure to afford Intermediate 14, 3-(4-(4-(((l-(4- aminophenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2,6- dione (190 mg, 99%). LCMS (ESI+) m/z 476.63 [M+H]+.
Intermediate 15
[0189] Step 1: Intermediate 15 was prepared by following the similar procedure described in Intermediate 13 using methyl 2-(4-(2-((tert- butoxycarbonyl)amino)ethoxy)phenyl)acetate (Reference: WO 2019/243576, 1.20 g, 3.88 mmol) in place of methyl 2-(4-(4-((fert-butoxycarbonyl)amino)piperidin-l-
yl)phenyl)acetate to afford Boc-protected Intermediate 15, tert-butyl (2-(4-(2,6- dioxopipcridin-3-yl)phcnoxy)cthyl)carbamatc (0.740 g, 55%). LCMS (ESI+) m/z 347.07 [M- H] . ’H NMR (400 MHz. CDC13) 5 10.78 (s, 1H. NH). 7.12 (d, J = 8.4 Hz. 2H). 6.99 (br t, J = 6.2 Hz, 1H), 6.88 (d, J = 8.4 Hz, 2H), 3.94 (t, J = 6.0 Hz, 2H), 3.78 (dd, J = 11.4, 5.0 Hz, 1H), 3.34 - 3.24 (m, 2H), 2.72 - 2.58 (m, 1H). 2.52 - 2.45 (m, 1H), 2.23 - 2.10 (m, 1H), 2.07 - 1.98 (m, 1H). 1.38 (s, 9H).
[0190] Step 2: The Boc group was taken off by standard TFA/DCM procedure to give Intermediate 15, TFA salt of 3-(4-(2-aminoethoxy)phenyl)piperidine-2, 6-dione (97%). LCMS (ESI+) m/z 249.24 [M+H]+.
Intermediate 16
[0191] Intermediate 16 was prepared by following the same procedure described in Intermediate 14 using Intermediate 15 (0.500 g, 2.01 mmol) in place of Intermediate 13, afforded Intermediate 16, 3-(4-(2-(((l-(4-aminophenyl)piperidin-4-yl)methyl)amino) ethoxy )phenyl)piperidine-2, 6-dione, (0.21 g, 42% and 56% for two steps). LCMS (ESI ) m/z 435.45 [M-H]-.
Intermediate 17
3-(4-((l-((l-(4-aminophenyl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)phenyl)piperidine-
2,6-dione (FIG. 19)
[0192] Intermediate 17 was prepared by following the same procedure described in Intermediate 14 using 3-(4-(pipcridin-4-yloxy)phcnyl)pipcridinc-2,6-dionc (0.250 g, 0.867 mmol) in place of Intermediate 13, afforded Intermediate 17, 3-(4-((l-((l-(4- aminophenyl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)phenyl) piperidine-2, 6-dione, (0.18 g, 57% and 74% for two steps). LCMS (ESI+) m z 477.65 [M+H]+.
Intermediate 18
[0193] Step 1 : To a mixture of 3 -bromopiperidine-2, 6-dione (0.500 g, 2.60 mmol) in DMF (5 mL) were added 4-piperidylmethanol (330 mg, 2.86 mmol) and DIEA (673 mg, 5.21 mmol) at 20 °C. Then the mixture was stirred at 80 °C for 12 h under N2. LCMS showed the starting material consumed and the desired product was detected. The mixture was filtered and the filtrate was purified by prep-HPLC (NH4HCO3 Condition) to afford 3-[4- (hydroxymethyl)-l-piperidyl]piperidine-2, 6-dione (0.250 g, 37% yield, 87.62% purity). LCMS (ESI+) m/z 227.2 [M+H]+, RT: 0.496 min. ’H NMR (400 MHz, DMSO-d6) 8 10.54 (br s, 1H, NH), 4.38 (br s, 1H, OH), 3.40 - 3.34 (m, 2H), 3.26 - 3.18 (m, 2H), 2.82 - 2.70 (m, 2H), 2.59 - 2.50 (m, 2H), 2.40 - 2.30 (m, 1H). 2.06 - 1.93 (m, 1H), 1.88 - 1.79 (m, 1H), 1.66 - 1.55 (m, 2H), 1.39 - 1.25 (m, 1H), 1.14 - 1.01 (m, 2H).
[0194] Step 2: To a mixture of 3-[4-(hydroxymethyl)-l-piperidyl]piperidine-2,6- dione from Step 1 (0.250 g, 968 pmol, 87.62% purity) in DCM (3 mL) were added TEA (980 mg, 9.68 mmol), pyridine- sulfur trioxide (986 mg, 6.20 mmol) and DMSO (756 mg, 9.68 mmol) at 0 °C. The mixture was stirred at 40 °C for 1 h under N2. LCMS showed the starting material consumed and the desired product was detected. The mixture was poured into H2O (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (5 mL), dried over anhydrous Na2SO4, concentrated in vacuum to give Intermediate 18, l-(2,6-dioxo-3-piperidyl)piperidine-4-carbaldehyde (0.150 g, 68% yield, 98.30% purity). LCMS (ESI+) m/z 225.2 [M+H]+, RT: 0.513 min.
Intermediate 19
[0195] Step 1: To a mixture of Intermediate 18 (0.150 g, 658 pmol, 98.30% purity) in DCM (5 mL) were added tert-butyl A-(4-piperazin-l-ylphenyl)carbamate (182 mg. 658 pmol) and NaBH(OAc)3 (279 mg, 1.32 mmol) at 0 °C. The mixture was stirred at 20 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into H2O (10 mL). The mixture was extracted with DCM (3 x 10 mL). The organic phase was washed with brine (10 mL), dried over anhydrous NaiSCL, concentrated in vacuum to give Boc-protected Intermediate 19, rert-butyl (4-(4- ((2',6'-dioxo-[l,3'-bipiperidin]-4-yl)methyl) piperazin- l-yl)phenyl)carbamate (0.400 g, 44% yield). The crude product was used in the next step without purification. LCMS (ESI+) m/z. 486.3 [M+H]+, RT: 1.739 min.
[0196] Step 2: Standard TFA/DCM Boc deprotection was used. The residue was purified by Prep-TLC (EA: MeOH = 3: 1, Rf = 0.4) to afford pure Intermediate 19, 3-((4-(4- aminophenyl)piperazin-l-yl)methyl)-[l,3'-bipiperidine]-2',6'-dione (0.120 g, 71% yield). LCMS (ESI+) m/z 386.2 [M+H]+, RT: 1.134 min.
Intermediate 21
[0197] Step 1: To a solution of l-bromo-3 -nitrobenzene (250 mg, 1.24 mmol) in toluene (8.0 mL) was added 4-piperidylmethanol (171. mg, 1.49 mmol), CS2CO3 (807 mg, 2.48 mmol), BINAP (77.1 mg, 124 pmol) and Pd(OAc)2 (27.8 mg, 124 pmol) at 25 °C in the glove box. The mixture was stirred at 100 °C for 12 h. LCMS showed the starting material
was consumed and main product with desired MS was detected. Seven additional reactions were set up as detailed above. After cooling to rt, all eight reaction mixtures were combined. The reaction solution was filtered through celite and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by MPLC (Biotage, SiO2): (eluting with PE:EA = 1:0 to 2:1) to give (l-(3-nitrophenyl)piperidin-4-yl)methanol (0.900 g, 3.51 mmol. 35% yield, 92.14% purity). LCMS (ESI+) m/z 237.1 [M+H]+. RT: 0.587 min. ’H NMR (400 MHz, CDC13) 87.73 (t, 7 - 2.2 Hz, 1H), 7.63 (dd, J= 8.2, 1.6 Hz, 1H), 7.36 (t, J = 8.2 Hz, 1H), 7.21 (dd, J = 8.2, 2.0 Hz, 1H). 3.87 - 3.78 (m, 2H), 3.58 (d, J = 6.3 Hz, 2H), 2.85 (td, J = 12.4, 2.4 Hz, 2H), 1.90 (br d, 7 = 13.4 Hz, 2H), 1.80 - 1.67 (m, 1H), 1.41 (qd, J = 12.2, 4.4 Hz, 2H).
[0198] Step 2: To a solution of (l-(3-nitrophenyl)piperidin-4-yl)methanol from Step 1 (0.900 g, 3.51 mmol, 92.14% purity) in THF (30.0 mL) was added Pd/C (369 mg, 351 pmol, 10% purity, 10% Pd on charcoal, wet, containing 50% water) at 25 °C. The mixture was degassed with hydrogen for three times and then stirred at 25 °C for 12 h under H2 (15 psi). LCMS showed the starting material was consumed and main product with desired MS was detected. The reaction solution was filtered through celite and the filtrate was concentrated under reduced pressure to give Intermediate 21, (l-(3-aminophenyl)piperidin- 4-yl)methanol, (0.500 g, 2.09 mmol, 59% yield, 86.03% purity). The crude product was used for the next step directly without purification. LCMS (ESI+) m/z 207.1 [M+H]+, RT: 0.477 min. XH NMR (400 MHz, DMSO-d6) 8 6.81 (t, 7= 7.9 Hz, 1H), 6.14 (d, 7= 1.6Hz, 1H), 6.1O (dd, 7 = 7.9, 1.6 Hz, 1H), 5.99 (dd, 7 = 7.9, 1.4 Hz, 1H), 4.69 (br s, 2H, NH2), 3.56 (br d, 7 = 12.3 Hz, 2H), 3.27 (d. 7 = 6.2 Hz, 2H), 2.54 (td, 7 = 12.0. 2.0 Hz, 2H), 1.70 (br d, 7 = 12.1 Hz, 2H), 1.54 - 1.40 (m, 1H), 1.19 (qd, 7 = 12.2, 3.8 Hz, 2H).
[0199] Intermediate 22 was prepared by following the similar procedure described in Intermediate 7 using Intermediate 21 (0.500 g, 2.09 mmol, 86.03% purity) in
place of [l-(4-aminophenyl)-4-piperidyl]methanol, to afford 1 -(3-((2,6-dioxopiperidin-3- yl)amino)phcnyl)pipcridinc-4-carbaldchydc, with yields at 46% and 26% for Step 1 and Step 2 respectively.
[0200] Analytical data for Step 1 product: LCMS (ESI+) m/z 318.2 [M+H]+, RT: 0.315 min. ’H NMR (400 MHz, CDC13) 8 8.08 (br s. 1H), 7.11 (t, J = 8.1 Hz, 1H), 6.45 (dd, J = 8.4. 2.0 Hz, 1H), 6.29 (t, J = 2.1 Hz. 1H). 6.17 (dd, J = 8.0. 2.0 Hz. 1H). 4.67 (br s. 1H). 4.09 (dd, J = 12.0, 4.4 Hz, 1H), 3.69 (br d, J - 12.3 Hz, 2H), 3.55 (d, J = 6.4 Hz, 2H), 2.91 - 2.83 (m, 1H), 2.81 - 2.68 (m, 3H), 2.62 - 2.53 (m, 1H), 1.90 (qd, J = 13.0, 4.8 Hz. 1H), 1.85 (br d, J = 12.3 Hz, 2H), 1.69 - 1.62 (m, 1H), 1.40 (qd, J = 12.2, 4.0 Hz, 2H).
[0201] Analytical data for Intermediate 22: LCMS (ESI+) m/z 316.2 [M+H]+, RT: 1.357 min.
Intermediate 23 te/7-butyl 6-(4-(2,6-dioxopiperidin-3-yl)phenyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate
[0202] Step 1: To a solution of 2,6-bisbenzyloxy-3-bromo-pyridine (5.000 g, 13.50 mmol) in dioxane (100 mL) were added (4-boronophenyl)boronic acid (4.500 g, 27.01 mmol), Pd(dppf)Cl2 (1.50 g, 2.03 mmol), H2O (20 mL), K2CO3 (5.700 g, 27.01 mmol) at 25 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with EA (3 x 10 mL). The organic combined organic layers were washed with brine (3 x 10 mL) and dried over NaiSCL. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 35: 1) to give [4-(2,6- bisbenzyloxy-3-pyridyl)phenyl]boronic acid (2.0 g, 26% yield, 71.76% purity). LCMS (ESI+) m/z 412.2 [M+H]+, RT: 0.977 min. 'H NMR (400 MHz, DMSO-d6) 8 8.03 (s, 2H), 7.80 (d, J
= 8.2 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 8.2 Hz, 2H), 7.46 - 7.42 (m, 2H), 7.41 - 7.29 (m, 8H), 6.56 (d, J= 8.1 Hz, 1H), 5.48 (s, 2H), 5.39 (s, 2H).
[0203] Step 2: To a solution of the boronic acid from Step 1 (2.00 g, 3.49 mmol, 71.76% purity) in DCM (40 mL) were added tert-butyl 2,6-diazaspiro[3.3]heptane-2- carboxylate (346 mg, 1.74 mmol) and TEA (1.40 g, 13.8 mmol), Cu(OAc)z (634 mg, 3.49 mmol,) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was diluted with water (10 mL) and extracted with EA (3 x 10 mL). The organic combined organic layers were washed with brine (3 x 10 mL) and dried over Na2SO4. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 20: 1) to give tert-butyl 6-[4-(2,6- bisbenzyloxy-3-pyridyl)phenyl]-2,6-diazaspiro[3.3]heptane-2-carboxylate (400 mg, 19% yield, 93.02% purity). LCMS (ESI+) m/z 564.3 [M+H]+, RT: 1.110 min. 'H NMR (400 MHz, DMSO-d6) 87.64 (d, J = 8.1 Hz, 1H), 7.45 - 7.26 (m, 12H), 6.50 (d, J= 8.1 Hz, 1H), 6.44 (d, J = 8.7 Hz. 2H), 5.38 (s. 2H). 5.35 (s, 2H). 4.02 (br s. 4H). 3.93 (s, 4H). 1.38 (s, 9H).
[0204] Step 3: To a solution of the product from Step 2 (400.0 mg, 660 pmol, 93.02% purity) in THF (10 mL) were added Pd/C (10%, 66 mg, 62 pmol) at 25 °C. The reaction was stirred at 25 °C under H2 atmosphere (15 psi) for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was filtered and the filter cake was washed with THF (20mL), the collected filtrate was concentrated to give Intermediate 23, tert-butyl 6-(4-(2,6-dioxopiperidin-3-yl)phenyl)-2,6- diazaspiro[3.3]heptane-2-carboxylate (250.0 mg, 84% yield, 85.44% purity). LCMS (ESI+) m/z 386.2 [M+H]+, RT: 0.793 min.
Intermediate 24
3-(4-(6-((l-(4-aminophenyl)piperidin-4-yl)methyl)-2,6-diazaspiro[3.3]heptan-2- yl)phenyl)piperidine-2, 6-dione (FIG. 25)
[0205] Step 1 for the preparation of Intermediate 24 was Boc deprotection of Intermediate 23 under standard TFA/DCM condition with yield 98% and 86.25% purity. LCMS (ESI+) m/z 286.2 [M+H]+, RT: 0.516 min.
[0206] Step 2 for the preparation of Intermediate 24 was followed the same procedure described in Intermediate 14 using de-Boc Intermediate 23 from Step 1 (180 mg, 544 pmol, 86.25% purity in place of Intermediate 13, to react with tert-butyl (4-(4- formylpiperidin-l-yl)phenyl)carbamate (Reference: WO 2007/075783) and afforded Boc- protected Intermediate 24 (200 mg, 46% yield, 71.01% purity). LCMS (ESI+) m/z 574.4 [M+H]+, RT: 0.865 min.
[0207] Step 3 for the preparation of Intermediate 24 was under standard TFA/DCM condition. The reaction was stirred at 25 °C for 12 h. LCMS showed the starting material consumed and the desired product was detected. The reaction was concentrated under reduced pressure to give Intermediate 24, 3-(4-(6-((l-(4-aminophenyl)piperidin-4- yl)methyl)-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)piperidine-2, 6-dione, (100 mg, 51% yield, 59.48% purity). LCMS (ESI+) m/z 474.3 [M+H]+, RT: 0.686 min.
Intermediate 25
[0208] Step 1: To a stirred solution of 4-(2,6-bis(benzyloxy)pyridin-3-yl)phenol (Reference: WO 2022/012622, 1 -30 g, 3.39 mmol), tert-butyl (4- hydroxybutyl)carbamate (0.962 g, 5.09 mmol) and triphenylphosphine (1.334 g, 5.085 mmol) in THF (10 mL) at 0 °C, Diisopropyl azodicarboxylate (1.028 g, 5.085 mmol) was slowly added and the mixture was stirred at rt for 16 h. After completion of reaction, water (10 mL) was added to quench the reaction. The mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL) and DCM (100 mL). After separating the phases, the aqueous phase was further extracted with DCM (100 mL) and the combined organic phase was concentrated under reduced pressure to get residue. The crude
product was purified by silica gel chromatography using 0 to 30% EtOAc in petroleum ether (PE) to obtain tert-butyl (4-(4-(2,6-bis(bcnzyloxy)pyridin-3- yl)phenoxy)butyl)carbamate (1.75 g, 93%). LCMS (ESI ) m/z 553.37 [M-H] .
[0209] Step 2: To a stirred solution of tert-butyl (4-(4-(2,6- bis(benzyloxy)pyridin-3-yl)phenoxy)butyl)carbamate from Step 1 (1.70 g, 3.07 mmol) in methanol (20 mL) under nitrogen atmosphere, 10% Palladium on activated carbon (50% wet, 0.5 g) was added and the resulting mixture was hydrogenated using hydrogen balloon for 16 h. The mixture was filtered through celite bed and celite bed was washed with EA (40 mL). The organic layer was concentrated to give crude compound. The crude compound was purified by silica gel flash chromatography using 0 to 50% EA in PE to get tert-butyl (4-(4- (2,6-dioxopiperidin-3-yl)phenoxy)butyl)carbamate (605 mg, 52%). LCMS (EST) m/z 375.19 [M-H]“. ’ H NMR (400 MHz, DMSO-d6) 5 10.78 (s, 1H), 7.11 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.84 (t, J = 5.2 Hz, 1H), 3.94 (t, J = 6.4 Hz, 2H), 3.78 (dd, J = 11.4, 5.0 Hz. 1H), 2.98 (q, J = 6.4 Hz, 2H). 2.71 - 2.58 (m, 1H), 2.52 - 2.43 (m, 1H), 2.22 - 2.10 (m, 1H), 2.06 - 1.96 (m, 1H), 1.73 - 1.63 (m, 2H), 1.57 - 1.47 (m, 2H), 1.37 (s, 9H).
[0210] Step 3: To a stirred solution of tert-butyl (4-(4-(2,6-dioxopiperidin-3- yl)phenoxy)butyl)carbamate (500 mg) in DCM from Step 2 at 0 °C, trifluoroacetic acid ( 1 mL) was added and the resulting mixture was stirred at it for 1 h. After completion of reaction, the mixture was concentrated under reduced pressure to give residue. The residue was triturated with EA (5 mL) to get TFA salt of Intermediate 25, 3-(4-(4- aminobutoxy)phenyl)piperidine-2, 6-dione (0.475 g, 95%). LCMS (ESI+) m/z 277.48 [M+H]+.
Intermediate 26
[0211] Intermediate 26 was prepared by following the same procedure described in Intermediate 14 using Intermediate 25 (TFA salt, 550 mg, 1.463 mmol) in place of Intermediate 13 to react with l-(4-nitrophenyl)piperidin-4-one, afforded Intermediate 26, 3-(4-(4-((l-(4-aminophenyl)piperidin-4-yl)amino)butoxy)phenyl)piperidine-2, 6-dione, (0.400 g, 57% and 88% for two steps).
[0212] Analytical data for Step 1 product: LCMS (ESI+) m/z 481.67 [M+H]+. !H NMR (400 MHz, DMSO-d6) 5 10.79 (s. 1H, NH), 8.05 (d, J = 9.4 Hz. 2H), 7.13 (d, J = 8.6 Hz, 2H), 7.06 (d, J = 9.4 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 4.15 - 4.02 (m, 2H), 3.98 (t, J = 6.2 Hz, 2H), 3.78 (dd, J = 11.2, 4.8 Hz, 1H), 3.14 - 3.02 (m, 3H), 2.91 - 2.79 (m, 2H). 2.70 - 2.60 (m, 1H), 2.55 - 2.44 (m, 1H), 2.22 - 2.10 (m, 1H), 2.04 - 1.94 (m, 3H), 1.82 - 1.72 (m, 2H), 1.72 - 1.59 (m, 2H), 1.49 - 1.35 (m, 2H).
[0213] Analytical data for Intermediate 26: LCMS (ESI ) m/z 449.48 [M-H]’.
Intermediate 27
3-[4-[4-(4-aminophenyl)piperazin-l-yl]phenyl] piperidine-2,6-dione (FIG. 28)
[0214] Step 1 : To a solution of [4-(2,6-dibenzyloxy-3-pyridyl)phenyl]boronic acid (1 g, 2.43 mmol) in DCM (20 mL) were added tert-butyl N-(4-pipcrazin-l- ylphenyl)carbamate (404.6 mg, 1.46 mmol), Cu(OAc)2 (441.6 mg, 2.43 mmol) and TEA (984.2 mg, 9.73 mmol) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The organic combined organic layers were washed with brine (3 xx 10 mL) and dried over NaoSCL. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 30: 1) to give tert-butyl N-[4-[4-[4-(2,6-dibenzyloxy-3-pyridyl)phenyl]piperazin-l- yl]phenyl] carbamate (400.3, mg, 12.19% yield, 47.62% purity) as a yellow solid. LCMS (ESI+) m/z 643.4 [M+H]+.
[0215] Step 2: To a solution of tert-butyl N-[4-[4-[4-(2,6-dibenzyloxy-3- pyridyl)phenyl]piperazin-l-yl] phenyl] carbamate (400.3 mg, 296.3 pmol) in THF (10 mL) were added Pd/C (6.28 mg, 29.634 pmol, 50% purity) at 25 °C. The reaction was stirred at 25 °C under H2 atmosphere (15 psi) for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was filtered and the filter cake was washed with THF (30 mL), the collected filtrate was concentrated to give tert-butyl N-[4-[4-[4-(2,6- dioxo-3-piperidyl)phenyl]piperazin-l-yl] phenyl] carbamate (160.0 mg, 99.43% yield, 67.11% purity) as a yellow solid. LCMS (ESI+) m/z 465.3 [M+H]+.
[0216] Step 3: To a solution of tert-butyl N-[4-[4-[4-(2,6-dioxo-3- piperidyl)phenyl]piperazin-l-yl] phenyl]carbamate (160.0 mg, 231.14 pmol) in DCM (4 mL) were added TFA (0.4 mL) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The reaction was concentrated under reduced pressure to give 3-[4-[4-(4-aminophenyl)piperazin-l- yl]phenyl]piperidine-2, 6-dione (Intermediate 27) (100.0 mg, 97.18% yield, 81.86% purity)as yellow oil. LCMS (ESI+) m/z 365.2 [M+H]+.
Intermediate 28
3-[4-[4-[2-(4-aminophcnyl)cthyl]pipcrazin-l-yl]phcnyl]pipcridinc-2,6-dionc
[0217] Step 1: To a solution of [4-(2,6-dibenzyloxy-3-pyridyl)phenyl]boronic acid (3.0 g, 7.29 mmol) in DCM (30 mL) were added tert-butyl piperazine- 1 -carboxylate (1.4 g, 7.29 mmol). Cu(OAc)2 (1.32 g, 7.29 mmol) and TEA (2.9 g. 29.18 mmol) at 20 °C. The reaction was stirred at 20 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (30 mL) and extracted with DCM (3 x 30 mL). The combined organic layers were washed with brine (3 xx 20 mL) and dried over Na2SO4. After filtered, the filtrate was concentrated to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 20: 1) to give tert-butyl 4-[4-(2,6-dibenzyloxy-3-pyridyl)phenyl]piperazine-l- carboxylate (0.7 g, 10.9% yield, 63.17% purity) as a yellow solid. LCMS (ESI+) m/z 552.3 [M+H]+.
[0218] Step 2: To a solution of tert-butyl 4-[4-(2,6-dibenzyloxy-3- pyridyl)phenyl]piperazine- 1 -carboxylate (0.7 g, 801.54 pmol) in THF (20 mL) was added Pd/C (85.3 mg, 80.15 pmol, 10% purity) at 20 °C. The reaction was stirred at 20 °C under H2 atmosphere (15 psi) for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was filtered and the filter cake was washed with THF (30 mL), the collected filtrate was concentrated to give tert-butyl 4-[4-(2,6-dioxo-3- piperidyl)phenyl]piperazine- 1 -carboxylate (0.4 g, 95.5% yield, 71.53% purity) as a yellow solid. LCMS (ESI+) /n/z 374.2 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 5 10.77 (s, 1H), 7.07 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 3.73 (dd, J = 11.1, 4.9 Hz, 1H), 3.50 - 3.41 (m, 4H), 3.12 - 3.02 (m, 4H), 2.63 (ddd, J = 17.1, 11.4, 5.2 Hz, 1H), 2.48 (br s, 1H), 2.20 - 2.08 (m, 1H), 2.05 - 1.96 (m, 1H), 1.42 (s. 9H).
[0219] Step 3: A solution of tert-butyl 4-[4-(2,6-dioxo-3- piperidyl)phenyl]piperazine- 1 -carboxylate (0.4 g, 766.16 pmol) in DCM (10 mL) were added
TFA (1 mL) at 0 °C. The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The reaction was concentrated under reduced pressure to give 3-(4-piperazin-l-ylphenyl)piperidine-2.6-dione (0.25 g, 96.6% yield, 80.94% purity) as a yellow solid. LCMS (ESI+) m/z 274.2 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.79 (s, 1H), 8.78 (br s, 1H), 7.11 (d, J= 8.5 Hz, 2H), 6.95 (d, J= 8.6 Hz, 2H), 3.76 (dd, J = 11.2. 4.9 Hz, 1H). 3.38 - 3.28 (m, 4H). 3.24 (br s. 4H), 2.64 (ddd, J = 17.2, 11.6. 5.3 Hz, 1H), 2.49 - 2.41 (m, 1H), 2.22 - 2.09 (m, 1H), 2.05 - 1.95 (m, 1H).
[0220] Step 4: To a solution of 3-(4-piperazin-l-ylphenyl)piperidine-2, 6-dione (0.25 g, 740.32 pmol) and tert-butyl N-[4-(2-oxoethyl)phenyl]carbamate (209.02 mg, 888.38 pmol) in DCM (6 mL) was added DIEA (191.4 mg, 1.48 mmol) and AcOH (44.5 mg, 740.32 pmol, 42.34 pL) at 25 °C. The reaction was stirred at 25 °C for 2 h. NaBH(OAc)s (313.8 mg,
1.48 mmol) was added to the mixture and the mixture was stirred at 20 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL) and dried over NaiSO4. After filtered, the filtrate was concentrated under reduced pressure to give tert-butyl N-[4-[2-[4-[4-(2,6-dioxo- 3-piperidyl)phenyl]piperazin-l-yl]ethyl]phenyl]carbamate (0.3 g, 44.0% yield, 53.52% purity) as a yellow solid. LCMS (ESI+) m/z 493.3 [M+H]+.
[0221] Step 5: A solution of tert-butyl N-[4-[2-[4-[4-(2,6-dioxo-3- piperidyl)phenyl]piperazin-l-yl]ethyl]phenyl]carbamate (0.3 g, 325.94 pmol) in DCM (6 mL) were added TFA (0.6 mL) at 0 °C. The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The reaction was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC (NH4HCO3 Condition) to afford 3-[4-[4-[2-(4-aminophenyl)ethyl]piperazin-l- yl]phenyl]piperidine-2, 6-dione (Intermediate 28) (0.1 g, 74.0% yield, 94.69% purity) as a yellow solid. LCMS (ESI+) m/z 393.2 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.77 (s, 1H), 7.04 (d, J = 8.8 Hz. 2H), 6.88 (dd, J = 8.4, 6.9 Hz, 4H), 6.52 - 6.44 (m, 2H), 4.81 (s, 2H), 3.72 (dd, J = 10.9, 4.9 Hz, 1H), 3.15 - 3.06 (m, 4H), 2.68 - 2.58 (m, 2H), 2.57 - 2.53 (m, 4H),
2.49 - 2.41 (m, 4H), 2.19 - 2.07 (m, 1H), 2.05 - 1.96 (m, 1H).
Intermediate 29
[0222] Step 1: To a solution of tert-butyl N-(4-oxocyclohexyl)carbamate (500.0 mg, 2.34 mmol) in DCM (10 mL) were added l-(4-nitrophenyl)piperazine (485.83 mg, 2.34 mmol) and NaBH(OAc)3 (993.7 mg, 4.69 mmol) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL) and dried over NaiSCL. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 3: 1) to give tert-butyl N-[4-[4-(4-nitrophenyl)piperazin-l-yl] cyclohexyl] carbamate (400.0 mg, 42.18% yield, 100.00% purity) as a white solid. LCMS (ESI+) m/z 405.2 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 8 8.10 - 8.00 (m, 2H), 7.06 - 6.98 (m, 2H), 3.42 (br d, J = 4.4 Hz. 4H), 3.32 (br d. J = 2.1 Hz, 1H), 2.59 (br s, 4H), 2.27 - 2.21 (m, 1H), 1.75 - 1.58 (m. 4H), 1.50 - 1.40 (m, 4H). 1.38 (t, J = 4.9 Hz, 9H).
[0223] Step 2: A solution of tert-butyl N-[4-[4-(4-nitrophenyl)piperazin-l- yl]cyclohexyl]carbamate (400.0 mg, 988.87 pmol, 100.00% purity) in HCl/dioxane (10 mL) at 25 °C. The reaction was stirred at 25° C for 12 h. LCMS showed the starting material was consumed and main product with desired MS was detected. The mixture was concentrated under reduced pressure to give 4-[4-(4-nitrophenyl)piperazin-l-yl]cyclohexanamine (300.2 mg, 99.67% yield, 84.78% purity) as a yellow solid. LCMS (ESI+) m/z 305.2 [M+H]+. ‘H NMR (400 MHz, DMSO-d6) 8 8.11 (d, J = 9.3 Hz, 2H), 7.21 - 7.04 (m, 2H), 4.26 - 4.13 (m, 2H), 3.60 (br s, 1H). 3.53 (br s, 2H), 3.37 (br s, 2H), 3.29 - 3.10 (m, 2H), 2.62 - 2.53 (m. 2H), 2.29 - 2.05 (m, 2H), 2.04 - 1.94 (m, 4H), 1.77 - 1.56 (m, 2H), 1.49 - 1.36 (m, 1H).
[0224] Step 3: To a solution of 4-[4-(4-nitrophenyl)piperazin-l- yl]cyclohexanamine (300.2 mg, 835.58 pmol, 84.78% purity) in DMF (8 mL) were added 3- bromopiperidine-2, 6-dione (240.6 mg, 1.25 mmol) and DIEA (539.9 mg, 4.18 mmol) at 25 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the reaction was completed
and the desired compound was detected. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The organic combined organic layers were washed with brine (3 x 10 mL) and dried over NaiSCL- After filtered, the filtrate was concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (NH4HCO3 Condition) to afford 3-[[4-[4-(4-nitrophenyl)piperazin-l-yl]cyclohexyl]amino]piperidine- 2,6-dione (150.3 mg, 41.02% yield, 94.94% purity) as a yellow solid. LCMS (ESI+) m z 416.2 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.85 - 10.48 (m, 1H), 8.05 (d, J = 9.5 Hz, 2H), 7.08 - 6.96 (m, 2H), 3.43 (br d, J = 3.9 Hz, 4H), 3.40 (br d, J = 4.9 Hz. 2H), 2.81 (br s, 1H), 2.58 (br d, J = 4.6 Hz, 4H), 2.54 (br d, J = 4.9 Hz, 2H), 2.22 (br s, 1H), 2.04 - 1.95 (m, 1H), 1.75 - 1.68 (m, 1H), 1.65 (br d, J = 9.0 Hz, 4H), 1.53 - 1.39 (m, 4H).
[0225] Step 4: To a solution of 3-[[4-[4-(4-nitrophenyl)piperazin-l- yl]cyclohexyl]amino]piperidine-2, 6-dione (150.3 mg, 342.76 pmol, 94.94% purity) in THF (2 mL) was added Pd/C (5.7 mg, 34.28 pmol, 30% purity) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the stalling material consumed and the desired product was detected. The mixture was filtered and the filter cake was washed with THF (10 mL). The collected filtrate was concentrated to give 3-[[4-[4-(4-aminophenyl)piperazin-l- yl]cyclohexyl] amino] piperidine-2, 6-dione (Intermediate 29) (100.0 mg, 53.13% yield, 70.20% purity) as a yellow solid. LCMS (ESI+) m/z 386.2 [M+H]+.
Intermediate 30
[0226] Step 1: To a solution of 4-bromobenzaldehyde (5 g, 27.02 mmol) in ethyl 3-oxobutanoate (EAA) (7.74 g, 59.45 mmol) was added piperidine (1 mL) at 0 °C dropwise. The mixture was then stirred at 20 °C for 3 h. The precipitated solid was filtered out and triturated by cold EtOH to give diethyl 2,4-diacetyl-3-(4-bromophenyl)pentanedioate (5 g, 11.7 mmol. 43.2 %) as white solid. The crude solid was then added into aqueous solution of KOH (20 M, 50 mL). The mixture was stirred at 80 °C for 3 h. LCMS showed desired product
was formed. After cooling to rt, cone. HC1 was added slowly to the mixture to adjust pH to 3. The formed solid was filtered out, washed with water to give 3-(4-bromophcnyl) pentanedioic acid as a white solid (3.9 g, 13.58 mmol, 50.26% yield). ’H NMR (400 MHz, DMSO-d6) 8 12.10 (br s, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.27 - 7.20 (m, 2H), 3.52 - 3.19 (m, 1H), 2.73 - 2.58 (m, 2H), 2.57 - 2.52 (m, 1H), 2.50 - 2.47 (m, 1H).
[0227] Step 2: 3-(4-bromophenyl)pentanedioic acid (2.8 g, 9.75 mmol) and urea (1.46 g, 24.38 mmol) was mixed together and was stirred at 160 °C for 3 h. LCMS showed desired product was formed. The mixture was then cooled to rt. The obtained solid was dissolved in EA and washed with water (3x). The organic layer was concentrated with reduced pressure to give 4-(4-bromophenyl)piperidine-2, 6-dione (1 g, 3.73 mmol, 38.25% yield) as a brown solid. LCMS (ESI+) m/z 268.0 (M+H)+.
[0228] Step 3: To a solution of 4-(4-bromophenyl)piperidine-2, 6-dione (500 mg, 1.31 mmol) 1,4-dioxa- 8-azaspiro[4.5]decane (373.84 mg, 2.61 mmol, 334.68 pL) in dioxane (10 mL) was added CS2CO3 (1.28 g, 3.92 mmol) l,3-bis[2,6-bis(l-propylbutyl)phenyl]-4,5- dichloro-2H-imidazol-l-ium-2-ide;3-chloropyridine;dichloropalladium (126.99 mg, 130.55 pmol) . The mixture was then stirred at 100 °C for 5 h under the protection of N2. Another batch was set up with the same procedure. LCMS showed desired product was formed. The mixture was extract with EA (3 x 100 mL) and washed with saturated NH4CI aqueous solution. The organic layer was then dried over Na2SO4, filtered and concentrated by reduced pressure to give the crude residue, which was further purified by silica column with eluent of EA:PE = 1: 1. 4-[4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]piperidine-2, 6-dione (230 mg, 696.17 pmol, 53.33% yield) was obtained as a white solid. LCMS (ESI+) 331 [M+H]+. 'H NMR (400 MHz, CDCI3) 87.81 (br s, 1H), 7.01 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 3.92 (s, 4H), 3.33 - 3.21 (m, 5H), 2.89 - 2.76 (m. 2H), 2.70 - 2.55 (m, 2H), 1.86 - 1.69 (m, 4H).
[0229] Step 4: To a solution of 4-[4-(l,4-dioxa-8-azaspiro[4.5]decan-8- yl)phenyl]piperidine-2, 6-dione (230 mg, 302.68 pmol) in formic acid (2.3 mL) was stirred at 90 °C. LCMS showed desired product was formed. The reaction was washed with saturated NH4CI aqueous solution and extracted by EA (2 x 20 mL). The organic layer was combined and concentrated by reduced pressure. The crude reside was purified by prep-TLC with pure EA. 4- [4-(4-oxo- 1 -piperidyl)phenyl]piperidine-2 ,6-dione (80 mg, 139.70 pmol, 46.15%
yield) was formed as a white solid. 'H NMR (400 MHz, CDCh) 87.75 (br s, 1H), 7.07 (d, J = 8.7 Hz, 2H), 6.89 (d, 7 = 8.7 Hz, 2H), 3.54 (t, J = 6.1 Hz, 4H), 3.37 - 3.23 (m, 1H), 2.93 - 2.76 (m, 2H), 2.66 (dd, J = 11.4, 17.4 Hz, 2H), 2.49 (t, J = 6.1 Hz, 4H).
Intermediate 31
2- ally 1 - 6- [4- [4-(aminomethy 1)- 1 -piperidyl] anilino] - 1 - [(7R)-7-ethy 1-7 -hydroxy-5 ,6- dihydrocyclopenta[b]pyridin-2-yl]pyrazolo[3,4-d]pyrimidin-3-one (FIG. 32)
[0230] Step 1: To a solution of tert-butyl (piperidin-4-ylmethyl)carbamate (10 g, 70.87 mmol) and l-fluoro-4-nitrobenzene (18.23 g, 85.05 mmol) in DMF (20 mL) was added DIEA (18.32 g, 141.74 mmol). The mixture was stirred at 60 °C for 12 h. LCMS showed one major peak with desired MS was detected. The reaction was added to water (50 mL) and the mixture was filtered. The filter cake was collected by suction filtration and dried in vacuum to give tert-butyl ((l-(4-nitrophenyl)piperidin-4-yl)methyl)carbamate (23 g, 68.58 mmol, 96.76% yield) as a yellow solid. LCMS (ESI+) m/z. 336.2 [M+H]+. 'H NMR (400 MHz. DMSO-d6) 8 8.03 (d, J = 9.1 Hz, 2H), 7.00 (br d. J = 9.3 Hz, 2H), 6.91 (br t, J = 5.4 Hz, 1H), 4.04 (br d, J = 13.3 Hz, 2H), 2.95 (br t, J = 12.4 Hz, 2H), 2.84 (br t, J = 5.9 Hz, 2H), 1.76 - 1.62 (m, 3H), 1.38 (s, 9H), 1.13 (q, J = 11.3 Hz, 2H).
[0231] Step 2: A solution of tert-butyl ((l-(4-nitrophenyl)piperidin-4- yl)methyl)carbamate (23 g, 68.58 mmol) in HCl/EtOAc (4 M, 30 mL) was stirred at 25 °C for 2 h. LCMS showed the starting material consumed and a new spot was detected. The mixture was concentrated under reduced pressure at 40 °C to give crude l-(4-nitrophenyl)piperidin-4- yl)methanamine (16 g, 99.17% yield) as a yellow solid, which was used to next step without further purification. 'H NMR (400 MHz, DMSO-d6) 6 8.25 (br s, 3H), 8.06 - 7.99 (m, 2H), 7.72 (br s, 2H), 7.07 - 7.00 (m, 2H), 4.07 (br d, J = 13.4 Hz, 2H), 3.03 - 2.90 (m, 2H), 2.71 (quin, J = 5.9 Hz, 2H), 2.00 - 1.90 (m, 1H), 1.85 (br d, J = 13.1 Hz, 2H), 1.22 (dq, J = 3.8, 12.2 Hz, 2H).
[0232] Step 3: To a solution of (l-(4-nitrophenyl)piperidin-4-yl)methanamine (16 g, 68.00 mmol) and TFAA (21.42 g, 102.01 mmol) in DCM (200 mL) was added TEA (20.64 g, 204.01 mmol). The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The reaction was purified directly without work-up. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100: 1 to 2: 1) to give 2,2,2-trifluoro-N-((l-(4-nitrophenyl)piperidin-4-yl) methyl)acetamide (22 g, 89.48% yield, 91.633% purity) as a white solid. LCMS (ESI+) m/z 332.1 [M+H]+.
[0233] Step 4: To a solution of 2,2,2-trifluoro-N-((l-(4-nitrophenyl)piperidin-4- yl)methyl) acetamide (22 g, 66.41 mmol) in THF (220 mL) was added Pd/C (141.34 g, 132.81 mmol, 10% purity) at 2 0°C. The mixture was stirred at 20 °C for 12 h. LCMS showed one major peak with desired MS was detected. The reaction was filtered and the filter cake was washed with THF (200 mL). The combined filtration was concentrated to give the crude product, which was purified by column chromatography on silica gel (eluted with THF:EA = 1: 100 to 3:1) to give N-((l-(4-aminophenyl)piperidin-4-yl)methyl)-2,2,2-trifluoroacetamide (13 g, 35.34% yield, 54.4% purity) as a brown solid. LCMS (ESI+) m/z 302.1 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 59.50 (br t, J = 5.4 Hz, 1H), 7.05 - 6.73 (m, 2H), 6.71 - 6.39 (m, 2H), 6.36 - 5.80 (m, 2H), 3.41 (br d, J = 4.6 Hz, 2H), 3.14 (br t, J = 6.1 Hz, 2H), 2.62 (br s, 2H), 1.70 (br s. 3H), 1.30 (br d. J = 11.7 Hz. 2H).
[0234] Step 5: To a solution of (R)-2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridine-2-yl)-6-(methylthio)-l,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (5 g, 13.04 mmol) in toluene (50 mL) was added m-CPBA (5.29 g, 26.08 mmol, 85% purity) at 20 °C. The reaction was stirred at 25 °C for 2 h, then a solution of N-((l-(4- aminophenyl)piperidin-4-yl)methyl)-2,2,2-trifluoroacetamide (4.71 g, 15.65 mmol) and DIEA (8.43 g, 65.19 mmol) in DMF (50 mL) was added to the reaction dropwise at 0 °C. The reaction was stirred at 25 °C for 12 h. Additional one reaction was set up as described as above and the reactions were combined for work-up. The reaction was poured into water (100 mL) and extracted with EA (200 mL). The organic layer was dried over NaiSCk and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography on silica gel (eluted with EA) to give (R)-N-((l-(4-((2-allyl-l-(7-ethyl-7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-
d]pyrimidin-6-yl)amino)phenyl)piperidin-4-yl)methyl)-2,2,2-trifluoroacetamide (11 g, 17.28 mmol, 66.25% yield) as a yellow solid. ’H NMR (400 MHz, CDC13) 8 8.81 (s, 1H), 7.73 - 7.67 (m, 2H), 7.46 (br d, J = 8.4 Hz, 2H), 6.92 (br d, J = 8.9 Hz, 2H). 6.49 (br s. 1H). 5.70 (tdd, J = 6.2, 10.4, 16.8 Hz, 1H), 5.03 (d, J = 10.3 Hz, 1H), 4.93 (d, 7 = 17.1 Hz, 1H), 4.90 - 4.80 (m, 1H), 4.78 - 4.64 (m, 1H), 3.68 (br d, 7 = 12.3 Hz, 2H), 3.37 (t, 7 = 6.4 Hz, 2H), 3.14 - 2.98 (m, 1H). 2.95 - 2.82 (m, 1H), 2.72 (br t, 7 = 11.4 Hz, 2H), 2.40 (ddd, 7 = 4.5, 8.6. 13.4 Hz, 2H), 2.29 - 2.20 (m, 1H), 2.05 - 1.97 (m, 1H), 1.90 - 1.81 (m, 3H), 1.80 - 1.71 (m, 1H), 1.70 - 1.59 (m, 1H), 1.48 (dq, 7 = 3.4, 12.0 Hz, 2H), 1.01 (t, 7 = 7.4 Hz, 3H).
[0235] Step 6: To a solution of N-[[l-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopentafb] pyridin-2-yl] -3-oxo-pyrazolo [3 ,4-d]pyrimidin-6-yl] amino]phenyl] -4- piperidyl]methyl]-2,2,2-trifluoro-acetamide (10 g, 15.71 mmol) in MeOH (300 mL) was added K2CO3 (21.71 g, 157.07 mmol). The reaction was stirred at 30 °C for 48 h. LCMS showed the reaction was completed. The reaction was diluted with water (300 mL) and extracted with DCM (5 x 300 mL). The organic layer was dried over NaiSCL and filtered. The filtrate was concentrated to give 2-ally 1-6- [4- [4-(aminomethyl)-l -piperidyl] anilino]-l - [(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]pyrazolo[3,4-d]pyrimidin-3- one (Intermediate 31) (9 g, 14.98 mmol, 95.38% yield, 90% purity) as a yellow solid. LCMS (ESI+) zn/z 541.3 [M+H]+. ’ H NMR (400 MHz, DMSO-d6) 8 10.29 - 9.94 (m, 1H), 8.82 (s, 1H), 7.94 (br d, 7 = 7.1 Hz, 1H), 7.70 (d, 7 = 8.3 Hz, 1H), 7.57 (br s, 2H), 6.92 (br d, 7 = 9.0 Hz, 2H), 5.67 (tdd, 7 = 6.0, 10.6, 16.8 Hz, 1H), 5.08 (br s, 1H), 5.OO (d, 7= 10.3 Hz, 1H), 4.86 (br d, 7 = 17.0 Hz, 1H), 4.80 - 4.71 (m, 1H), 4.57 (br dd, 7 = 5.8, 16.0 Hz, 1H), 3.65 (br d, 7 = 12.0 Hz, 2H), 3.07 - 2.92 (m, 1H), 2.90 - 2.66 (m. 2H), 2.62 - 2.54 (m, 2H), 2.45 (d, 7 = 6.1 Hz, 2H), 2.21 (ddd, 7 = 5.8, 8.2, 13.4 Hz, 1H), 2.08 - 1.97 (m, 1H), 1.90 (br dd, 7 = 7.3, 13.6 Hz, 1H), 1.85 - 1.67 (m, 3H). 1.59 - 1.39 (m, 1H), 1.38 - 1.28 (m, 1H), 1.28 - 1.13 (m, 2H), 0.88 (t, 7 = 7.4 Hz, 3H).
Intermediate 33
3-((3-(4-aminopiperidin-l-yl)phenyl)amino)piperidine-2, 6-dione (FIG. 33)
[0236] Step 1 : To a solution of l-bromo-3-nitrobenzene (10.0 g, 40.16 mmol) in toluene (200 mL) were added BINAP (2.5 g, 4.02 mmol), Pd(OAc)i (901.6 mg, 4.02 mmol), tert-butyl piperidin-4-ylcarbamate (8.1 g, 40.16 mmol) and CS2CO3 (26.17 g, 80.32 mmol) at 25 °C. The reaction was stirred at 100 °C for 12 h. LCMS showed the starting material was consumed and the desired product was detected. The reaction was concentrated under reduced pressure to give the product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 25: 1) to give tert-butyl N-(l-(3-nitrophenyl)piperidin- 4-yl)carbamate (6.0 g, 40.8% yield, 87.87% purity) as a yellow solid. LCMS (ESI+) m/z 322.1 [M+H]+. ‘H NMR (400 MHz, DMSO-d6) 57.62 (t, J = 2.2 Hz, 1H), 7.53 (dd, J = 7.8, 1.0 Hz, 1H), 7.44 (t, J = 8.1 Hz, 1H), 7.40 (d, J = 1.5 Hz, 1H), 6.87 (br d, J = 7.8 Hz, 1H), 3.77 (br d, J = 13.2 Hz, 2H), 3.45 (br dd, J = 8.4, 1.9 Hz, 1H), 2.92 - 2.84 (m, 2H), 1.81 (br d, J = 11.0 Hz, 2H), 1.50 - 1.42 (m, 2H), 1.39 (s, 9H).
[0237] Step 2: To a solution of tert-butyl N-[l-(3-nitrophenyl)-4- piperidyl]carbamate (6.0 g, 16.41 mmol) in THF (30 mL) was added Pd/C (17.4 g, 16.41 mmol, 30% purity) at 25 °C. The reaction was stirred at 25 °C for 12 h. TLC showed the starting material consumed and a new spot was detected. The mixture was filtered and the filter cake was washed with THF (50 mL). The collected filtrate was concentrated to give tert-butyl N-[l-(3-aminophenyl)-4-piperidyl]carbamate (4.0 g, 41.84% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) 8 = 6.90 - 6.78 (m, 1H). 6.73 (br d, J = 7.6 Hz, 1H), 6.17 - 6.07 (m, 1H), 5.99 (dd, 7 = 7.7, 1.2 Hz, 1H), 4.81 (s, 1H), 3.60 (t, 7 = 6.4 Hz, 1H), 3.51 (br d, 7 = 12.7 Hz, 1H), 3.40 - 3.17 (m, 2H), 2.86 (br d, 7 = 12.3 Hz, 1H), 2.67 - 2.58 (m, 1H), 2.39 (dt, 7 = 12.0, 2.0 Hz. 1H), 1.80 - 1.70 (m, 2H). 1.61 (br d. 7 = 11.0 Hz, 1H). 1.38 (d, 7 = 5.9 Hz, 9H), 1.26 - 1.12 (m, 1H).
[0238] Step 3: To a mixture of tert-butyl (l-(3-aminophenyl)piperidin-4- yl)carbamate (4.0 g, 6.86 mmol) in dioxane (40 mL) were added 3-bromopiperidine-2, 6-dione (3.9 g, 20.59 mmol), DIEA (1.7 g, 13.73 mmol, 2.4 mL) and Nal (205.7 mg, 1.37 mmol) at 25 °C. The mixture was stirred at 60 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was diluted with water (30 mL) and extracted with DCM (3 x 30 mL). The organic combined organic layers were washed with brine (3 x 30 mL) and dried over Na^SCL. After filtering, the filtrate was concentrated under reduced pressure to give tert-butyl (l-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-
yl)carbamate (1.5 g, 3.11 mmol, 45.3% yield) as a yellow solid. LCMS (EST+) m/z 403.2 [M+H]+.
[0239] Step 4: To a solution of tert-butyl (l-(3-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-4-yl) carbamate (1.5 g, 3.11 mmol) in DCM (8 mL) was added TFA (0.8 mL) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the starting material was consumed and the main product with desired MS was detected. The mixture was concentrated under reduced pressure to give 3-((3-(4-aminopiperidin-l- yl)phenyl)amino)piperidine-2, 6-dione (Intermediate 33) (0.4 g, 19.5% yield, 43.96% purity) as a yellow solid. LCMS (ESI+) m/z 303.2 [M+H]+.
Intermediate 34 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b] pyridin-2-yl]-6-[4-(4-oxo-l- piperidyl)anilino]pyrazolo[3,4-d]pyrimidin-3-one (FIG. 34)
[0240] Step 1: A solution of tert-butyl (4-(4-oxopiperidin-l-yl)phenyl)carbamate (1.00 g, 3.44 mmol) in DCM (10 mL) and TFA (1 mL) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure to give l-(4- aminophenyl)piperidin-4- one (0.50 g, 76.31% yield) as a yellow solid. LCMS (ESI+) m/z 191.2 [M+H]+.
[0241] Step 2: To a solution of l-(4-aminophenyl)piperidin-4-one (0.50 g, 2.63 mmol) in toluene (3 mL) were added DIEA (622.15 mg, 4.81 mmol) and 2-allyl-l-[(7R)-7- ethyl-7 -hydroxy-5, 6-dihydrocyclopenta[b]pyridin-2-yl]-6-methylsulfonyl-pyrazolo[3, 4- d]pyrimidin-3-one (Huang et al., J. Med. Chem. (2021) 64: 13004-13024, 1.00 g, 2.41 mmol) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was diluted with water (10 mL) and extracted with EA (3 x 10 mL). The organic combined organic layers were washed with
brine (3 x 10 mL) and dried over Na SCL. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100:0 to 20: 1) to give 2-allyl-l-[(7R)-7- ethyl-7 -hydroxy-5, 6-dihydrocyclopenta[b]pyridin-2-yl] -6- [4-(4-oxo- 1 - piperidyl)anilino]pyrazolo[3,4-d]pyrimidin-3-one (0.30 g, 23.71% yield) as a yellow solid.
LCMS (ESI+) m/z 526.2 [M+H]+.
Intermediate 35
[0242] Step 1: To a solution of 3-(4-aminophenyl)piperidine-2, 6-dione (0.60 g, 1.72 mmol) and tert-butyl N-(2-bromoethyl)carbamate (384.8 mg, 1.72 mmol) in DMF (12.0 mL) was added DIEA (443.9 mg, 3.43 mmol) at 20 °C. The mixture was stirred at 80 °C for 12 h under N2. LCMS showed the starting material was consumed completely. The mixture was concentrated in vacuum to give a residue. The residue was purified by prep-HPLC (NH4HCO3 condition) to afford tert-butyl N-[2-[4-(2,6-dioxo-3- piperidyl)anilino]ethyl] carbamate (60.0 mg, 9.38% yield) as a white solid. LCMS (ESI+) m/z 348.2 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 5 10.72 (s. 1H). 6.98 - 6.78 (m, 3H), 6.52 (d. J = 8.5 Hz. 2H), 5.54 (br t, J - 5.2 Hz, 1H), 3.64 (dd, J - 10.5, 4.9 Hz, 1H), 3.05 (td, J - 11.0, 5.5 Hz, 4H), 2.66 - 2.55 (m, 1H). 2.47 - 2.40 (m, 1H), 2.14 - 2.05 (m, 1H), 2.05 - 1.94 (m, 1H), 1.38 (s, 9H).
[0243] Step 2: A mixture of tert-butyl N-[2-[4-(2,6-dioxo-3- piperidyl)anilino]ethyl]carbamate (60.0 mg, 161.15 pmol, 93.31% purity) in DCM (2.0 mL) and TFA (0.2 mL) was stirred at 20 °C for 2 h. TLC showed the starting material was consumed completely. The mixture was concentrated in vacuum to give 3-[4-(2- aminoethylamino)phenyl]piperidine-2,6-dione (TFA salt, 42.0 mg, 70.61% yield) as a yellow oil.
Intermediate 36
2-allyl-6-[4-(4-amino-l-pipcridyl)anilino]-l-[(7R)-7-cthyl-7-hydroxy-5,6- dihydrocy clopenta[b]pyridin-2-yl] pyrazolo[3 ,4-d]pyrimidin-3 -one (FIG. 36)
[0244] Step 1: To a solution of N-[l-(4-aminophenyl)-4-piperidyl]-2,2,2- trifluoro-acetamide (829.76 mg, 2.89 mmol) and 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopcnta[b]pyridin-2-yl]-6-mcthylsulfonyl-pyrazolo[3,4-d]pyrimidin-3-onc (1.00 g, 2.41 mmol) in DMF (10 mL) was added DIEA (622.16 mg, 4.81 mmol). The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed. The mixture was diluted with water (20 mL) and extracted with EA (3 x 30 mL). The organic layer was dried over Na SCM and filtered. The filtrate was concentrated under reduced pressure to give N-[l-[4- [[2-allyL 1 - [(7R)-7 -ethyl-7 -hydroxy-5, 6-dihydrocyclopenta[b]pyridin-2-yl] -3- oxopyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]-4-piperidyl]-2,2,2-trifluoro-acetamide (1.10 g, 73.4% yield) as a yellow solid. LCMS (ESI+) m/z 623.2 [M+H]+. }H NMR (400 MHz, DMSO-d6) 5 10.12 (br s, 1H), 9.35 (br d, 7 = 7.8 Hz, 1H), 8.82 (s, 1H), 7.93 (br d, J = 7.3 Hz, 1H), 7.76 - 7.64 (m, 1H). 7.58 (br s. 2H), 6.94 (br d, J = 9.0 Hz, 2H), 5.71 - 5.61 (m, 1H), 5.04 (s, 1H), 4.99 (dd, J = 10.3, 1.0 Hz, 1H), 4.92 - 4.82 (m, 1H), 4.77 (br d, J = 14.4 Hz, 1H), 4.57 (br dd, J = 15.4, 5.6 Hz, 1H), 3.69 (br d, J = 12.5 Hz, 2H), 3.04 - 2.91 (m, 1H), 2.83 - 2.65 (m, 3H), 2.26 - 2.16 (m. 1H). 2.07 - 2.00 (m, 2H), 1.94 - 1.83 (m, 2H), 1.78 - 1.61 (m, 3H), 0.87 (t, J = 7.4 Hz, 3H).
[0245] Step 2: To a solution of N-[l-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl] -3 -oxo-pyrazolo [3 ,4-d]pyrimidin-6-y 1] am i no] phcny 1] -4- piperidyl]-2,2,2-trifluoro-acetamide (1.00 g, 1.61 mmol) in MeOH (50 mL) was added K2CO3 (1.78 g. 12.85 mmol). The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give 2-allyl-6-[4- (4-amino-l-pipcridyl)anilino]-l-[(7R)-7-cthyl-7-hydroxy-5,6- dihydrocyclopcnta[b]pyridin- 2-yl]pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 36) (0.96 g, 90.8% yield) as a white
solid. LCMS (ESI+) mJz 527.3 [M+H]+ . ’ H NMR (400 MHz, DMS0-d6) 5 10.22 - 9.95 (m, 1H), 8.87 - 8.75 (m, 1H), 7.93 (br d, J = 7.3 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.64 - 7.44 (m, 2H), 6.91 (br d, J= 8.9 Hz, 2H), 5.77 - 5.56 (m. 1H), 5.14 - 5.03 (m, 1H). 5.00 (br d. J= 10.1 Hz, 1H), 4.86 (br d, J = 17.2 Hz, 1H), 4.75 (br d, J = 12.8 Hz, 1H), 4.57 (br dd, J = 15.6, 5.6 Hz, 1H), 3.62 - 3.44 (m, 2H), 3.30 (br s, 2H), 3.09 - 2.90 (m, 2H), 2.83 - 2.71 (m, 2H), 2.71 - 2.60 (m, 2H), 2.26 - 2.12 (m. 1H). 2.07 - 1.99 (m, 1H), 1.95 - 1.83 (m, 1H). 1.83 - 1.63 (m. 3H), 1.40 - 1.28 (m, 1H), 0.87 (br t, J - 7.4 Hz, 3H).
Intermediate 37
[0246] Step 1: To a solution of 4-(3-bromophenyl)piperidine-2, 6-dione (1 g, 3.73 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (194.96 mg, 1.36 mmol) in dioxane (20 mL) were added CS2CO3 (1.33 g, 4.08 mmol) and l,3-bis[2,6-bis(l-propylbutyl)phenyl]-4,5-dichloro- imidazol-2-ylidene]-dichloro-(3-chloropyridin- 1-ium- l-yl)palladium (92.79 mg, 136.16 pmol) 25 °C under N2. The reaction was stirred at 70 °C under N2 for 12 h. LCMS showed the reaction was completed and the desired product was detected. The reaction was diluted with water (100 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SC>4. After filtering, the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 99: 1 to 10:90) to give 4-(3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl)piperidine- 2, 6-dione (0.16 g, 484.29 pmol, 35.57% yield) as a yellow solid. LCMS (ESI+) m/z 331.2 [M+H]+.
[0247] Step 2: A solution of 4-(3-(l,4-dioxa-8-azaspiro[4.5]decan-8- yl)phenyl)piperidine-2, 6-dione (0.15 g, 454.03 pmol) in HCOOH (1.5 mL) was stirred at 90 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The reaction was cooled to 25 °C and quenched with saturated NaHCCL solution. The resulting mixture was extracted with EA (100 mL). The organic layer was dried over Na2SO4. After filtered, the filtrate was concentrated under reduced pressure to give 4-(3-(4-
oxopiperidin-l -yl)phenyl)piperidine-2, 6-dione (Intermediate 37) (0.11 g, 384.18 pmol, 84.62% yield), which was used to next step without further purification. LCMS (ESI+) m/z 287.1 [M+H]+. !H NMR (400 MHz, DMSO-d6) 5 10.83 (br s, 1H). 7.19 (t, J = 7.9 Hz. 1H), 6.98 (s, 1H), 6.89 (dd, 7 = 2.0, 8.1 Hz, 1H), 6.70 (d, 7 = 7.7 Hz, 1H), 3.60 (t, 7 = 5.9 Hz, 4H), 3.40 - 3.34 (m, 1H), 2.82 (dd, 7 = 11.4, 16.8 Hz, 2H), 2.66 (d, 7 = 4.3 Hz, 1H), 2.61 (d, 7 = 4.4 Hz. 1H), 2.40 (t. 7 = 5.9 Hz, 4H).
Intermediate 38
4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-3-oxo- pyrazolo [3 ,4-d]pyrimidin-6-yl] amino]phenyl]piperazin- 1 -yl]butanal (FIG. 38)
[0248] To a solution of 2-allyl-l-[(7R)-7-cthyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-6-(4-piperazin-l-ylanilino)pyrazolo[3,4-d]pyrimidin-3- one (Intermediate 8) (0.1 g, 195.08 umol) in THF (5 mL) were added butanedial (503.83 mg, 5.85 mmol) and NaBH(OAc)3 (82.69 mg, 390.16 umol,) at 20 °C for 2 h under N2. LCMS showed the starling material was consumed completely. The mixture was poured into H2O (5 mL). The mixture was extracted with EA (3 x 5 mL). The organic phase was washed with brine (10 mL), dried over anhydrous NarSCL and concentrated in vacuum to give a residue,, which was purified by prep-TLC to afford 4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]butanal (Intermediate 38) (0.082 g, 101.60 umol, 52.08% yield, 72.20% purity) as a yellow solid. LCMS (ESI+) m/z 583.4 [M+H]+.
Intermediate 40
3-[4-[4- [[4-(4- aminophcnyl)pipcrazin-l-yl]mcthyl]-4-hydroxy-l- piperidyl]anilino]piperidine-2, 6-dione (FIG. 39)
[0249] Step 1: To a mixture of tert-butyl 4-oxopiperidine- 1 -carboxylate (20.00 g, 100.38 mmol) in ACN (200 mL) were added trimethylsulfoxonium iodide (26.51 g, 120.45 mmol) and KOH (8.45 g, 150.57 mmol) at 20 °C, and the mixture was stirred at 20 °C for 12 h. TLC (PE:EA = 1: 1) showed the starting material was consumed completely. The mixture was poured into H2O (150 mL). The mixture was extracted with EA (3 x 150 mL). The organic phase was washed with brine (150 mL), dried over anhydrous NaiSOr and concentrated in vacuum to give a residue. The residue was used for nest step reaction directly without purification. l-(4-nitrophcnyl)pipcrazinc (20.00 g, 46.71% yield) was obtained as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) 1 H NMR (400 MHz, DMSO-d6) 53.66 (br d, J = 12.5 Hz, 2H), 2.99 (br s, 2H), 2.89 - 2.54 (m, 2H), 1.55 - 1.42 (m, 4H), 1.38 (s, 9H).
[0250] Step 2: To a solution of tert-butyl N-(l-oxaspiro[2.5]octan-6-yl)carbamate (10.00 g, 23.44 mmol, 50.00% purity) and l-(4-nitrophenyl)piperazine (5.83 g, 28.13 mmol) in MeOH (100 mL) was added DIEA (9.09 g, 70.33 mmol, 12.25 mL). The reaction was stirred at 60 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA =4 0:60) to give the pure tert-butyl 4-hydroxy-4-((4-(4-nitrophenyl)piperazin-l- yl)methyl)piperidine- 1 -carboxylate (8.00 g, 81.15% yield) was obtained as yellow oil. LCMS (ESI+) m/z 421.3 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 8 8.04 (d, J = 9.4 Hz, 2H), 7.00 (d, J = 9.4 Hz, 2H), 4.27 (s. 1H), 3.60 (br d, J = 12.8 Hz, 2H), 3.47 - 3.38 (m. 4H). 3.10 (br s, 2H), 2.67 - 2.60 (m, 4H), 2.30 (s, 2H), 1.48 - 1.42 (m, 4H), 1.38 (s, 9H).
[0251] Step 3: To a solution of tert-butyl 4-hydroxy-4-[[4-(4- nitrophenyl)piperazin-l-yl]methyl]piperidine -1 -carboxylate (8.00 g, 19.02 mmol, 100% purity) in THF (160 mL) was added Pd/C (10%, 2.02 g) under N2 atmosphere. The suspension
was degassed and purged with H2 (3x). The mixture was stirred under H2 (15 psi) at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give tert-butyl 4-[[4-(4- aminophenyl)piperazin-l-yl]methyl]-4-hydroxy -piperidine- 1 -carboxylate (7.00 g, 88.02% yield) as a white solid. LCMS (ESI+) m/z 391.1 [M+H]+.
[0252] Step 4: To a solution of tert-butyl 4-[[4-(4-aminophenyl)piperazin-l- yl]methyl]-4-hydroxy-piperidine -1 -carboxylate (7.00 g, 16.75 mmol, 93.42% purity) in DCM (70 mL) were added TFAA (3.87 g, 18.42 mmol, 2.56 mL) and TEA (3.39 g, 33.49 mmol, 4.66 mL). The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give a product, which was used in the next step without further purification. Tert-butyl 4-hydroxy-4-[[4-[4-[(2,2,2-trifluoroacetyl)amino]phenyl]piperazin- l-yl]methyl] piperidine- 1 -carboxylate (6.00 g, 67.77% yield, 92.02% purity) was obtained as a yellow oil. LCMS (ESI+) m/z 487.3 [M+H]+. ’H NMR (400 MHz. CDCI3) 5 7.92 (br s, 1H), 7.52 - 7.40 (m, 2H), 6.92 (d, J = 8.9 Hz, 2H), 4.03 - 3.83 (m, 2H), 3.37 - 3.06 (m, 6H), 2.90 (s, 3H), 2.74 - 2.68 (m, 1H), 2.61 - 2.28 (m, 2H), 1.62 (br s, 3H), 1.47 (s, 9H).
[0253] Step 5: A mixture of tert-butyl 4-hydroxy-4-[[4-[4-[(2,2,2-trifluoroacetyl) amino]phenyl] piperazin- l-yl]methyl]piperidine-l -carboxylate (6.00 g, 11.35 mmol, 92.02% purity) in TFA (60 mL) and DCM (6 mL) was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give a product, which was used in the next step without further purification. 2,2,2-trifluoro-N-(4-(4-((4-hydroxypiperidin-4-yl)methyl)piperazin-l- yl) phenyl)acetamide (4.00 g, 85.65% yield) was obtained as a black solid. LCMS (ESI+) m/z 387.2 [M+H]+.
[0254] Step 6: To a solution of 2,2,2-trifluoro-N-[4-[4-[(4-hydroxy-4- piperidyl)methyl]piperazin-l-yl] phenyl] acetamide (3.85 g, 9.36 mmol, TFA salt) and 1- fluoro-4-nitro-benzene (1.10 g, 7.80 mmol, 827.07 L) in DMF (20 mL) was added DIEA (5.04 g, 38.98 mmol, 6.79 mL). The reaction was stirred at 80 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into water (20 mL) and extracted with EA (3 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated under
reduced pressure to give 2,2,2-trifluoro-N-[4-[4-[[4-hydroxy-l-(4-nitrophenyl)-4- pipcridyl]mcthyl]pipcraz in- l-yl]phcnyl] acetamide (2.00 g, 46.05% yield, 91.09% purity) as a white solid. LCMS (ESI+) m/z 508.3 [M+H]+. ’ H NMR (400 MHz, DMS0-d6) 5 11.02 (s, 1H), 8.02 (d, J = 9.5 Hz, 2H), 7.48 (d, J = 8.9 Hz, 2H), 7.01 (d, J = 9.5 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 4.40 (s, 1H), 3.76 (br d, J = 13.2 Hz, 2H), 3.09 (br d, J = 4.2 Hz, 5H), 2.66 (br s, 4H), 2.34 (s, 2H), 1.61 (br d, J = 3.9 Hz. 4H).
[0255] Step 7: To a solution of 2,2,2-trifluoro-N-[4-[4-[[4-hydroxy-l-(4- nitrophenyl)-4-piperidyl]methyl] piperazin- l-yl]phenyl] acetamide (2.00 g, 3.59 mmol) in MeOH (20 mL) was added K2CO3 (992.24 mg, 7.18 mmol). The mixture was stirred at 20 °C for 2 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give 4-[[4-(4- aminophenyl)piperazin-l-yl] methyl] -l-(4-nitrophenyl)piperidin-4-ol (1.50 g, 36.12% yield) as a white solid. LCMS (ESI+) m/z 412.3 [M+H]+.
[0256] Step 8: To a solution of 4-[[4-(4-aminophenyl)piperazin-l-yl]methyl]-l- (4-nitrophenyl)piperidin-4-ol (1.50 g, 1.30 mmol, 35.57% purity) in DCM (15 mL) were added BOC2O (311.27 mg, 1.43 mmol) and TEA (262.41 mg, 2.59 mmol). The mixture was stirred at 20 °C for 12 h. The mixture was concentrated under reduced pressure at 40 °C to give tert-butyl N-[4-[4-[[4-hydroxy- l-(4-nitrophenyl)-4-piperidyl]methyl]piperazin- 1- yl]phenyl] carbamate (0.80 g, 96.13% yield) as a yellow oil. LCMS (ESI+) m/z 512.4 [M+H]+.
[0257] Step 9: To a solution of tert-butyl N-[4-[4-[[4-hydroxy-l-(4-nitrophenyl)- 4-piperidyl]methyl]piperazin-l-yl]phenyl]carbamate (0.80 g, 1.25 mmol) in THF (10 mL) was added Pd/C (10%, 182.38 mg) under N2 atmosphere. The suspension was degassed and purged with H2 (3x). The mixture was stirred under H2 (15 psi) at 20 °C for 2 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered over celite. The filtrate was concentrated under reduced pressure to give tert-butyl N- [4-[4-[[l-(4-aminophenyl)-4-hydroxy-4-piperidyl]methyl]piperazin-l-yl]phenyl] carbamate (0.60 g, 88.62% yield) as a yellow oil. The product was used to the next step without further purification. LCMS (ESI+) m/z 482.4 [M+H]+.
[0258] Step 10: To a solution of tert-butylN-[4-[4-[[l-(4-aminophenyl)-4- hydroxy-4-piperidyl]methyl] piperazin- l-yl]phenyl]carbamate (0.60 g, 1.10 mmol) in dioxane (8 mL) and 3-bromopiperidine-2, 6-dione (212.10 mg, 1.10 mmol) were added DIEA
(428.30 mg, 3. 1 mmol) and Nal (16.56 mg, 110.46 pmol,). The mixture was stirred at 100 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was poured into water (10 mL) and extracted with EA (3 x 10 mL). The combined organic layer was washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 1: 1) to give tert- butylN-[4-[4-[[l-[4-[(2,6-dioxo-3-piperidyl)amino]phenyl]-4-hydroxy-4- piperidyl]methyl]piperazin-l-yl]phenyl]carbamate (0.60 g, 86.75% yield) as a white solid. LCMS (ESI+) m/z 593.4 [M+H]+.
[0259] Step 11: A solution of tert-butyl N-[4-[4-[[l-[4-[(2,6-dioxo-3- piperidyl)amino]phenyl]-4-hydroxy -4-piperidyl]methyl]piperazin-l-yl]phenyl]carbamate (0.3 g, 479.11 pmol, 94.66% purity) in TFA (0.3 mL) and DCM (3 mL) was stirred at 20 °C for 12 h. The mixture was concentrated under reduced pressure at 40 °C to give 3 -[4- [4- [[4- (4- aminophenyl)piperazin- l-yl]methyl]-4-hydroxy- 1 -piperidyl] anilino]piperidine-2, 6-dione (0.15 g, 33.17% yield) as a yellow oil. LCMS (ESI+) m/z 493.2 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.75 (br s, 1H), 9.01 (br s, 1H), 7.27 (br d, J = 8.2 Hz, 2H), 6.85 - 6.72 (m, 4H), 6.59 (br d, J = 8.7 Hz, 2H), 5.33 (d, J = 7.2 Hz, 1H), 4.23 - 4.13 (m, 1H), 4.07 (s, 1H), 3.09 - 2.98 (m, 6H), 2.95 - 2.83 (m, 2H), 2.76 - 2.64 (m, 5H), 2.60 - 2.53 (m, 2H), 2.32 (s, 2H), 2.10 (dt, J = 8.7, 4.2 Hz, 1H), 1.91 - 1.75 (m, 1H), 1.73 - 1.61 (m, 2H). 1.56 (br d, J = 12.3 Hz, 2H).
Intermediate 43
2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-3-oxo- pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]ethyl methanesulfonate (FIG. 40)
[0260] Step 1: To a mixture of 2-(4-aminophenyl)ethanol (120.0 mg, 874.77 pmol) and (R)-2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-
(methylsulfonyl)-l ,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (436.1 mg, 1.05 mmol) in DMF (3 mL) was added DIEA (226.1 mg, 1.75 mmol) in one portion at 20 °C under N2. The mixture was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE:EA = 100: 1 to 0: 1) to give 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- [b]pyridin-2-yl]-6-[4-(2-hydroxyethyl)anilino]pyrazolo[3,4-d]pyrimidin-3-one (330.0 mg, 75.93%). LCMS (ESI+) ni/z 473.2 [M+H]+.
[0261] Step 2: To a solution of product obtained from above Step 1 (330.0 mg, 664.21 pmol) in DCM (6 mL) were added TEA (134.4 mg, 1.33 mmol) and MsCl (83.7 mg, 730.63 pmol) in one portion at 25 °C under N2. The mixture was stirred at 25 °C for 1 h. TLC showed the starting material consumed and a new spot was detected. The reaction was purified by prep-TLC (PE:EA = 1:1, Rf=0.5) to give 2-[4-[[2-allyl-l-[(7R)-7-ethyl-7- hydroxy- 5,6-dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]ethyl methanesulfonate (Intermediate 43) (160.0 mg, 43%).
Intermediate 44
[0262] Step 1: To a solution of tert-butyl 4-(4-aminophenyl)-l,4-diazepane-l- carboxylate (1.5 g, 5.04 mmol,) and 3-bromopiperidine-2, 6-dione (1.0 g, 5.54 mmol) in DMF (40 mL) was added NaHCCh (846.9 mg, 10.08 mmol) at 20 °C. The mixture was stirred at 60 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated in vacuum to give tert-butyl 4-[4-[(2,6-dioxo-3- piperidyl)amino]phenyl]-l,4-diazepane-l -carboxylate (1.0 g, 42%), which was used to next step without further purification. LC/MS (ESI) m/z 403.3 [M+H]+.
[0263] Step 2: To a solution of product obtained from above Step 1 (0.60 g, 1.29 mmol) in DCM (20 mL) and TFA (2 mL) was stirred at 25 °C for 2 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated
under reduced pressure at 40 °C to give the crude product. The crude product was purified by prcp-HPLC to give 3-[4-(l,4-diazcpan-l-yl)anilino]pipcridinc-2,6-dionc (150.0 mg, 36%). LC/MS (ESI) m/z 303.3 [M+H]+.
Intermediate 47 and Intermediate 48
(R)-2-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3- oxo-2, 3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)-2-hydroxyethyl methane sulfonate and (S)-2-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)-2-hydroxyethyl methane sulfonate (FIG. 42)
[0264] Step 1: 2-allyl-6-[4-(l,2-dihydroxyethyl)anilino]-l-[(7R)-7-ethyl-7- hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]pyrazolo[3,4-d]pyrimidin-3-one (31.35% yield) was synthesized from l-(4-aminophenyl)ethane-l,2-diol and (R)-2-allyl-l-(7-ethyl-7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-(methylsulfonyl)-l,2-dihydro-3H- pyrazolo[3,4-d]pyrimidin-3-one using 2-propanol as solvent. LC/MS (ESI) m/z 489.3 [M+HJ+.
[0265] Step-2: [2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]-2- hydroxy-ethyl] methanesulfonate (26% yield) was synthesized from the product obtained in above Step 1 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 43. The product obtained was further subjected to SFC purification to afford [(2R)-2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-3- oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]-2-hydroxy-ethyl] methanesulfonate (Intermediate 47) (39% yield) and [(2S)-2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3- oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]-2 - hydroxy-ethyl] methanesulfonate (Intermediate 48) (42% yield).
Intermediate 50 3-[4-[4-[[l-(4-aminophenyl)-4- piperidyl]amino]-l-piperidyl]anilino]piperidine-2, 6-dione (FIG. 43)
[0266] Step 1: tert-butyl N-[4-[4-[[l-[4-[(2,6-dioxo-3-piperidyl)amino]phenyl]- 4-piperidyl]amino]-l-piperidyl]phenyl]carbamate (0.3 g, 27.85%) was synthesized from 3- ((4-(4-aminopiperidin-l-yl)phenyl)amino)piperidine-2, 6-dione and tert-butyl N-[4-(4-oxo-l- piperidyl)phenyl] carbamate . LC/MS (LCMS) m/z 577.4 [M+H]+.
[0267] Step 2: 3-[4-[4-[[l-(4-aminophenyl)-4- piperidyl]amino]-l- piperidyl]anilino]piperidine-2, 6-dione (53.26% yield) was synthesized from the product obtained in above Step 1 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 44. LC/MS (ESI) m/z 477.3 [M+H]+.
Intermediate 51 (2-(3-(2,6-dioxopiperidin-3-yl)benzyl)-2-azaspiro[3.3]heptan-6-yl)methyl methanesulfonate (FIG. 44)
[0268] Step 1: To a mixture of 2,6-dibenzyloxy-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)pyridine (7.29 g, 8.73 mmol) and 2-(3-bromophenyl)-l,3-dioxolane (2.00 g, 8.73 mmol) in Dioxane (90 mL) and H2O (9 mL) were added Pd(dppf)C12 (638.8 mg, 873.09 umol) and K2CO3 (2.41 g, 17.46 mmol) at 25 °C under N2. The mixture was stirred at 100 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was extracted with EA (3 x 100 mL). The combined organic was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluted with PE: EA
= 100: 1 to 0: 1 , Rf = 0.4) to give 2,6-dibenzyloxy-3-[3-(l ,3-dioxolan-2-yl)phenyl] pyridine (2.00 g 50.43%). LC/MS (ESI) m/z 440.3 [M+H]+.
[0269] Step 2: To a solution of 2,6-dibenzyloxy-3-[3-(l,3-dioxolan-2- yl)phenyl]pyridine (2.00 g, 4.40 mmol, 96.72% purity) in THF (40 mL) were added Pd/C (0.47 g, 0.44 mmol, 10% purity) and TEA (445.5 mg, 4.40 mmol) at dropwise atmosphere under N2. The reaction was stirred at 25 °C for 12 h under H2 (15 psi). LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered and the filter cake was washed with THF (50 mL), the collected filtrate was concentrated to give 3-[3-(l,3-dioxolan-2-yl)phenyl] piperidine-2, 6-dione (1.29 g, 55.20%). LC/MS (ESI) m/z 262.23 [M+H]+.
[0270] Step 3: To a solution of 3-[3-(l,3-dioxolan-2-yl)phenyl]piperidine-2,6- dione (1.29 g, 4.94 mmol) in THF (20 mL) was added aqueous HC1 (39.52 mmol 10.05 mL, 2 M) in one portion at 25 °C under N2. The mixture was stirred at 55 °C for 3 h. TLC showed the reaction was completed and new spot was detected. The mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by column chromatography on silica gel (eluted with PE: EA = 100: 1 to 0:1, Rf = 0.4) to afford 3-(2,6- dioxo-3-piperidyl)benzaldehyde (521 mg, 86.86%). !H NMR (400 MHz, DMSO-d6) 8 10.86 (s, 1H), 7.40 - 7.22 (m, 5H), 5.71 (s, 1H), 4.09 - 4.01 (m, 2H), 4.00 - 3.93 (m, 2H), 2.73 - 2.63 (m, 1H), 2.51 - 2.46 (m, 1H), 2.21 (dq. J = 12.3, 4.5, Hz 1H), 2.10 - 1.98 (m, 1H).
[0271] Step 4: 3-[3-[[6-(hydroxymethyl)-2-azaspiro[3.3]heptan-2-yl]methyl] phenyl] piperidine-2, 6-dione (19.53% yield) was synthesized from the product obtained in above Step 3 and 2-azaspiro[3.3]heptan-6-ylmethanol. LC/MS (ESI) m/z 329.2 [M+H]+.
[0272] Step 5: [2-[[3-(2,6-dioxo-3-piperidyl)phenyl]methyl]-2- azaspiro[3.3]heptan-6-yl]methyl methanesulfonate (Intermediate 51) (47.19% yield) as a white solid was synthesized from the product obtained in above Step-4 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 43. LC/MS (ESI) m/z 407.2 [M+H]+.
Intermediate 52
[0273] Step 1: To a solution of 2-[4-(2,6-dibenzyloxy-3-pyridyl)phenyl]ethanol (WO2023/098656 Al ) (0.7 g, 1.07 mmol) in DCM (40.0 mL) was added DMP (1.44 g, 3.4 mmol, 1.05 mL) at 0 °C. The reaction was stirred at 25 °C for 2 h. TLC (PE: EA = 1:1, Rf =0.5) showed the starting material consumed and a new spot was detected. The reaction was quenched with HoO (50.0 mL) at 25 °C and extracted with DCM (3 x 50.0 mL). The organic layer was dried over NaiSCk. After filtration, the filtrate was concentrated under reduced pressure to give the crude product, which was purified by column chromatography on silica gel (eluted with PE: EA = 100: 1 to 1: 1) to give 2-[4-(2,6-dibenzyloxy-3- pyridyl)phenyl] acetaldehyde (0.6 g, 86.14%). LC/MS (ESI) m/z 410.2 [M+H]+.
[0274] Step 2: l-[2-[4-(2,6-dibenzyloxy-3-pyridyl) phenyl]ethyl]-4-(4- nitrophenyl)piperazine (45.44% yield) was synthesized from product obtained from above Step 1 and l-(4-nitrophenyl)piperazine.
[0275] Step 3: 3-[4-[2-[4-(4-aminophenyl)piperazin-l- yl]ethyl]phenyl]piperidine-2, 6-dione (76.52% yield) was synthesized from product obtained from above Step 2 and by following a similar procedure as described in Step 2 for the synthesis of Intermediate 46.
Intermediate 53 l-((l-(4-(2,6-dioxopipcridin-3-yl)phcnyl)pipcridin-4-yl)mcthyl)azctidin-3-yl methanesulfonate (FIG. 46)
[0276] Step
l-[4-(2,6-dibenzyloxy-3-pyridyl)phenyl]piperidine-4- carbaldehyde (31.38% yield) was synthesized by following a similar procedure as described in Step 1 for the synthesis of Intermediate 52. LC/MS (ESI) m/z 479.23 [M+H]+.
[0277] Step 2: l-[[l-[4-(2,6- dibenzyloxy-3-pyridyl)phenyl]-4- piperidyl] methyl] azetidin-3-ol (53 % yield) was synthesized from the product obtained in above Step 1. LC/MS (ESI) m/z 536.3 [M+H]+.
[0278] Step 3: 3-[4-[4-(hydroxymethyl)-l-piperidyl]phenyl]piperidine-2, 6-dione (95% yield) was synthesized from the product obtained in above Step 2. LC/MS (ESI) m/z 358.2 [M+H]+.
[0279] Step 4: [l-[[l-[4-(2,6-dioxo-3-piperidyl)phenyl]-4- piperidyl] methyl] azetidin-3-yl] methane sulfonate (41% yield) was synthesized from the product obtained in above Step 3. LC/MS (ESI) m/z 436.2 [M+H]+.
In termediate 54
[0280] Step 1: To a solution of methyl 2-[4-[[tertbutyl(dimethyl)silyl]oxymethyl]phenyl]acetate (2.1 g, 7.13 mmol) in DMF (80 mL) were added prop-2-enamide (1.01 g, 14.26 mmol) and tBuOK (1.60 g. 14.26 mmol) at 0 °C. The reaction was stirred at 0 °C for 1 h. TLC (PE:EA = 1: 1, RIM). ) showed the reaction was completed and the desired product was detected. The reaction was quenched with saturated
NH4CI solution and extracted with EA (50 mL). The organic layer was washed with brine (30 mL), dried over NaiSCU and filtered. The filtrate was concentrated to give the crude product, which was purified by flash column on silica gel to give 3-[4-[[tert- butyl(dimethyl)silyl]oxymethyl]phenyl]piperidine-2, 6-dione (1.6 g, 67%). 'H NMR (400 MHz, CDCI3) 5 7.93 (br s, 1H), 7.23 (d, J = 8.1 Hz, 2H), 7.07 (d, J = 8.1 Hz, 2H), 4.63 (s, 2H), 3.69 (dd, J = 5.3, 9.2 Hz. 1H). 2.68 - 2.46 (m, 2H), 2.24 - 2.10 (m, 2H), 0.84 (s. 9H). 0.00 (s, 6H).
[0281] Step 2: To a solution of 3-[4-[[tert- butyl(dimethyl)silyl]oxymethyl]phenyl]piperidine-2, 6-dione (1.6 g, 4.80 mmol) in THF (20 mL) was added aqueous HC1 solution (2 N, 2 mL) at 25 °C. The reaction was stirred at 25°C for 1 h. TLC (PE:EA = 1: 1, Rf=0.2) showed the reaction was completed. The reaction was concentrated under reduced pressure to give 3-(4-(hydroxymethyl)phenyl)piperidine-2,6- dione (0.8 g, 76%), which was used to next step without further purification.
[0282] Step 3: To a solution of 3-[4-(hydroxymethyl)phenyl]piperidine-2, 6-dione (0.42 g, 1.92 mmol) in DCM (30 mL) was added DMP (1.22 g, 2.87 mmol) at 0 °C. The reaction was stirred at 0 °C for 1 h. TLC showed the reaction was completed. The reaction was quenched with saturated NaHCCh solution and extracted with DCM (3 x 15 mL). The organic layer was dried over Na SCL and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography on silica gel (eluted with PE:EA = 50: 1 to 5: 1) to give 4-(2,6-dioxo-3-piperidyl)benzaldehyde (Intermediate 54) (0.3 g, 72%).
Intermediate 55
(2-(4-(2,6-dioxopiperidin-3-yl)benzyl)-2-azaspiro[3.3]heptan-6-yl)methyl methanesulfonate
[0283] Step 1: To a solution of 2-azaspiro[3.3]heptan-6-ylmethanol (0.3 g, 1.89 mmol) in THF (10 mL) were added 4-(2,6-dioxo-3-piperidyl)benzaldehyde (Intermediate 54, 409.9 mg, 1.89 mmol) and NaBH(OAc)s (799.8 mg, 3.77 mmol) and TBSC1 (284.4 mg,
1.89 mmol, 231.2 pL) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired compound was detected. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic layers were washed with brine (3 x 10 mL) and dried over NaoSCU- After filtration, the filtrate was concentrated under reduced pressure to give 3-[4-[[6-(hydroxymethyl)-2- azaspiro[3.3]heptan-2-yl] methyl]phenyl]piperidine-2, 6-dione (0.1 g, 12.5%). LC/MS (ESI) m/z 329.2 [M+H]+.
[0284] Step 2: [2-[[4-(2,6-dioxo-3-piperidyl)phenyl] methyl]-2- azaspiro[3.3]heptan-6-yl]methyl methanesulfonate (Intermediate 55) (61% yield) was synthesized from the product obtained in above Step 2 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 43. LC/MS (ESI) m/z 407.2 [M+H]+.
Intermediate 56
[0285] Step 1: To a mixture of 3-(4-aminophenyl)piperidine-2, 6-dione (0.70 g, 2.00 mmol, 58.45% purity) and 3-bromopropan-l-ol (278.5 mg, 2.00 mmol) in DMF (14 mL) was added DIEA (517.8 mg, 4.01 mmol) in one portion at 25 °C under N2. The mixture was stirred at 80 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 60 °C to give the crude product. The crude product was purified by prep-TLC (PE: EA = 0: 1, Rf = 0.4) to give 3-[4- (3-hydroxypropylamino)phenyl]piperidine-2, 6-dione (0.15 g, 15.49%).
[0286] Step 2: 3 -[4-(2,6-dioxo-3-piperidyl)anilino] propyl methanesulfonate (47% yield) was synthesized from the product obtained in above Step 1 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 43. LC/MS (ESI) m/z 436.2 [M+H]+.
Intermediate 57
[0287] 4-(2,6-dioxopiperidin-3-yl)phenethyl methanesulfonate (Intermediate 57) (57% yield) was synthesized from 3- [4-(2-hydroxyethyl)phenyl]piperidine-2, 6-dione by following a similar procedure as described in Step 2 for the synthesis of Intermediate 43. LC/MS (ESI) m/z 329.1 [M+H]+.
Intermediate 58
[0288] 2-[4-(2,6-dioxo-3-piperidyl)anilino]ethyl methanesulfonate (22.27%) was synthesized from 3-[4-(2-hydroxyethylamino)phenyl]piperidine-2, 6-dione.
Intermediate 60
[0289] Step 1: To a mixture of 3-(4-bromophenyl)propan-l-ol (0.5 g, 2.32 mmol) in Dioxane:H2O = 10: 1 (11 mL) were added 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-pyridine (1.16 g, 2.79 mmol), Pd(dppf)Ch (85.05 mg, 116.23 pmol) and K2CO3 (642.56 mg, 4.65 mmol,) at 20 °C. The mixture was stirred at 100 °C for 12 h under N2. LCMS showed the starting material consumed and the desired product was detected. The
mixture was poured into H2O (10 mL). The mixture was extracted with EA (3 x 10 mL). The organic phase was washed with brine (5 mL), dried over anhydrous NaiSCL and concentrated in vacuum to give reduced pressure to give a residue. The crude product was purified by column chromatography on silica gel (eluted with PE: EA = 100: 1 to 10: 1) to give 3-[4-(2,6- dibenzyloxy-3-pyridyl)phenyl]propan-l-ol (0.5 g, 37.13%) as a white solid. LC/MS (ESI) m/z 426.2 [M+H]+.
[0290] Step 2: 3-[4-(3-hydroxypropyl)phenyl]piperidine-2, 6-dione (38% yield) was synthesized from the product obtained in above Step 1 by following a similar procedure as described in Step 2 for the synthesis of Intermediate 46.
[0291] Step 3: 3-[4-(2,6-dioxo-3-piperidyl)phenyl]propanal (Intermediate 60) (50% yield) was synthesized from the product obtained in above Step 2 by following a similar procedure as described in Step 1 for the synthesis of Intermediate 52.
Example 1: 3-((4-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)benzyl)piperazin-l-yl)phenyl) amino)piperidine-2, 6-dione (Compound 1)
[0292] To a mixture of Intermediate 1 (80.0 mg, 170 pmol, 84% purity) in i- PrOH (1 mL) were added a solution of 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[£]pyridin-2-yl]-6-methylsulfonyl-pyrazolo[3,4-< ]pyrimidin-3-one (Huang et al., J. Med. Chem. (2021) 64: 13004-13024, 70.8 mg, 170 pmol) in z’-PrOH (0.5 mL) at 20 °C. Then the mixture was stirred at 80 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was purified by prep- HPLC (NH4HCO3 condition) to afford Compound 1, 3-[4-[4-[[4-[[2-allyl-l-[(7R)-7-ethyl- 7-hydroxy-5,6-dihydrocyclopenta[/?]pyridin-2-yl]-3-oxo-pyrazolo[3,4-<7]pyrimidin-6- yl]amino]phenyl]methyl]piperazin-l-yl]anilino]piperidine-2, 6-dione (10.3 mg, 8% yield, 97.17% purity). LC/MS (ESI) m/z 729.4 [M+H]+, RT: 2.696 min. ’ H NMR (400 MHz, DMSO-d6) 8 10.74 (br s, 1H, NH), 10.25 (br s, 1H, NH), 8.88 (s, 1H), 7.92 (d, J = 8.1 Hz,
1H), 7.70 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 6.74 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 5.68 (tdd, J = 16.8, 10.6, 5.8 Hz, 1H), 5.37 (d, J = 7.3 Hz, 1H), 5.05 (s, 1H, OH), 5.00 (dd, J = 10.3, 1.0 Hz, 1H), 4.86 (dd, J = 17.1, 1.0 Hz, 1H), 4.76 (br dd, J = 16.1, 4.9 Hz, 1H), 4.56 (br dd, J = 16.0, 6.1 Hz, 1H), 4.18 (ddd, 7 = 11.3, 6.9, 4.8 Hz, 1H), 3.47 (s, 2H), 3.04 - 2.87 (m, 5H), 2.85 - 2.65 (m, 2H), 2.62 - 2.53 (m, 1H), 2.49 - 2.44 (m, 4H), 2.20 (ddd, J = 13.5, 8.3, 5.8 Hz, 1H), 2.10 (ddd, J = 13.3. 8.7, 4.4 Hz. 1H). 2.01 (ddd, 7 - 13.4, 8.4, 5.3 Hz, 1H), 1.94 - 1.77 (m, 2H), 1.76 - 1.64 (m, 1H), 0.87 (t. 7 - 7.4 Hz, 3H).
Example 2: 3-((4-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-dJpyrimidin-6- yl)amino)phenethyl)piperazin-l-yl) phenyl)amino)piperidine-2, 6-dione (Compound 2)
[0293] Compound 2 was prepared by following the similar procedure described in Example 1 using Intermediate 2 (0.120 g, 294 pmol ) in place of Intermediate 1, afforded the desired titled product Example 2, 3-((4-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7- dihydro-5/7-cyclopenta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7-pyrazolo[3,4-<7]pyrimidin-6- yl)amino)phenethyl)piperazin- l-yl)phenyl)amino)piperidine-2, 6-dione after purification (13.8 mg. 18.6 pmol, 6.3% yield. 100% purity). 'l l NMR (400 MHz, DMSO-d6) 5 10.75 (s, 1H. NH). 10.21 (br s. 1H, NH), 8.87 (s. 1H). 7.91 (d, J = 8.1 Hz, 1H), 7.70 (d. J = 8.1 Hz. 1H), 7.65 (br d, J - 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 6.76 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 5.74 - 5.61 (m. 1H), 5.37 (br d, J = 6.0 Hz, 1H, NH), 5.05 (br s, 1H, OH), 5.00 (dd, J = 9.2, 1.0 Hz, 1H), 4.86 (dd, J = 17.1, 1.0 Hz, 1H), 4.75 (br dd, J = 15.7, 3.8 Hz, 1H), 4.56 (br dd, J = 16.0, 6.1 Hz, 1H), 4.24 - 4.13 (m, 1H), 3.01 - 2.90 (m, 5H), 2.80 - 2.68 (m, 4H), 2.60 - 2.48 (m. 7H), 2.26 - 2.15 (m, 1H), 2.15 - 2.06 (m, 1H). 2.01 (ddd. J = 13.4, 8.4, 5.3 Hz, 1H), 1.95 - 1.77 (m, 2H), 1.76 - 1.64 (m, 1H), 0.87 (t, J = 7.4 Hz, 2H).
Example 3: 3-((4-(4-(4-((2-allyl-l-((R)-7-cthyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)phenyl) amino )piperidine-2,6-dione (Compound 3)
[0294] Compound 3 was prepared by following the similar procedure described in Example 1 using Intermediate 3 (70.0 mg, 175 pmol 94.91% purity) in place of Intermediate 1. The mixture was filtered and the filtrate was concentrated to give a residue, which was purified by prep-HPLC (NH4HCO3 condition) to give Compound 3, 3-((4-(4-(4- ((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3- dihydro-lH-pyrazolo[3,4-<7]pyrimidin-6-yl)amino)phenyl)piperazin-l- yl)phenyl)amino)piperidine-2, 6-dione (12.0 mg, 9.4% yield, 98.42% purity). LC/MS (ESI ) m/z 713.4 [M-H]-, RT: 2.681 min. 'H NMR (400 MHz, DMSO-d6) 8 10.51 - 10.38 (m, 1H, NH), 9.74 (s, 1H, NH), 8.78 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 8.9 Hz, 2H), 6.96 (d, J = 8.9 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.69 (d, J = 8.8 Hz, 2H), 5.78 - 5.63 (m, 1H), 5.17 (d, J = 7.0 Hz, 1H). 5.02 (d, J = 10.4 Hz, 1H), 4.94 (d. J = 17.6 Hz, 1H), 4.76 - 4.68 (m, 1H), 4.71 (s, 1H, OH), 4.62 - 4.54 (m, 1H), 4.17 (ddd, J = 10.7, 6.3, 4.9 Hz, 1H), 3.30 - 3.21 (m, 4H), 3.16 - 3.08 (m, 4H), 3.08 - 3.04 (m, 1H), 3.00 - 2.95 (m, 1H), 2.85 - 2.76 (m. 1H), 2.73 - 2.63 (m, 1H). 2.28 - 2.13 (m, 2H), 2.12 - 2.02 (m, 1H). 1.98 - 1.82 (m, 2H), 1.81 - 1.69 (m, 1H), 0.90 (t, J = 7.5 Hz, 3H).
Example 4: 3-((4-(4-(3-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b] pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6yl)amino)phenyl)propyl) piperazin- l-yl)phenyl)amino)piperidine-2, 6-dione (Compound 4)
[0295] Compound 4 was prepared by following the similar procedure described in Example 1 using Intermediate 4 (80.0 mg, 193 pmol) in place of Intermediate 1. The mixture was filtered and the filtrate was concentrated to give a residue, which was purified by prep-HPLC (FA condition) to give Compound 4, 3-((4-(4-(3-(4-((2-allyl-l-((R)-7-ethyl-7- hydroxy-6,7-dihydro-5/7-cyclopenta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro- 1 H-pyrazolo[3,4- d]pyrimidin-6-yl)amino)phenyl)propyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione, (18.4 mg, 24.1 pmol, 7.8% yield, 99% purity). LC/MS (ESI+) mJz 757.4 [M+H]+. RT: 2.155 min. ’ H NMR (400 MHz, DMSO-d6) 8 10.75 (br s, 1H, NH), 10.21 (br s, 1H, NH), 8.87 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.65 (br d. J = 8.1 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 6.75 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 5.73 - 5.61 (m, 1H), 5.37 (d, J = 7.2 Hz, 1H), 5.05 (br s, 1H), 5.00 (d, J = 9.7 Hz, 1H), 4.86 (br d, J = 17.4 Hz, 1H), 4.81 - 4.70 (m, 1H). 4.56 (brdd, J = 16.0, 6.0 Hz. 1H), 4.23 - 4.13 (m, 1H). 3.02 - 2.96 (m, 1H). 2.94 (br s, 4H), 2.83 - 2.65 (m, 2H), 2.60 - 2.54 (m, 3H), 2.49 - 2.45 (m, 4H), 2.31 (br t, J = 7.0 Hz, 2H), 2.20 (ddd, J = 13.4, 8.1, 5.6 Hz, 1H), 2.15 - 2.06 (m, 1H), 2.01 (ddd, J = 13.4, 8.4, 5.3 Hz, 1H), 1.95 - 1.80 (m. 2H). 1.80 - 1.65 (m, 3H), 0.87 (t, J = 7.4 Hz. 3H).
Example 5: 3-((3-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)phenyl) amino)piperidine-2,6-dione (Compound 5)
[0296] Compound 5 was prepared by following the similar procedure described in Example 1 using Intermediate 6 (0.250 g, 333 pmol, 50.47% purity) in place of Intermediate 1. The mixture was filtered and the filtrate was concentrated to give a residue, which was purified by prep-HPLC (NH4HCO3 condition) to give Compound 5, 3-((3-(4-(4- ((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3- dihydro-lH-pyrazolo[3,4-<7]pyrimidin-6-yl)amino)phenyl)piperazin-l- yl)phenyl)amino)piperidine-2, 6-dione, (24.4 mg, 10% yield, 100% purity). LC/MS (ESI+) m/z 715.3 [M+H]+, RT: 2.179 min. ‘H NMR (400 MHz. DMSO-d6) 5 10.77 (br s, 1H, NH), 10.32 - 10.03 (m, 1H, NH), 8.83 (s, 1H), 7.94 (br d, J = 5.6 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.67 - 7.54 (m, 2H), 6.99 (d, 7 = 8.1 Hz, 1H), 6.95 (dd, J = 8.0, 8.0 Hz, 1H), 6.34 (s, 1H), 6.26 (dd. J = 8.0, 1.6 Hz, 1H). 6.18 (dd, J = 8.0, 1.6 Hz, 1H), 5.73 - 5.61 (m, 2H), 5.05 (s, 1H), 5.00 (dd, J = 10.2, 1.2 Hz, 1H), 4.86 (dd, J = 17.1, 1.2 Hz, 1H), 4.82 - 4.70 (m, 1H), 4.62 - 4.51 (m, 1H), 4.38 - 4.29 (m, 1H), 3.23 (s, 8H), 3.03 - 2.93 (m, 1H), 2.83 - 2.70 (m, 2H), 2.59 (td, J = 17.6. 4.2 Hz, 1H), 2.27 - 2.16 (m. 1H), 2.11 (td, J = 8.6, 4.1 Hz, 1H), 2.02 (ddd, J = 13.5, 8.5, 5.3 Hz, 1H), 1.95 - 1.80 (m, 2H), 1.71 (qd, J = 13.8, 7.1 Hz, 1H), 0.87 (t, J = 7 A Hz, 3H).
Example 6: 3-((4-(4-((4-(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)piperidin-l-yl)phenyl)amino)piperidine-2, 6-dione
[0297] To a mixture of Intermediate 7 (0.34 g, 648 pmol, 60.12% purity) in DCM (2 mL) were added Intermediate 8 (332 mg, 648 pmol,) and DIEA (168 mg, 13.0 pmol,) at 25 °C. The mixture was stirred at 25 °C for 0.5 h under N2. AcOH (77.9 mg, 13.0 pmol) and NaBH(OAc)a (275 mg, 1.30 mmol) was added to the mixture at 0 °C. The mixture was stirred at 25 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered and the filter was concentrated to give the residue.
The residue was purified by prep-HPLC (NH4HCO3 Condition) to give Compound 6, 3-((4- (4-((4-(4-((2-allyl-l-((/?)-7-cthyl-7-hydroxy-6,7-dihydro-5H-cyclopcnta[h]pyridin-2-yl)-3- oxo-2, 3-dihydro-lH-pyrazolo[3,4-7]pyrimidin-6-yl)amino)phenyl)piperazin-l- yl)methyl)piperidin-l-yl)phenyl)amino) piperidine-2, 6-dione, (43.2 mg, 8.2% yield, 100% purity). LC/MS (ESI+) m/z 812.4 [M+H]+, RT: 1.936 min.
NMR (400 MHz, DMSO-d6) 5 10.75 (s, 1H. NH). 10.19 - 10.03 (m, 1H. NH). 8.82 (s, 1H). 7.93 (br d. J = 7.6 Hz, 1H). 7.69 (d, 7 = 8.1 Hz, 1H), 7.58 (br s, 2H), 6.92 (br d, 7 = 8.9 Hz, 2H), 6.76 (d, J= 8.9 Hz, 2H), 6.60 (d, J = 8.8 Hz, 2H), 5.73 - 5.60 (m, 1H), 5.35 (d, J = 7.3 Hz, 1H. NH), 5.05 (s, 1H), 5.00 (dd, J = 10.2, 1.0 Hz, 1H), 4.85 (br d, J = 17.4 Hz, 1H), 4.80 - 4.70 (m, 1H), 4.57 (br dd, J = 15.7, 5.5 Hz, 1H), 4.22 - 4.13 (m, 1H), 3.42 - 3.32 (m, 3H), 3.31 (s, 4H), 3.10 (br s, 4H), 3.02 - 2.92 (m, 1H), 2.82 - 2.68 (m, 2H). 2.62 - 2.53 (m, 2H), 2.48 - 2.45 (m, 2H), 2.26 - 2.15 (m, 3H), 2.10 (dt, J = 8.9, 4.9 Hz, 1H), 2.02 (ddd, J = 13.4, 8.5, 5.3 Hz, 1H), 1.88 (br dd, J = 12.7, 5.5 Hz, 1H), 1.86 - 1.75 (m, 3H), 1.70 (br dd, J = 13.6, 7.3 Hz, 1H), 1.61 (br d, J = 3.9 Hz, 1H), 0.87 (t, 7 = 7.4 Hz, 3H).
Example 7 : 3-(4-(4-(( 1 - (4-((2- ally 1- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H-cyclopenta[b] pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperidin- 4-yl) amino)piperidin-l-yl)phenyl)piperidine-2,6-dione (Compound 7)
[0298] Compound 7 was prepared by following the similar procedure described in Example 1 using Intermediate 10 (0.150 g, 0.325 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by prcp-HPLC (Column/dimcnsions: X-SELECT C18 (19*250*5um) Mobile phase
A: 0.1 % formic acid in in water; Mobile phase B: Acetonitrile; Gradient (Time/%B): 0.01/10, 1/10, 10/30, 15/30, 15.01/100, 18/100, 18.01/10, 20/10. Flow rate: 16 mL/min.; Solubility: Acetonitrile + THF + water) to obtain Compound 7, 3-(4-(4-((l-(4-((2-allyl-l-((7?)-7-ethyl- 7 -hydroxy-6, 7-dihydro-5/7-cyclopenta[i] pyridin-2-yl)-3-oxo-2,3-dihydro-l/7-pyrazolo[3,4- ^]pyrimidin-6-yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2,6- dione (57 mg, 22%). LC/MS (ESI+) /z 797.59 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 5 10.77 (s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.69 (d, J =
8.4 Hz, 1H), 7.57 (br s, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.4 Hz. 2H), 6.90 (d, J =
8.8 Hz, 2H), 5.72 - 5.60 (m, 1H), 5.05 (br s, 1H, OH), 5.00 (d, J = 9.6 Hz, 1H), 4.86 (d, J =
17.2 Hz, 1H), 4.81 - 4.70 (m, 1H), 4.62 - 4.50 (m, 1H), 3.75 - 3.57 (m, 5H), 3.03 - 2.85 (m,
3H), 2.85 - 2.57 (m, 7H), 2.50 - 2.45 (m, 1H). 2.25 - 1.83 (m, 8H), 1.77 - 1.65 (m, 1H). 1.48 - 1.33 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H). Formate ion peak observed in 1 H NMR.
Example 8: 3-(4-(4-(( 1 - (4-((2- ally 1- 1 -((R)-7-ethyl-7 -hydroxy-6,7 -dihydro-5H-cyclopenta[b] pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperidin- 4-yl) methyl)piperazin-l-yl)phenyl)piperidine-2, 6-dione (Compound 8)
[0299] Compound 8 was prepared by following the similar procedure described in Example 1 using Intermediate 12 (0.100 g, 0.217 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by prep-HPLC (Column/dimensions: X-SELECT C18 (19*250*5um) Mobile phase A: 5mM ammonium acetate in water. Mobile phase B: Acetonitrile; Gradient (Time/%B): 0.01/25, 1/25, 15/60, 17.5/60, 17.6/100, 20/100, 20.1/25, 23/25. Flow rate: 18 mL/min.; Solubility: THF + ACN + water) to obtain Compound 8, 3-(4-(4-((l-(4-((2-allyl-l-((7?)-7-
ethyl-7-hydroxy-6,7-dihydro-5/7-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7- pyrazolo[3,4-<7]pyrimidin-6yl)amino)phcnyl)pipcridin-4-yl)mcthyl)pipcrazin-l- yl)phenyl)piperidine-2, 6-dione (9 mg. 5%). LC/MS (ESI+) m z 797.50 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 8 10.77 (s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.56 (br s, 2H), 7.06 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz. 2H), 6.89 (d, J = 8.4 Hz. 2H), 5.73 - 5.60 (m. 1H). 5.05 (s, 1H. OH). 5.00 (d, J = 9.2 Hz, 1H), 4.87 (d, J = 17.2 Hz, 1H), 4.80 - 4.70 (m, 1H), 4.60 - 4.50 (m, 1H), 3.758 - 3.69 (m, 1H), 3.64 (br d, J = 12.0 Hz, 2H), 3.17(br s, 4H), 3.01 - 2.92 (m, 1H), 2.85 - 2.72 (m, 1H), 2.69 - 2.55 (m, 7H), 2.50 - 2.45 (m, 1H), 2.25 - 2.04 (m, 4H), 2.04 - 1.95 (m, 2H), 1.94 - 1.83 (m, 1H), 1.83 (br d, J = 12.0 Hz, 2H), 1.76 - 1.64 (m, 2H), 1.32 - 1.17 (m, 2H), 0.87 (t, J = 7.2 Hz, 3H).
Example 9: 3-(4-(4-(((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl) methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0300] Compound 9 was prepared by following the similar procedure described in Example 1 using Intermediate 14 (0.190 g, 0.399 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by prep-HPLC (Column/dimensions: X-SELECT C18 (19*250*5um); Mobile phase A: 10 mM ammonium acetate in water; Mobile phase B: acetonitrile; Gradient (Time/%B): 0.01/25, 2/25, 10/45, 15/45, 15.1/100, 20.5/100, 20.6/45, 22.5/45. Flow rate: 18 mL/min.; Solubility: ACN + water + THF) to obtain Compound 9, 3-(4-(4-((( 1 -(4-((2-allyl-
l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3-dihydro- lH-pyrazolo[3,4-<7]pyrimidin-6-yl)amino)phcnyl)pipcridin-4-yl)mcthyl)amino)pipcridin-l- yl)phenyl)piperidine-2, 6-dione (35 mg, 11%). LC/MS (ESI+) m/z 811.62 [M+H]+.
NMR (400 MHz, DMSO-d6) 6 10.77 (s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.92 (d, J = 7.2 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.56 (br s, 2H), 7.03 (d, J = 8.4 Hz, 2H), 9.91 (d, J = 9.0 Hz. 1H), 6.88 (d, J = 9.0 Hz. 1H), 5.72 - 5.60 (m. 1H). 5.05 (s, 1H. OH). 5.00 (d, J = 9.2 Hz, 1H), 4.87 (d, J = 17.2 Hz, 1H), 4.80 - 4.70 (m, 1H), 4.60 - 4.50 (m, 1H), 3.75 - 3.67 (m, 1H), 3.65 - 3.55 (m, 4H), 3.02 - 2.92 (m, 1H). 2.85 - 2.55 (m, 7H), 2.52 - 2.40 (m, 1H), 2.25 - 2.15 (m, 1H), 2.15 - 2.06 (m, 1H), 2.05 - 1.95 (m, 2H), 1.93 - 1.75 (m, 7H), 1.73 - 1.65 (m, 1H), 1.55 - 1.42 (m, 1H), 1.40 - 1.18 (m, 4H), 0.87 (t, J = 7.2 Hz, 3H).
Example 10: 3-(4-(2-((( 1 -(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl) methyl)amino)ethoxy)phenyl)piperidine-2, 6-dione
[0301] Compound 10 was prepared by following the similar procedure described in Example 1 using Intermediate 16 (0.210 g, 0.481 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by RP-HPLC (Column/dimensions: X-SELECT C18 (19*250*5um); Mobile phase A: 5mM ammonium acetate in water; Mobile phase B: acetonitrile; Gradient (Time/%B): 0.01/20, 1/20, 10/45, 14/45, 14.1/100, 17/100, 17.1/20, 20/20; Flow rate: 17 mL/min.; Solubility: ACN + THF + water) to obtain Compound 10, 3-(4-(2-(((l-(4-((2-allyl- l-((R)-7- ethyl-7-hydroxy-6,7-dihydro-5Z/-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7-
pyrazolo[3,4-ri]pyrimidin-6-yl)amino)phenyl)piperidin-4- yl)mcthyl)amino)cthoxy)phcnyl)pipcridinc-2,6-dionc (23 mg, 6%). LC/MS (ESI+) m/z 772.58
10.77 (s. 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.93 (d, J = 72 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.56 (br s, 2H), 7.13 (d, J = 8.8 Hz, 2H), 6.93-6.89 (m, 4H), 5.72 - 5.60 (m, 1H), 5.01 (s, 1H, OH), 5.00 (d, J = 9.2 Hz, 1H), 4.87 (d. J = 17.2 Hz, 1H). 4.80 - 4.70 (m. 1H), 4.60 - 4.50 (m, 1H), 4.01(t, J = 5.6 Hz. 2H), 3.78 (dd, J - 11.4, 5.0 Hz, 1H), 3.63 (br d, J - 12.0 Hz, 2H), 3.03 - 2.92 (m, 1H), 2.88 (br s, 2H), 2.85 - 2.70 (m, 1H), 2.70 - 2.52 (m, 3H). 2.48 - 2.42 (m, 1H), 2.25 - 2.10 (m, 2H), 2.07 - 1.95 (m, 2H), 1.94 - 1.75 (m, 5H), 1.75 - 1.65 (m, 1H), 1.60 - 1.47 (m, 1H), 1.30 - 1.18 (m, 2H), 0.87 (t, J= 7.2 Hz, 3H).
Example 11 : 3 -(4- (( 1 -(( 1 -(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl) methyl)piperidin-4-yl)oxy)phenyl)piperidine-2, 6-dione
[0302] Compound 11 was prepared by following the similar procedure described in Example 1 using Intermediate 17 (0.210 g, 0.481 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by RP-HPLC (Column/dimensions: X-SELECT C18 (19*250*5um); Mobile phase A: lOmM ammonium acetate in water; Mobile phase B: 100% Acetonitrile; Gradient (Time/%B): 0.01/20, 1/30, 15/60, 15.1/100. 17/100, 17.1/30, 20/30; Flow rate: 17 mL/min.; Solubility: water + ACN + THF) to obtain Compound 11, 3-(4-(( 1 -((1 -(4-((2-allyl- 1-((7?)-7-
ethyl-7-hydroxy-6,7-dihydro-5/7-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7- pyrazolo[3,4-<7]pyrimidin-6-yl)amino)phcnyl)pipcridin-4-yl)mcthyl)pipcridin-4- yl)oxy)phenyl)piperidine-2,6-dione (16 mg, 6%). LC/MS (ESI+) m/z 812.60 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 5 10.77 (s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.92 (d, 7 = 7.2 Hz, 1H), 7.69 (d. J = 8.4 Hz, 1H), 7.56 (br s, 2H), 7.11 (d, J = 8.8 Hz, 2H), 6.93 - 6.86 (m, 4H), 5.72 - 5.60 (m. 1H), 5.05 (s. 1H, OH), 5.00 (d. J = 9.2 Hz, 1H), 4.87 (d. J = 17.2 Hz. 1H), 4.80 - 4.70 (m, 1H), 4.60 - 4.50 (m, 1H), 4.40 - 4.30 (m, 1H), 3.77 (dd, J - 11.4, 5.0 Hz, 1H), 3.63 (br d, J = 12.0 Hz, 2H), 3.03 - 2.90 (m, 1H), 2.83 - 2.73 (m, 1H). 2.73 - 2.55 (m, 5H), 2.48 - 2.42 (m, 1H), 2.25 - 2.10 (m, 5H), 2.08 - 1.85 (m, 4H), 1.82 - 1.75 (m, 5H), 1.76
- 1.66 (m, 1H), 1.68 - 1.56 (m, 2H), 1.30 - 1.14 (m, 2H), 0.87 (t, 7 = 7.2 Hz, 3H).
Example 12: 4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl) -[l,3'-bipiperidine]-2',6'-dione (Compound 12)
[0303] Compound 12 was prepared by following the similar- procedure described in Example 1 using Intermediate 19 (0.120 g, 209 pmol, 67.05% purity) in place of Intermediate 1 . The mixture was stirred at 80 °C for 12 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered and the filter was concentrated to give the residue which was purified by RP-HPLC (FA condition) to obtain Compound 12, 4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-577- cyclopenta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7-pyrazolo[3.4-<7]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)-[l,3'-bipiperidine]-2',6'-dione, (24.1 mg, 16% yield, 100.00% purity). LC/MS (ESI+) ni/z 721.4 [M+H]+, RT: 1.892 min.
NMR (400 MHz, DMSO-de) 5 10.56 (s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.92 (br d, J = 7.5 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.57 (br d, J = 1.3 Hz, 2H), 6.91 (br d, J = 9.0 Hz, 2H), 5.66 (tdd, J = 17.0, 10.4, 6.0 Hz. 1H), 5.05 (s, 1H, OH), 4.99 (dd, J = 10.4, 1 .1 Hz, 1H). 4.85 (br
dd, 7 = 17.0, 1.1 Hz, 1H), 4.80 - 4.68 (m, 1H), 4.56 (br dd, 7 = 15.8, 5.3 Hz, 1H), 3.37 (dd, 7 = 10.9, 4.3 Hz, 1H), 3.08 (br s, 4H), 3.02 - 2.91 (m, 1H), 2.83 - 2.70 (m, 3H), 2.63 - 2.52 (m, 3H), 2.48 (br s, 4H). 2.46 - 2.35 (m, 1H), 2.25 - 2.13 (m. 1H), 2.17 (d, 7 = 7.2 Hz, 2H), 2.08 - 1.95 (m, 2H), 1.94 - 1.80 (m, 2H), 1.76 - 1.63 (m, 3H), 1.58 - 1.45 (m, 1H), 1.15 - 1.01 (m, 2H), 0.87 (t, 7 = 7.4 Hz, 3H).
Example 13: 3-((3-(4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3.4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)piperidin-l-yl)phenyl)amino)piperidine-2, 6-dione
[0304] Compound 13 was prepared by following the similar procedure described in Example 6 using Intermediate 22 (150 mg, 228 pmol, 48.01% purity) in place of Intermediate 7 to react with Intermediate 8. The mixture was stirred at rt for 2 h. LCMS showed the starting material was consumed and main product with desired MS was detected. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA condition) to give Compound 13, 3-((3-(4-((4-(4-((2-allyl- 1- ((R)-7-ethyl-7-hydroxy-6.7-dihydro-5//-cyclopenta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro-l/7- pyrazolo[3 ,4-<7]pyrimidin-6-yl)amino)phenyl)piperazin- 1 -yl)methyl)piperidin- 1 - yl)phenyl)amino)piperidine-2, 6-dione (11.5 mg, 6% yield, 100% purity) was obtained. LC/MS (ESI+) m/z 812.4 [M+H]+, RT: 1.982 min. ’H NMR (400 MHz, DMSO-d6) 8 10.75 (br s, 1H, NH), 10.12 (br s, 1H, NH), 8.82 (s, 1H), 7.93 (br d, 7= 7.4 Hz, 1H), 7.69 (d, 7= 8.1 Hz, 1H), 7.58 (br s, 2H), 6.92 (br d, 7 = 8.8 Hz, 2H), 6.90 (t, 7 = 8.1 Hz, 1H), 6.27 (s, 1H), 6.19 (dd, 7 = 8.1, 1.2 Hz, 1H), 6.11 (dd. 7 = 8.1, 1.2 Hz. 1H), 5.72 - 5.61 (m, 1H). 5.59 (d, 7 = 7.5 Hz, 1H, NH), 5.05 (s, 1H, OH), 4.99 (dd, 7 = 10.4, 0.8 Hz, 1H), 4.85 (br d, 7 = 17.6 Hz, 1H), 4.81 - 4.68 (m, 1H), 4.62 - 4.52 (m, 1H), 4.34 - 4.26 (m, 1H). 3.60 (br d, 7 = 11.4 Hz, 2H), 3.10 (br s, 4H), 3.02 - 2.93 (m, 1H), 2.82 - 2.69 (m, 2H), 2.65 - 2.55 (m, 3H), 2.50 (br s,
4H), 2.25 - 2.16 (m, 3H), 2.14 - 2.07 (m, 1H), 2.06 - 1.97 (m, 1H), 1.95 - 1.82 (m, 2H), 1.78 (br d, 7= 12.5 Hz, 2H), 1.74 - 1.63 (m, 2H), 1.27 - 1.14 (m, 2H), 0.87 (t, 7 = 7.4 Hz, 3H).
Example 14: 3-(4-(6-(( 1 -(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl) methyl)-2,6-diazaspiro[3.3]heptan-2-yl)phenyl)piperidine-
[0305] Compound 14 was prepared by following the similar’ procedure described in Example 1 using Intermediate 24 (100 mg, 126 pmol, 59.48% purity) in place of Intermediate 1, afforded the desired titled product Compound 14, 3-(4-(6-((l-(4-((2-allyl- l-((7?)-7-ethyl-7-hydroxy-6,7-dihydro-5//-cyclopenta[/?Jpyridin-2-yl)-3-oxo-2,3-dihydro- lH-pyrazolo[3,4-7]pyrimidin-6-yl)amino)phenyl)piperidin-4-yl)methyl)-2,6- diazaspiro[3.3]heptan-2-yl)phenyl)piperidine-2,6-dione, (23 mg, 22% yield, 97.53% purity). LCMS (ESI+) m/z 809.3 [M+H]+, RT: 1.982 min. ‘H NMR (400 MHz, DMSO-d6) 8 10.74 (s, 1H, NH), 10.10 (br s, 1H, NH), 8.81 (s, 1H), 7.92 (br d, J = 7.5 Hz, 1H), 7.69 (br d, J = 8.1 Hz, 1H), 7.56 (br s, 2H), 7.00 (br d, J = 8.1 Hz, 2H), 6.90 (br d, J = 8.6 Hz. 2H), 6.38 (br d, J = 8.3 Hz, 2H), 5.71 - 5.61 (m, 1H), 5.05 (s, 1H, OH), 5.00 (d, J = 10.4Hz, 1H), 4.85 (d, J = 17.2 Hz, 1H), 4.81 - 4.70 (m, 1H), 4.63 - 4.50 (m, 1H), 3.84 (br s, 4H), 3.69 (br dd, J = 10.6, 4.8 Hz, 1H), 3.60 (br d, J = 10.9 Hz, 1H), 3.27 (br s, 4H). 3.01 - 2.92 (m, 1H), 2.84 - 2.73 (m, 1H), 2.65 - 2.53 (m, 3H), 2.48 - 2.40 (m, 1H), 2.27 (br d, J = 6.3 Hz, 2H), 2.26 - 2.16 (m, 1H), 2.13 - 2.06 (m, 1H), 2.06 - 1.95 (m. 2H), 1.93 - 1.84 (m, 1H), 1.80 - 1.65 (m, 3H), 1.43 - 1.32 (m, 1H), 1.30 - 1.13 (m, 2H), 0.87 (br t, J = 7.3 Hz, 3H).
Example 15: 3-(4-(4-((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl) amino)butoxy)phenyl)piperidine-2, 6-dione (Compound 16)
[0306] Compound 15 was prepared by following the similar procedure described in Example 1 using Intermediate 26 (388 mg, 0.860 mmol) in place of Intermediate 1. The mixture was stirred at rt for 48 h. The crude was diluted with saturated sodium bicarbonate solution (50 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product. The crude product was purified by silica gel flash chromatography using 0 to 10% MeOH in DCM as eluent to get enriched product (250 mg) which was further purified by RP-HPLC (Column/dimensions: XB RIDGE C8 (19*150*5um); Mobile phase A: lOmM ammonium acetate in water; Mobile phase B: acetonitrile; Gradient (Time/%B): 0.1/10, 1/10, 10/40, 13/40, 13.1/100, 17/100, 17.1/10, 19/10; Flow rate: 18 mL/min.; Solubility: Acetonitrile + THF + water) to obtain Compound 15, 3-(4-(4-((l-(4-((2-allyl- 1- ((7?)-7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[/?]pyridin-2-yl)-3-oxo-2,3-dihydro-lH- pyrazolo[3,4-ri]pyrimidin-6-yl)amino)phenyl)piperidin-4- yl)amino)butoxy)phenyl)piperidine-2, 6-dione (111 mg, 18%). LCMS (ESI+) m/z 786.64 [M+H]+. ’ H NMR (400 MHz, DMSO-d6) 8 10.77 (br s, 1H, NH), 10.11 (br s, 1H, NH), 8.81 (s, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.55 (br s, 2H), 7.11 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 9.2 Hz, 2H), 6.88 (d. J = 8.4 Hz, 2H), 5.73 - 5.60 (m, 1H), 5.01 (br s, 1H, OH), 4.99 (d, J = 9.6 Hz, 1H), 4.85 (d, J = 17.2 Hz, 1H), 4.82 - 4.70 (m, 1H), 4.62 - 4.50 (m, 1H), 3.96 (t, J= 6.4 Hz, 2H), 3.77 (dd. J= 11.4, 5.0 Hz, 1H), 3.62 - 3.52 (m, 2H), 3.03 - 2.92 (m, 2H), 2.83 - 2.72 (m, 1H), 2.72 - 2.63 (m, 3H), 2.61 (t, J = 6.8 Hz, 2H), 2.52 - 2.43 (m,
1H), 2.25 - 2.07 (m, 2H), 2.06 - 1.95 (m, 2H), 1.95 - 1.83 (m, 3H), 1.80 - 1.65 (m, 3H), 1.61
- 1.50 (m, 2H), 1.40 - 1.30 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H).
Example 16: 3-(4-(4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0307] Compound 16 was prepared by following the similar procedure described in Example 6 using l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbaldehyde
(Reference: WO 2022/012622, P150, 58.6 mg, 0.195 mmol) in place of Intermediate 7 to react with Intermediate 8. The mixture was stirred at rt for 16 h. The reaction was quenched with water (35 mL) and extracted with dichloromethane (2 x 50 mL). The organic layer was washed with water (20 mL) and saturated sodium bicarbonate solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by prep-HPLC (Column/dimensions: x-BRIDGE C8; Mobile phase A: 5mM ammonium acetate; Mobile phase B: Acetonitrile; Gradient (Time/%B): 0.01/20, 1/20, 10/45, 15/45, 15.1/100, 19/100, 19.1/20, 22/20; solubility: Acetonitrile + THF + water; Flow rate: 18 mL/minutes) to get Compound 16, 3-(4-(4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7- dihydro-5/7-cyclopenta[Z?]pyridin-2-yl)-3-oxo-2,3-dihydro-l//-pyrazolo[3,4-i/]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)piperidin-l-yl)phenyl)piperidine-2, 6-dione (33 mg, 21%). LCMS (ESI+) m/z 797.73 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 8 10.77 (br s, 1H, NH), 10.11 (br s, 1H, NH), 8.82 (s, 1H), 7.93 (d. J = 6.8 Hz, 1H), 7.70 (d, J = 8.0 Hz. 1H), 7.56 (br s, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 5.75 - 5.60 (m, 1H), 5.05 (br s, 1H, OH), 5.00 (d, J = 10.4 Hz, 1H), 4.86 (d, J = 17.2 Hz, 1H), 4.82 - 4.70 (m, 1H), 4.62 - 4.50 (m, 1H), 3.72 (dd, J = 11.0, 5.0 Hz, 1H), 3.67 (br d, J = 12.4 Hz, 2H), 3.11 (br s, 4H), 3.05 - 2.93 (m, 1H), 2.85 - 2.73 (m, 1H), 2.72 - 2.57 (m, 4H), 2.53 -
-I l l-
2.43 (m, 3H), 2.38 - 2.07 (m, 3H), 2.06 - 1.95 (m, 3H), 1.93 - 1.83 (m, 1H), 1.81 (br d, 7 = 11.6 Hz, 2H), 1.78 - 1.65 (m, 3H), 1.30 - 1.15 (m, 2H), 0.87 (t, 7 = 7.2 Hz, 3H).
Example 17: 3-[4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]phenyl]piperidine-2, 6-dione (Compound 17)
[0308] To a solution of 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b] pyridin-2-yl]-6-methylsulfonyl-pyrazolo[3,4-d]pyrimidin-3-one (186.6 mg, 449.24 pmol) in iPrOH (2 mL) was added 3-[4-[4-(4-aminophenyl)piperazin-l- yl]phenyl]piperidine-2, 6-dione (Intermediate 27) (100.0 mg, 224.62 pmol) at 25 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered, and the filter was concentrated to give a residue. The residue was purified by prep-HPLC (NH4HCO3 Condition) to afford 3- [4- [4- [4- [ [2 - ally 1- 1 - [(7R)-7 -cthyl-7-hy droxy-5 ,6-dihydrocyclopcnta[b]pyridin-2-y 1] -3-oxo- pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]piperazin-l-yl]phenyl]piperidine-2, 6-dione (Compound 17) (30.0 mg, 19.09% yield, 100.00% purity) as a yellow solid. LCMS (ESI) m/z 700.3 [M+H], RT: 2.266 min. ’H NMR (400 MHz, DMSO-d6) 5 10.78 (s, 1H), 10.25 - 10.05 (m, 1H). 8.83 (s, 1H). 8.03 - 7.85 (m, 1H). 7.70 (d, 7 = 8.1 Hz. 1H), 7.66 - 7.49 (m. 2H). 7.09 (d, J = 8.6 Hz, 2H), 6.99 (br t, J = 9.3 Hz, 4H), 5.67 (tdd, J = 16.9, 10.6, 5.9 Hz, 1H), 5.09 - 4.95 (m, 2H), 4.85 (br d. J = 17.1 Hz, 1H). 4.81 - 4.69 (m, 1H), 4.57 (br dd, J = 15.4, 4.9 Hz, 1H), 3.75 (dd, J = 11.1, 4.9 Hz, 1H), 3.29 - 3.23 (m, 8H), 3.04 - 2.91 (m, 1H), 2.83 - 2.72 (m, 1H), 2.68 - 2.60 (m, 1H), 2.47 - 2.41 (m, 1H), 2.27 - 2.09 (m, 2H), 2.08 - 1.96 (m, 2H), 1.89 (qd, J = 13.8, 7.0 Hz. 1H), 1.78 - 1.64 (m, 1H), 0.87 (t, J = 7.4 Hz, 3H).
Example 18: 3-[4-[4-[2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]ethyl]piperazin- l-yl]phenyl]piperidine-2, 6-dione (Compound 18)
[0309] To a solution of 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-6-methylsulfonyl-pyrazolo[3,4-d]pyrimidin-3-one (200.5 mg, 482.51 pmol) in iPrOH (2 mL) was added 3-[4-[4-[2-(4-aminophenyl)ethyl]piperazin-l- yl]phenyl] piperidine-2, 6-dione (Intermediate 28) (0.1 g, 241.25 pmol) at 20 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered, and the filter was concentrated to give the residue. The residue was purified by prep-HPLC (NH4HCO3 Condition) to afford 3- [4- [4-[2-[4- [ [2- ally 1- 1 - [(7R)-7 -ethyl-7 -hydroxy-5 ,6-dihydrocyclopenta[b]pyridin-2-yl] -3- oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]ethyl]piperazin-l-yl]phenyl]piperidine- 2, 6-dione (Compound 18) (22.0 mg, 12.5% yield, 100% purity) as a yellow solid. LCMS (ESI+) m/z 728.3 [M+H]+. XH NMR (400 MHz, DMSO-d6) 8 10.77 (s, 1H), 10.29 - 10.14 (m, 1H), 8.87 (s, 1H), 7.91 (d, J= 8.1 Hz, 1H), 7.74 - 7.58 (m, 3H), 7.21 (d, J= 8.5 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz. 2H), 5.67 (tdd, J = 16.8, 10.6. 5.9 Hz, 1H), 5.05 (s, 1H), 5.00 (dd, J = 10.3, 1.3 Hz, 1H), 4.86 (dd, 7= 17.0, 1.3 Hz, 1H), 4.75 (br dd, J= 15.6, 4.4 Hz, 1H), 4.56 (br dd, 7 = 16.1, 6.1 Hz, 1H), 3.73 (dd, 7 = 10.9, 4.9 Hz, 1H), 3.18 - 3.07 (m, 4H), 2.99 - 2.89 (m. 1H), 2.81 - 2.70 (m, 3H). 2.68 - 2.61 (m, 1H), 2.61 - 2.53 (m, 6H). 2.48 - 2.41 (m, 1H), 2.24 - 2.06 (m, 2H), 2.05 - 1.95 (m, 2H), 1.94 - 1.83 (m, 1H), 1.76 - 1.64 (m, 1H), 0.86 (t, 7 = 7.4 Hz, 3H).
Example 19: 3-[[4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]cyclohexyl]amino]piperidine-2, 6-dione (Compound 19)
[0310] To a solution of 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl] -6-methylsulfonyl-pyrazolo[3,4-d]pyrimidin-3-one (151.3 mg, 364.20 pmol) in iPrOH (2 mL) was added 3-[[4-[4-(4-aminophenyl)piperazin-l- yl]cyclohexyl] amino] piperidine-2, 6-dione (Intermediate 29) (100.0 mg, 182.10 pmol, 70.20% purity) at 25 °C. The reaction was stirred at 80 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered, and the filter was concentrated to give the residue. The residue was purified by prep-HPLC (NH4HCO3 Condition) to afford 3-[[4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]cyclohexyl]amino]piperidine-2, 6-dione (Compound 19) (15.0 mg, 11.43% yield, 100% purity) as a yellow solid. LCMS (ES1+) m/z 721.4 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 5 10.70 (br s, 1H), 10.21 - 10.01 (m, 1H), 8.82 (s, 1H), 7.92 (br d, J = 7.4 Hz, 1H), 7.69 (d, J = 8.3 Hz, 1H), 7.57 (br s, 2H). 6.91 (br d, J = 8.9 Hz, 2H), 5.67 (tdd, J = 16.8, 10.5, 5.9 Hz, 1H), 5.04 (s, 1H), 4.99 (dd, J = 10.2, 0.9 Hz, 1H), 4.85 (br d, J= 17.9 Hz, 1H), 4.81 - 4.68 (m, 1H), 4.56 (br dd, J = 15.8, 5.8 Hz, 1H), 3.42 (dd, J = 10.4, 4.8 Hz, 1H), 3.09 (br s, 4H), 3.02 - 2.91 (m, 1H), 2.85 - 2.72 (m, 2H). 2.65 - 2.57 (m, 4H), 2.57 - 2.52 (m, 3H), 2.25 - 2.15 (m, 2H), 2.02 (ddd, J= 12.9, 7.6, 5.2 Hz, 2H), 1.94 - 1.84 (m, 1H), 1.76 - 1.58 (m, 6H), 1.48 (br d, J = 7.4 Hz, 4H), 0.87 (t. J = 7.4 Hz, 3H).
Example 20: (R)-4-(4-(4-(((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0311] To a solution of 4-(4-(4-oxopiperidin-l-yl)phenyl)piperidine-2, 6-dione (Intermediate 30) (0.05 g, 174.63 pmol) and (R)-2-allyl-6-((4-(4-(aminomethyl)piperidin-l- yl)phenyl)amino)-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-l,2- dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 31) (94.41 mg, 174.63 pmol) in DCM (1 mL) was added AcOH (1.05 mg, 17.46 pmol, 1 pL) to adjust pH=5-6. Then NaBH(OAc)3 (74.02 mg, 349.25 pmol) was added at 25 °C after 2 h. The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep-HPLC (NH4HCO3 Condition) to give the pure product (R)-4-(4-(4-(((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2,6-dione (Compound 20) (0.012 g, 14.48 pmol, 8.29% yield, 97.88% purity) was obtained as a white solid. LCMS (ESI+) ni/z 833.5 [M+Na]+. ’H NMR (400 MHz. DMSO-d6) 5 10.79 (s, 1H), 10.17 - 10.03 (m, 1H), 8.81 (s, 1H), 7.97 - 7.86 (m, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.56 (br d, J = 3.5 Hz, 2H), 7.11 (d, J = 8.8 Hz, 2H), 6.97 - 6.83 (m, 4H), 5.67 (tdd, J = 16.8, 10.5, 6.0 Hz, 1H), 5.04 (s. 1H), 5.02 - 4.97 (m, 1H), 4.85 (br d, J = 17.4 Hz, 1H), 4.81 - 4.69 (m, 1H), 4.61 - 4.51 (m, 1H), 3.71 - 3.52 (m, 4H), 3.01 - 2.93 (m, 1H), 2.79 - 2.65 (m, 5H), 2.64 - 2.55 (m, 4H), 2.47 - 2.46 (m, 1H), 2.25 - 2.11 (m, 2H), 2.06 - 1.97 (m, 1H), 1.93 - 1.78 (m, 5H),
1.70 (br dd, J = 13.6, 7.4, Hz, 1H), 1.57 - 1.41 (m, 2H), 1.38 - 1.19 (m, 5H), 0.87 (t, J = 7.4 Hz, 3H).
Example 21 : 3-((3-(4-(( 1 -(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)amino)piperidine-2, 6-dione (Compound 21)
[0312] To a solution of 3-((3-(4-aminopiperidin-l-yl)phenyl)amino)piperidine- 2, 6-dione (Intermediate 33) (0.2 g, 290.77 pmol) in MeOH (0.5 rnL) were added (R)-2-allyl- l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-oxopiperidin-l- yl)phenyl)amino)-l,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 34) (50.9 mg, 96.92 pmol) and DIEA (125.2 mg, 969.23 pmol, 168.8 pL) AcOH (11.6 mg, 193.85 pmol, 11.10 pL) NaBHsCN (9.1 mg, 145.38 pmol) at 25 °C. The reaction was stirred at 25 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered, and the filter was concentrated to give the residue. The residue was purified by prep-HPLC (NH4HCO3 Condition) to afford 3-((3-(4-((l-(4-((2-allyl-l-((R)-7- ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH- pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l- yl)phenyl)amino)piperidine-2, 6-dione (Compound 21) (9.0 mg, 10.8% yield, 95.18% purity) as a yellow solid. LCMS (ESI+) mJz 812.4 [M+H]+.
NMR (400 MHz, DMSO-d6) 6 10.75 (br s, 1H), 10.18 - 10.00 (m, 1H), 8.81 (s, 1H), 7.93 (br d, J = 7.5 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.56 (br s, 2H), 6.97 - 6.90 (m, 2H), 6.90 - 6.85 (m, 1H), 6.27 (s, 1H), 6.19 (br d, J = 8.1 Hz, 1H), 6.11 (br d, J = 7.9 Hz, 1H), 5.73 - 5.62 (m. 1H), 5.62 - 5.54 (m, 1H), 5.05 (s, 1H), 5.00 (br d, J = 10.3 Hz, 1H), 4.85 (br d, J = 17.1 Hz, 1H), 4.81 - 4.67 (m, 1H), 4.64 - 4.49 (m, 1H), 4.37 - 4.23 (m, 1H), 3.68 - 3.48 (m, 4H). 3.01 - 2.91 (m, 1H), 2.85 - 2.62 (m, 8H), 2.56 (br s, 2H), 2.26 - 2.15 (m, 1H), 2.14 - 2.06 (m. 1H), 2.01 (ddd, J = 13.3, 8.4. 5.2 Hz, 1H). 1.96
- 1.76 (m, 6H), 1.70 (br dd, J = 13.6, 7.4 Hz, 1H), 1.40 - 1.22 (m, 4H), 0.87 (t, J = 7.4 Hz,
3H).
Example 22: 3 - [4- [2- [ [ 1 - [4- [ [2 - ally 1- 1 - [(7R)-7 -ethyl-7-hydroxy-5 ,6- dihydrocyclopentas [b ] pyridin-2-yl] -3 -oxo-pyrazolo [3 ,4-d] pyrimidin-6-yl] amino] phenyl] -4- piperidyl] amino]ethylamino]phenyl]piperidine-2, 6-dione (Compound 22)
[0313] To a mixture of 3-[4-(2-aminoethylamino)phenyl]piperidine-2, 6-dione (Intermediate 35) (42.0 mg, 77.88 pmol, 67% purity, TFA salt) and 2-allyl-l-[(7R)-7-ethyl- 7-hydroxy-5.6-dihydrocyclopenta[b]pyridin-2-yl]-6-[4-(4-oxo-l- piperidyl)anilino]pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 34) (40.0 mg, 76.10 pmol) in DCM (1.0 mL) was added NaBH(OAc)s (32.3 mg, 152.21 pmol) at 20 °C under N2. The mixture was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep-HPLC (NH4HCO3 Condition) to give 3-[4-[2-[[l-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopentas[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]-4- piperidyl]amino]ethylamino]phenyl]piperidine-2, 6-dione (Compound 22) (18.0 mg, 31.25% yield) as a white solid. LCMS (ESI+) m/z 379.3 [M/2+H]+. ‘H NMR (400 MHz, DMSO-d6) 5 10.73 (s, 1H), 10.22 - 9.94 (m, 1H), 8.81 (s, 1H), 7.99 - 7.86 (m, 1H), 7.69 (d, J = 8.1 Hz,
1H), 7.63 - 7.47 (m, 2H), 7.01 - 6.82 (m, 4H), 6.54 (d, J = 8.6 Hz, 2H), 5.72 - 5.61 (m, 1H), 5.51 - 5.46 (m, 1H), 5.07 - 4.96 (m, 2H), 4.90 - 4.70 (m, 2H), 4.62 - 4.51 (m, 1H), 3.67 - 3.56 (m, 4H), 3.09 (br d, J = 5.6 Hz, 2H), 3.01 - 2.93 (m, 1H), 2.77 (br t, J = 5.8 Hz, 3H). 2.73 - 2.65 (m, 4H), 2.44 - 2.39 (m, 1H), 2.24 - 2.16 (m, 1H), 2.11 - 2.04 (m, 1H). 2.00 (ddd. J = 13.1,
8.3, 4.3 Hz, 2H), 1.94 - 1.86 (m, 3H), 1.75 - 1.67 (m, 1H), 1.42 - 1.32 (m, 2H), 0.87 (t, 7 = 7.3 Hz, 3H).
Example 23: (R)-4-(3-(4-((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0314] To a solution of 4-(3-(4-oxopiperidin-l-yl)phenyl)piperidine-2, 6-dione (Intermediate 37) (32.62 mg, 113.93 pmol) and (R)-2-allyl-6-((4-(4-aminopiperidin-l- yl)phenyl)amino)-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-l,2- dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 36) (0.05 g, 94.94 pmol) in DCM (1 mL) and MeOH (0.2 mL) was added AcOH (570.15 pg, 9.49 pmol) to adjust pH=5-6. Then NaBH(OAc)3 (40.24 mg, 189.89 pmol) was added at 25°C after 2 h. The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep-HPLC (NH3.H2O Condition) to give the pure product. (R)-4-(3-(4-((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 23) (0.019 g, 36.39 pmol, 38.33% yield, 99.72% purity) was obtained as a white solid. LCMS (ESI+) m/z 797.5 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 5 10.82 (br s, 1H), 10.11 (br d, J = 1.6 Hz. 1H). 8.81 (s, 1H), 7.93 (br d, J = 6.8 Hz, 1H), 7.69 (d. 7 = 8.1 Hz, 1H), 7.56 (br s, 2H), 7.14 (t, J = 7.9 Hz, 1H), 6.95 - 6.85 (m, 3H), 6.80 (br d, J = 8.3 Hz, 1H), 6.66 (d, 7 = 7.4 Hz, 1H), 5.73 - 5.61 (m, 1H), 5.05 (br s, 1H), 4.99 (br d, 7 = 10.1 Hz, 1H), 4.85 (br d, 7 = 17.1 Hz, 1H), 4.76 (br d, 7 = 11.0 Hz, 1H). 4.61 - 4.52 (m, 1H), 3.69 - 3.55 (m,
4H), 3.02 - 2.91 (m, 1H), 2.86 - 2.57 (m, 12H), 2.24 - 2.15 (m, 1H), 2.O8 - 1.97 (m, 1H), 1.95
- 1.82 (m, 5H), 1.70 (br dd, 7=13.7, 7.3 Hz, 1H), 1.43 - 1.20 (m, 5H), 0.87 (t, J = 7.4 Hz, 3H).
Example 24: (R)-3-(4-(4-(((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
(Compound 24A) and (S)-3-(4-(4-(((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-
5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
(Compound 24B)
[0315] 3-[4-[4-[[l-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl] -3 -oxo-pyrazolo [3 ,4-d]pyrimidin-6-y 1] aminojpheny 1] -4- piperidyl]methylamino]-l-piperidyl]phenyl]piperidine-2, 6-dione (Compound 9) (100 mg) was purified by chiral SFC purification (Column/dimensions : CHIRALPAK-AS-H (30*250)mm,5p; % CCh: 50%; % Co solvent: 50% (0.2% 7N Methanolic ammonia in ACN :
MeOH) (1 :1 ), Total flow: 110 mL/min.; Back Pressure: 100 bar; UV: 307 nm; Solubility: McOH; No. of injections: 3; Total purification time: 01:30 Hrs; Run time per injection: 24:50 minutes; Instrument details: Make/Model: SFC- 150-11. Nitrogen gas was purged into the collecting fraction to remove dissolved ammonia) to afford Peak 1: 48.0 mg (Compound 24A) as a pale yellow solid and Peak 2: 45.0 mg (Compound 24B) as a pale yellow solid. Note: Stereochemistry was assigned arbitrarily.
[0316] Peak 1: (R)-3-(4-(4-(((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7- dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 24A). LCMS (ESI ) m/z 809.56
10.76 (s, 1H), 10.11 (br s, 1H), 8.81 (s, 1H), 7.93 (d, J= 7.2 Hz, 1H), 7.70 (d, J= 8.4 Hz. 1H), 7.56 (br s, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.93-6.87 (m, 4H), 5.72-5.60 (m, 1H), 5.05 (s, 1H), 5.00 (d. J = 9.2 Hz, 1H), 4.87 (d, J = 17.2 Hz, 1H), 4.80-4.70 (m, 1H), 4.60-4.50 (m, 1H), 3.75-3.68 (m, 1H), 3.66-3.55 (m, 4H). 3.01-2.95 (m. 1H). 2.82-2.52 (m. 8H), 2.50-2.40 (m, 2H), 2.21-1.98 (m, 4H), 1.95-1.80 (m, 5H), 1.73-1.68 (m, 1H), 1.60-1.48 (m, 1H), 1.40-1.18 (m, 5H), 0.87 (t, 7 = 7.2 Hz. 3H).
[0317] Peak 2: (S)-3-(4-(4-(((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7- dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 24B). LCMS (ESI ) m/z 809.56 [M-H]’. ‘H NMR (400 MHz, DMSO-^): 8 10.76 (s, 1H), 10.11 (br s, 1H), 8.81 (s, 1H), 7.93 (d, 7= 7.6 Hz, 1H), 7.70 (d, 7= 8.4 Hz, 1H), 7.56 (br s, 2H), 7.03 (d, 7 = 8.4 Hz, 2H), 6.93-6.87 (m. 4H), 5.72-5.60 (m, 1H), 5.05 (s. 1H), 5.00 (d, 7 = 9.2 Hz, 1H), 4.87 (d, 7 = 17.2 Hz, 1H), 4.80-4.70 (m, 1H), 4.60-4.50 (m, 1H), 3.75-3.68 (m, 1H), 3.66-3.55 (m, 4H), 3.01-2.95 (m, 1H), 2.82-2.52 (m, 8H), 2.50-2.40 (m, 2H), 2.21-1.98 (m, 4H). 1.95-1.80 (m. 5H), 1.73-1.68 (m, 1H), 1.60-1.48 (m, 1H), 1.40-1.18 (m, 5H), 0.87 (t, 7= 7.2 Hz, 3H).
Example 25: (R)-4-(3-(4-(((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0318] To a solution of 4-(3-(4-oxopiperidin-l-yl)phenyl)piperidine-2, 6-dione (Intermediate 37) (0.05 g, 174.63 pmol) and (R)-2-allyl-6-((4-(4-(aminomethyl)piperidin-l- yl)phenyl)amino)-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-l,2- dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 31) (47.21 mg, 87.31 pmol) in DCM (1 mL) was added AcOH (524.33 pg, 8.73 pmol) to adjust pH=5-6. Then NaBH(OAc)3 (37.01 mg, 174.63 pmol) was added at 20 °C after 2 h. The reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep-HPLC (NH3H2O Condition) to give the pure product. (R)- 4-(3-(4-(((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3- oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperidin-4- yl)methyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 25) (0.01 g, 11.81 pmol, 13.53% yield, 94.14% purity) was obtained as a white solid. LCMS (ESI+) m/z 811.5 [M+H]+. ’H NMR (400 MHz. DMSO-d6) 8 10.81 (br s, 1H). 10.10 (br d. J = 4.1 Hz. 1H), 8.81 (s, 1H), 7.92 (br d, 7= 7.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.56 (br s, 2H), 7.14 (t, J = 7.9 Hz, 1H), 6.94 - 6.86 (m, 3H), 6.80 (dd, 7 =8.3, 1.8 Hz, 1H), 6.66 (d, 7= 7.6 Hz, 1H), 5.72 - 5.61 (m, 1H), 5.04 (s, 1H), 4.99 (d, 7 = 9.4 Hz, 1H), 4.85 (br d, 7 = 17.0 Hz, 1H), 4.80 - 4.70 (m, 1H), 4.60 - 4.51 (m, 1H), 3.63 (br d, 7 = 12.1 Hz, 4H), 3.02 - 2.92 (m, 1H), 2.84 - 2.68 (m, 5H), 2.64 (br d, 7 = 4.3 Hz. 2H), 2.60 (br d. 7 = 4.1 Hz, 2H), 2.55 (br d, 7 = 9.9 Hz, 2H), 2.48 (br s, 1H), 2.20 (ddd, 7=13.6, 8.3, 5.8 Hz, 1H), 2.01 (ddd, 7=13.4, 8.3, 5.3 Hz, 1H), 1.92
- 1.88 (m, 3H), 1.87 - 1.78 (m, 3H), 1.70 (br dd, J =13.6, 7.4 Hz, 1H), 1.52 - 1.44 (m, 1H), 1.38 - 1.21 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H).
Example 26: (R)-4-(4-(4-((l-(4-((2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione
[0319] To a solution of 4-(4-(4-oxopiperidin-l-yl)phenyl)piperidine-2, 6-dione (Intermediate 30) (0.05 g, 174.63 pmol) and (R)-2-allyl-6-((4-(4-aminopiperidin-l- yl)phenyl)amino)-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-l,2- dihydro-3H-pyrazolo[3.4-d]pyrimidin-3-one (Intermediate 36) (72.85 mg, 145.52 pmol) in DCM (1 mL) and MeOH (0.2 mL) was added AcOH (873.89 pg, 14.55 pmol) to adjust pH=5- 6. Then NaBH(OAc)3 (61.68 mg, 291.04 pmol) was added at 25 °C after 2 h and the reaction was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep-HPLC (FA Condition) to give the pure product. (R)-4-(4-(4-(( 1 -(4 -((2- ally 1- 1 -(7 -ethyl-7-hydroxy-6,7 -dihydro-5 H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 26) (0.0275 g, 33.62 pmol, 23.10% yield, 97.42% purity) was obtained as a yellow solid. LCMS (ESI+) m/z 797.5 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.79 (s, 1H), 10.27 - 9.92 (m, 1H), 8.81 (s, 1H), 7.92 (br d, J = 6.6 Hz, 1H). 7.69 (d, J = 8.1 Hz. 1H), 7.56 (br s, 2H), 7.12 (d, J = 8.6 Hz, 2H), 6.95 - 6.87 (m, 4H), 5.72 - 5.61 (m, 1H), 5.05 (br s, 1H), 4.99 (br d, J = 10.4 Hz, 1H), 4.85 (br d, J = 17.1 Hz, 1H), 4.81 - 4.70 (m, 1H), 4.61 - 4.51 (m, 1H), 3.67 - 3.58 (m. 4H). 3.01 - 2.93 (m, 1H), 2.86 - 2.66 (m. 10H), 2.61 (br dd, J = 4.4.
16.6 Hz, 3H), 2.20 (ddd, J =13.5, 8.2, 5.8 Hz, 1H), 2.01 (ddd, J =13.3, 8.3, 5.2 Hz, 1H), 1.94
- 1.84 (m, 5H), 1.70 (br dd, J =13.7, 7.3 Hz, 1H), 1.43 - 1.30 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H).
Example 27: 3 - [4- [4- [4- [4- [ [2 - ally 1- 1 - [ (7 S )-7 -ethy 1-7 -hydroxy-5 ,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]butylamino]phenyl]piperidine-2, 6-dione (Compound 27)
[0320] To a solution of 4-[4-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6- yl]amino]phenyl]piperazin-l-yl]butanal (Intermediate 38) (0.082 g, 101.60 pmol, 72.20% purity) in THF (2 mL) were added 3-(4-aminophenyl)piperidine-2, 6-dione (commercially available) (41.50 mg, 203.21 pmol), NaBH(OAc)s (43.07 mg, 203.21 pmol,) at 20 °C for 2 h under N2. LCMS showed the starting material was consumed completely. The mixture was concentrated in vacuum to give a residue, which was purified by prep-HPLC to afford 3-[4- [4-[4-[4-[[2-allyl-l-[(7S)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-3-oxo- pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]piperazin-l-yl]butylamino]phenyl]piperidine- 2, 6-dione (Compound 27) (0.021 g, 25.92% yield, 96.67% purity) as a yellow solid. LCMS (ESI+) m/z 771.4 [M+H]+.
NMR (400 MHz, DMSO-d6) 8 10.72 (br s, 1H), 10.12 (br s, 1H), 8.82 (s, 1H), 7.97 - 7.83 (m. 1H), 7.69 (br d, J = 8.1 Hz. 1H). 7.57 (br s, 2H), 6.96 - 6.85 (m, 4H), 6.52 (br d, J = 8.1 Hz, 2H), 5.76 - 5.59 (m, 1H), 5.52 (br t, J = 4.8 Hz, 1H), 5.05 (s, 1H), 4.99 (br d, J = 10.1 Hz, 1H), 4.85 (br d, J = 17.1 Hz, 1H), 4.80 - 4.70 (m, 1H). 4.62 - 4.51 (m, 1H), 3.63 (br dd, J = 10.3, 4.9 Hz, 1H), 3.09 (br s, 4H), 3.00 (m, 4H), 2.83 - 2.72 (m, 1H), 2.69 - 2.56 (m, 2H), 2.45 (br s, 1H), 2.41 (br s, 1H), 2.35 (br s, 2H), 2.25 - 2.15 (m, 1H), 2.13 - 1.95 (m, 4H), 1.93 - 1.83 (m, 1H), 1.70 (qd. J = 13.7, 6.9 Hz, 1H), 1.57 (br s, 4H). 0.87 (br t, J = 7.3 Hz, 3H).
Example 28: 3-((4-(4-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)-4-hydroxypiperidin-l-yl)phenyl)amino (piperidine-
[0321] To a solution of tert-butyl 4-[[4-(4-aminophenyl)piperazin-l-yl]methyl]-4- hydroxy-piperi dine- 1 -carboxylate (Intermediate 40) (0.15 g, 200.46 pmol, 52.19% purity) and 2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-6- methylsulfonyl-pyrazolo[3,4-d]pyrimidin- 3-one (166.57 mg, 400.93 pmol) in DMF (1.5 mL) was added DIEA (51.82 mg, 400.93 pmol, 69.83 pL) at 20 °C. The mixture was stirred at 20 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was filtered and the filter was concentrated to give the residue. The residue was purified by prep-HPLC (FA Condition) to afford 3-((4-(4-((4-(4-((2-allyl-l-((R)-7-ethyl-7- hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4- d]pyrimidin-6-yl)amino)phcnyl)pipcrazin- 1 -y l)mcthyl)-4-hydroxypipcridin- 1 - yl)phenyl)amino)piperidine-2, 6-dione (Compound 28) (40.0 mg, 22.95% yield, 95.23% purity) as a white solid. LCMS (ESI+) m/z 414.8 [M/2+H]+. 1 H NMR (400 MHz, DMSO-d6) 5 10.76 (s, 1H), 10.23 - 10.00 (m, 1H). 8.82 (s, 1H), 7.98 - 7.89 (m, 1H), 7.69 (d, 7 = 8.2 Hz, 1H), 7.65 - 7.47 (m, 2H), 6.91 (br d, J = 8.9 Hz, 2H), 6.76 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 5.67 (tdd. 7 - 5.9, 10.6, 16.8 Hz, 1H), 5.34 (d, 7= 7.1 Hz, 1H), 5.06 (s, 1H), 4.99 (d, 7 = 10.1 Hz, 1H), 4.85 (br d, 7 = 17.5 Hz, 1H), 4.81 - 4.67 (m, 1H), 4.57 (br dd, 7 = 4.1, 14.9 Hz, 1H), 4.18 (ddd, 7 = 4.8, 6.8, 11.2 Hz, 1H), 4.09 (s, 1H), 3.18 - 2.84 (m, 9H), 2.83 - 2.63 (m, 6H), 2.57 (td, 7 = 4.2, 17.6 Hz, 1H), 2.34 (s, 2H), 2.20 (ddd, 7 = 5.7, 8.1, 13.4 Hz, 1H), 2.15 - 2.06 (m, 1H), 2.01 (ddd, 7 = 5.4. 8.4, 13.4 Hz, 1H), 1.96 - 1.77 (m, 2H), 1.76 - 1.64 (m, 3H), 1.61 - 1.52 (m, 2H), 0.87 (t, 7 = 7.5 Hz, 3H).
Example 29: 3-((4-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenethyl)-l,4-diazepan-l-yl)phenyl)amino)piperidine-2, 6-dione (Compound 29)
[0322] To a solution of 2-[4-[[2-allyl-l-[(7R)-7-ethyl-7-hydroxy-5,6- dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]ethyl methanesulfonate (Intermediate 43) (160.0 mg, 290.58 pmol) and 3-[4-(l,4-diazepan-l- yl)anilino]piperidine-2, 6-dione (Intermediate 44) (141.5 mg, 435.87 pmol,) in dioxane (5 mb) was added DIEA (75.1 mg, 581.15 pmol) and Nal (4.4 mg, 29.06 pmol) in one portion at 25 °C under N2. The mixture was stirred at 100 °C for 12 h. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated under reduced pressure at 40 °C to give the crude product. The crude product was purified by prep- HPLC (NH4HCO3 condition) to afford Compound 29 (22.0 mg, 8.45%). LCMS (ESI+) m/z 757.3 [M+H]+.
NMR (400 MHz, DMSO-d6) 5 10.75 (s, 1H), 10.43 - 9.95 (m. 1H). 8.87 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.76 - 7.55 (m, 3H), 7.17 (br d, J = 8.4 Hz, 2H), 6.65 - 6.58 (m, 2H), 6.58 - 6.51 (m, 2H), 5.75 - 5.60 (m, 1H), 5.13 - 5.03 (m, 2H), 5.00 (d, J = 10.1 Hz, 1H), 4.86 (brd, J = 17.5 Hz, 1H). 4.81 - 4.70 (m, 1H), 4.57 (br dd. J = 15.8. 6.3 Hz, 1H).4.16 - 4.07 (m, 1H), 3.40 (br d, J - 4.0 Hz, 4H), 3.03 - 2.92 (m, 1H), 2.83 - 2.73 (m, 3H), 2.72 - 2.64 (m, 5H), 2.63 - 2.55 (m, 3H), 2.26 - 2.17 (m, 1H), 2.16 - 2.08 (m, 1H), 2.02 (ddd, J = 13.4, 8.3, 5.4 Hz, 1H), 1.95 - 1.77 (m, 4H), 1.71 (qd, J = 13.9, 7.1 Hz, 1H), 0.87 (t, J = 7.3 Hz, 3H).
Example 30: 3-((4-(4-((R)-2-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)-2-hydroxyethyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione
[0323] To a solution of 3 -(4-piperazin-l-ylanilino)piperidine-2, 6-dione (WO 2021/083949) (138.03 mg, 478.69 pmol) in THF (1 mL) were added (R)-2-(4-((2-allyl-l-((R)- 7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH- pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)-2-hydroxyethyl methanesulfonate
(Intermediate 47) (138.01 mg, 119.67 pmol) and TEA (36.33 mg, 359.02 pmol, 49.97 uL) at 20 °C. Then the mixture was stirred at 65 °C for 24 h under N2. LCMS showed the reaction was completed and the desired product was detected. The mixture was concentrated in vacuum to give a residue. The residue was purified hy prep-HPLC (FA Condition) to afford Compound 30 (9.1 mg, 9.69%). LCMS (ESI+) m/z 759.3 [M+H]+.
DMSO-d6) 5 10.75 (s. 1H), 10.24 (br s, 1H), 8.88 (s, 1H), 7.91 (d. J = 8.1 Hz, 1H), 7.70 (dd, J = 8.3, 3.6 Hz, 3H), 7.31 (d, J = 8.5 Hz, 2H), 6.75 (d, J = 8.9 Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 5.78 - 5.55 (m, 1H), 5.37 (br d, 7 = 7.1 Hz. 1H), 5.13 - 4.93 (m, 3H), 4.86 (dd, 7 = 17.1, 1.1 Hz, 1H), 4.71 (br dd, 7 = 7.8, 4.7 Hz, 2H), 4.58 (br d, 7 = 6.1 Hz, 1H), 4.25 - 4.11 (m, 1H), 3.03 - 2.82 (m, 5H), 2.81 - 2.67 (m, 2H), 2.62 (br s, 4H), 2.59 - 2.51 (m, 2H), 2.43 (br dd, 7 = 12.6, 4.5 Hz, 1H), 2.25 - 2.15 (m, 1H). 2.14 - 2.06 (m, 1H), 2.01 (br d, 7 = 5.1 Hz. 1H), 1.95 - 1.77 (m, 2H), 1.76 - 1.64 (m, 1H), 0.87 (t, 7 = 7.4 Hz, 3H).
Example 31: 3-((4-(4-((S)-2-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)-2-hydroxyethyl)piperazin-l-yl)phenyl)amino)piperidine-2, 6-dione
[0324] Compound 31 (5% yield) was synthesized from 3-(4-piperazin-l- ylanilino)piperidine-2, 6-dione and Intermediate 48 by following a similar procedure as described for the synthesis of Compound 30. LCMS (ESI+) m/z 759.3 [M+H]+. !H NMR (400 MHz, DMSO-d6) 8 10.76 (br s. 1H), 10.25 (br s, 1H), 8.88 (s, 1H). 7.91 (br d, J = 8.1 Hz, 1H), 7.69 (br dd, 7 = 8.1, 3.3 Hz, 3H), 7.31 (br d, J = 8.5 Hz, 2H), 6.75 (br d, J = 8.7 Hz, 2H), 6.60 (br d, J = 8.7 Hz, 2H), 5.75 - 5.60 (m, 1H), 5.38 (br d, J = 7.3 Hz, 1H), 5.08 (s, 1H), 5.00 (br d, J = 10.1 Hz, 2H), 4.85 (br d, J = 17.2 Hz, 1H), 4.80 - 4.67 (m. 2H). 4.56 (br dd, J = 16.2, 5.9 Hz, 1H), 4.23 - 4.13 (m, 1H), 2.93 (br s, 5H), 2.81 - 2.68 (m, 3H), 2.66 - 2.57 (m, 4H), 2.57 - 2.53 (m, 1H), 2.43 (br dd, 7 = 12.6, 4.4 Hz, 1H), 2.24 - 2.15 (m, 1H), 2.14 - 2.06 (m, 1H), 2.00 (ddd, 7 =13.2, 8.2, 5.4 Hz, 1H). 1.94 - 1.77 (m, 2H), 1.75 - 1.64 (m. 1H). 0.86 (br t, 7 = 7.3 Hz, 3H).
Example 32: 3-((4-(4-((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)piperidin-l -yl)phenyl)amino)piperidine-2, 6-dione
(Compound 32)
[0325] Compound 32 (30% yield) was synthesized from Intermediate 50 and (R)-2-allyl-l-(7-cthyl-7-hydroxy-6,7-dihydro-5H-cyclopcnta[b]pyridin-2-yl)-6- (methylsulfonyl)-l,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one using 2-propanol as solvent and in the presence of DIEA and at 20 °C for 12 h. LCMS (ESI+) m/z 812.4 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 8 10.75 (br s, 1H), 10.21 - 9.98 (m, 1H), 8.81 (s, 1H), 7.93 (br d, J = 7.4 Hz, 1H), 7.69 (d. J = 8.1 Hz, 1H), 7.56 (br s, 2H). 6.92 (br d, J = 9.0 Hz. 2H). 6.75 (d, J = 8.9 Hz, 2H), 6.60 (d, J = 8.9 Hz, 2H), 5.67 (tdd, J = 16.8, 10.5, 6.0 Hz, 1H), 5.35 (d, J = 7.3 Hz, 1H), 5.04 (s, 1H), 5.02 - 4.96 (m, 1H), 4.85 (br d, J = 17.0 Hz, 1H), 4.80 - 4.68 (m, 1H), 4.56 (br dd, J = 15.7, 5.4 Hz, 1H), 4.18 (ddd, J = 11.3, 6.9, 4.9 Hz, 1H), 3.59 (br d, J = 12.3 Hz, 2H), 3.36 (br s, 3H), 3.04 - 2.91 (m, 1H), 2.83 - 2.62 (m, 6H), 2.61 - 2.51 (m, 3H), 2.26 - 2.16 (m, 1H). 2.14 - 2.06 (m, 1H), 2.01 (ddd, J = 13.4, 8.4, 5.3 Hz, 1H). 1.94 - 1.78 (m, 6H), 1.70 (dd, J = 13.6, 7.3 Hz, 1H), 1.42 - 1.28 (m, 4H), 0.87 (t, J = 7.4 Hz, 3H)
Example 33: 3-(3-((6-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)-2-azaspiro[3.3]heptan-2- yl)methyl)phenyl)piperidine-2, 6-dione (Compound 34)
[0326] Compound 40 (10% yield) was synthesized from Intermediate 8 and Intermediate 51 by following a similar procedure as described in Example 29 for the synthesis of Compound 29. LCMS (ESI+) mJz 823.4 [M+H]+. 1 H NMR (400 MHz, DMSO- d6) 8 10.85 (s, 1H), 10.33 - 10.01 (m, 1H), 8.84 (s. 1H), 8.36 (s, 2H). 7.90 (br d, J = 8.1 Hz, 1H), 7.73 - 7.61 (m, 3H), 7.31 - 7.21 (m, 2H), 7.17 (s, 1H), 7.11 - 6.99 (m, 3H), 5.67 (tdd, J = 16.8, 10.7, 5.9 Hz, 1H), 5.00 (d, J = 9.8 Hz, 1H), 4.86 (br d, J = 17.3 Hz, 1H), 4.80 - 4.70 (m, 1H), 4.57 (br dd, J = 15.8, 5.1 Hz, 1H), 3.93 (br s, 2H), 3.88 - 3.77 (m, 7H), 3.67 (s, 2H), 3.55 - 3.50 (m, 4H), 3.01 - 2.91 (m, 1H), 2.83 - 2.73 (m, 1H), 2.65 (ddd, J = 17.1, 11.5, 5.3 Hz, 1H), 2.55 - 2.51 (m, 1H), 2.47 (s, 2H), 2.25 - 2.11 (m, 2H), 2.08 - 2.00 (m, 2H), 1.99 - 1.93 (m, 2H), 1.93 - 1.84 (m, 1H), 1.80 - 1.66 (m, 3H), 0.87 (t, J = 7.4 Hz, 3H).
Example 34: 3-(4-(2-(4-(4-((2-allyl-l-((R)-7-cthyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)ethyl)phenyl)piperidine-2, 6-dione (Compound 34)
[0327] Compound 34 (21% yield) was synthesized from Intermediate 52 and (R)-2-allyl-l-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6- (methylsulfonyl)-l,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one in the presence of i-PrOH and at 80 °C for 12 h under N2. LCMS (ESI+) m/z 728.4 [M+H]+. ’ H NMR (400 MHz, DMSO-d6) 5 10.81 (s. 1H), 10.18 - 10.06 (m, 1H), 8.82 (s, 1H). 7.93 (br d, J = 7.1 Hz, 1H), 7.69 (d, ./ = 8.1 Hz, 1H), 7.58 (br s, 2H), 7.24 - 7.17 (m, 2H), 7.17 - 7.09 (m, 2H), 6.93 (br d, J = 8.9 Hz, 2H), 5.67 (tdd, J = 16.8, 10.6, 5.9 Hz, 1H), 5.05 (s, 1H), 5.02 - 4.97 (m, 1H), 4.85 (br d, J = 17.1 Hz. 1H), 4.81 - 4.67 (m, 1H), 4.63 - 4.51 (m. 1H), 3.81 (dd, J = 11.3, 4.9 Hz, 1H), 3.11 (br s, 4H), 3.02 - 2.92 (m, 1H), 2.83 - 2.73 (m, 3H), 2.71 - 2.64 (m, 1H), 2.64 - 2.55 (m, 6H), 2.48 - 2.44 (m, 1H), 2.25 - 2.12 (m, 2H), 2.07 - 1.97 (m, 2H), 1.94 - 1.83 (m, 1H), 1.76 - 1.65 (m, 1H), 0.87 (t. J = 7.4 Hz, 3H).
Example 35: 3-(4-(4-((4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenethyl)amino)piperidin-l-yl)phenyl)piperidine-2, 6-dione (Compound 35)
[0328] Compound 35 (19% yield) was synthesized by following a similar procedure as described in Example 29 for the synthesis of Compound 29 from 3-[4-(4- amino-l-piperidyl)phenyl]piperidine-2, 6-dione (Intermediate 13) and 2-[4-[[2-allyl- 1- [(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-3-oxo-pyrazolo[3,4- d]pyrimidin-6-yl]amino]phenyl]ethyl methanesulfonate (Intermediate 43) using DMF as solvent. LCMS (ESI+) m/z 742.3 [M+H]+. 'H NMR (400 MHz, DMSO-d6) 8 10.76 (br s. 1H), 10.20 (br d, 7=2.50 Hz, 1H), 8.87 (s, 1H), 7.91 (d, 7=8.13 Hz, 1H), 7.62-7.72 (m, 3H), 7.18 (br d, 7=8.25 Hz. 2H), 7.02 (d, 7=8.50 Hz. 2H), 6.87 (d, 7=8.63 Hz, 2H), 5.59-5.74 (m, 1H), 5.06 (s, 1H), 5.00 (br d, 7=10.26 Hz, 1H), 4.86 (br d, 7=17.13 Hz, 1H), 4.75 (br dd, 7=15.13, 3.50 Hz, 1H), 4.56 (br dd, 7=15.95, 6.19 Hz, 1H), 3.71 (br dd, 7=10.82, 4.94 Hz, 1H), 3.57 (br s. 2H). 2.92-3.01 (m, 1H), 2.75-2.82 (m, 3H), 2.73 (br d, 7=5.88 Hz, 1H), 2.63- 2.71 (m, 4H), 2.56-2.63 (m, 2H), 2.41-2.47 (m, 1H), 2.14-2.24 (m, 1H), 2.08-2.14 (m, 1H), 1.97-2.07 (m, 2H), 1.84-1.92 (m, 3H), 1.70 (dq, 7=13.91, 7.12 Hz, 1H), 1.25-1.37 (m, 2H), 0.87 (t, 7=7.32 Hz, 3H).
Example 36: 3-(4-(4-((3-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin- 1 -yl)azetidin- 1 -yl)methyl)piperidin- 1 -yl)phenyl)piperidine-2,6- dione (Compound 36)
[0329] Compound 36 (9% yield) was synthesized from Intermediate 53 and
Intermediate 8 by following a similar procedure as described in Example 33 for the synthesis of Compound 33. LCMS (ESI+) m/z. 852.5 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 8 10.75 (s. 1H), 10.17 - 10.01 (m, 1H), 8.81 (s, 1H), 7.93 (br d, J = 7.9 Hz, 1H), 7.69 (d, 7 = 8.1 Hz,
1H), 7.58 (br d, 7 = 4.4 Hz. 2H), 7.03 (d, 7 = 8.6 Hz, 2H), 6.90 (br dd, 7 = 13.8, 8.9 Hz. 4H),
5.74 - 5.57 (m, 1H), 5.07 - 4.94 (m, 2H), 4.85 (br d, J = 17.4 Hz, 1H), 4.80 - 4.68 (m, 1H),
4.63 - 4.50 (m, 1H), 3.77 - 3.61 (m, 3H), 3.54 (br dd. J = 17.9, 10.4 Hz, 2H), 3.02 - 2.92 (m,
1H), 2.87 - 2.71 (m, 5H), 2.71 - 2.57 (m, 4H), 2.49 - 2.41 (m, 2H), 2.36 - 2.25 (m, 2H), 2.25 - 2.12 (m, 5H), 2.09 (br dd, J= 11.6, 3.4 Hz, 1H), 2.01 (ddd, J = 13.3, 8.2, 5.4 Hz, 2H), 1.89 (qd. J = 13.9, 7.1 Hz, 1H), 1.84 - 1.59 (m, 5H), 1.28 - 1.14 (m. 2H). 0.87 (t, J = 7.4 Hz, 3H).
Example 37: 3-(4-((6-((4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)methyl)-2-azaspiro[3.3]heptan-2- yl)methyl)phenyl)piperidine-2, 6-dione (Compound 37)
[0330] Compound 37 (4% yield) was synthesized from Intermediate 55 and Intermediate 8 by following a similar procedure as described in Example 33 for the synthesis of Compound 33. LCMS (ESI+) m/z 823.4 [M+H]+.
NMR (400 MHz. DMSO-d6) 8 11.05
- 10.53 (m, 1H), 10.31 - 10.06 (m, 1H), 8.84 (d, J = 1.3 Hz, 1H), 7.95 - 7.87 (m, 1H), 7.75 - 7.59 (m, 3H), 7.29 (d, J = 8.0 Hz, 1H), 7.20 (br d, J = 8.6 Hz, 1H), 7.18 - 7.08 (m, 2H), 7.02 (br d, J = 8.8 Hz, 2H). 5.75 - 5.59 (m, 1H), 5.00 (br d, J = 10.4 Hz. 1H), 4.86 (br d. J = 16.8 Hz, 1H), 4.80 - 4.66 (m, 1H), 4.62 - 4.50 (m, 1H), 4.48 - 4.28 (m, 1H), 3.92 (br s, 1H), 3.88 - 3.74 (m, 6H), 3.68 (br s. 1H), 3.66 (s, 2H), 3.48 (br d, J = 4.0 Hz, 3H), 3.42 (br s, 2H), 3.21 - 3.12 (m, 2H), 3.02 - 2.91 (m. 1H). 2.84 - 2.73 (m, 1H), 2.65 - 2.58 (m, 1H). 2.43 - 2.38 (m. 1H), 2.25 - 2.11 (m, 2H), 2.08 - 1.94 (m, 3H), 1.93 - 1.80 (m, 2H), 1.79 - 1.64 (m, 2H), 1.60
- 1.45 (m, 1H). 0.87 (t, J = 7.4 Hz, 3H).
Example 38: 3-(4-((3-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin- 1 -yl)propyl)amino)phenyl)piperidine-2, 6-dione (Compound 38)
[0331] Compound 38 (12% yield) was synthesized from Intermediate 56 and 2- allyl- 1 - [(7R)-7 -ethyl-7 -hydroxy-5, 6-dihydrocyclopenta[b]pyridin-2-yl] -6-(4-piperazin- 1 - ylanilino)pyrazolo[3,4-d]pyrimidin-3-one by following a similar procedure as described in Example 33 for the synthesis of Compound 33. LCMS (ESI+) m/z 757.4 [M+H]+. 1 H NMR (400 MHz, DMSO-d6) 5 10.73 (s, 1H), 10.24 - 9.99 (m, 1H), 8.83 (s, 1H), 7.94 (br d, J - 5.7 Hz, 1H), 7.70 (d, J = 8.2 Hz, 1H), 7.59 (br d, J = 4.6 Hz, 2H), 7.00 - 6.83 (m, 4H), 6.53 (d, J = 8.5 Hz, 2H), 5.77 - 5.53 (m, 2H), 5.08 - 4.96 (m, 2H), 4.91 - 4.82 (m, 1H), 4.81 - 4.70 (m, 1H), 4.63 - 4.53 (m, 1H), 3.64 (dd, J = 10.5, 5.1 Hz, 1H), 3.12 (br s, 4H), 3.06 (q, J = 6.2 Hz, 2H), 3.02 - 2.93 (m, 1H), 2.83 - 2.74 (m, 1H), 2.66 - 2.58 (m. 1H), 2.54 (br s, 4H), 2.48 - 2.41 (m, 3H), 2.25 - 2.16 (m, 1H), 2.12 - 1.96 (m, 3H), 1.95 - 1.85 (m, 1H), 1.73 (qd, J = 14.0, 6.9 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H).
Example 39: 3-(4-((( 1 -(4-((2-allyl- 1 -((R)-7 -ethyl-7 -hydroxy-6,7 -dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)methyl)phenyl)piperidine-2, 6-dione (Compound 39)
[0332] To a mixture of Intermediate 36 (0.08 g, 105.26 pmol) in MeOH (2 mL) were added Intermediate 54 (27.44 mg, 126.31 pmol), AcOH (6.32 mg, 105.26 pmol, 6.03 pL) and NaBHsCN (7.94 mg, 126.31 pmol), and the mixture was stirred at 20 °C for 1 h under N2. LCMS showed the starting material was consumed completely and desired product was formed. The mixture was purified by prep-HPLC (FA condition) purification to afford Compound 39 (19.0 mg. 24.76%). LCMS (ESI+) m/z 728.4 [M+H]+. ’H NMR (400 MHz. DMSO-d6) 8 10.85 (s, 1H), 10.21 - 10.05 (m, 1H), 8.82 (s, 1H), 8.23 (s, 1H), 8.03 - 7.82 (m, 1H), 7.70 (d, 7= 8.1 Hz, 1H), 7.57 (br d. J = 1.7 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.93 (br d, J = 8.9 Hz, 2H), 5.74 - 5.61 (m, 1H), 5.20 - 5.02 (m, 1H), 5.00 (br d, J= 9.8 Hz, 1H), 4.86 (br d, J= 17.2 Hz, 1H), 4.81 - 4.69 (m, 1H), 4.64 - 4.49 (m, 1H), 3.86 (br d, J = 5.0 Hz, 1H), 3.83 (s, 2H), 3.62 (br d, J = 11.9 Hz, 2H), 3.03 - 2.92 (m, 1H). 2.84 - 2.74 (m, 1H), 2.73 - 2.58 (m, 4H), 2.49 - 2.44 (m, 1H), 2.27 - 2.11 (m, 2H), 2.08 - 1.82 (m, 5H), 1.71 (qd, J = 13.8, 7.0 Hz, 1H), 1.46 (q, J = 10.1 Hz, 2H), 0.88 (t, 7 = 7.3 Hz, 3H).
Example 40: 3-(4-(2-((l-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperidin-4-yl)amino)ethyl)phenyl)piperidine-2, 6-dione (Compound 40)
[0333] Compound 40 (15% yield) was synthesized from Intermediate 57 and 2- allyl-6- [4-(4-amino- 1 -piperidyl)anilino]- 1 - [(7S)-7 -ethyl-7 -hydroxy-5, 6- dihydrocyclopenta[b]pyridin-2-yl]pyrazolo[3.4-d]pyrimidin-3-one (Intermediate 36) by following a similar procedure as described in Example 29 for the synthesis of Compound 29. LCMS (ESI+) m/z 742.3 [M+H]+. ’H NMR (400 MHz, DMSO-d6) 8 10.82 (br s, 1H), 10.23 - 10.02 (m, 1H). 8.81 (s, 1H), 7.93 (br d, J = 6.7 Hz, 1H), 7.69 (d. J = 8.1 Hz, 1H). 7.56 (br s, 2H), 7.29 - 7.08 (m, 4H), 6.92 (br d, J = 8.9 Hz, 2H), 5.66 (tdd, J = 16.8, 10.5, 5.9 Hz, 1H), 5.17 - 5.02 (m, 1H), 4.99 (dd, 7 = 10.2, 0.9 Hz, 1H), 4.85 (br d, 7 = 17.9 Hz, 1H), 4.81 - 4.66 (m, 1H), 4.56 (br dd, J = 15.5, 5.3 Hz, 1H), 3.81 (dd, J = 11.4, 4.9 Hz, 1H), 3.59 (br d, 7
= 12.2 Hz, 2H), 3.04 - 2.91 (m, 1H), 2.88 - 2.75 (m, 3H), 2.75 - 2.57 (m, 6H), 2.49 - 2.43 (m, 2H), 2.26 - 2.10 (m, 2H), 2.07 - 1.97 (m, 2H), 1.95 - 1.83 (m, 3H), 1.76 - 1.64 (m, 1H), 1.38 (q, J = 10.0 Hz, 2H), 0.87 (t, J = 7.4 Hz. 3H).
Example 41: 3-(4-((2-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin-l-yl)ethyl)amino)phenyl)piperidine-2, 6-dione (Compound 41)
[0334] Compound 41 (25% yield) was synthesized by following a similar procedure as described for the synthesis of Compound 38 using 2-((4-(2,6-dioxopiperidin-3- yl)phenyl)amino)ethyl methanesulfonate (Intermediate 58) in place of 3-((4-(2,6- dioxopiperidin-3-yl)phenyl)amino)propyl methane sulfonate. LCMS (ESI+) m/z 743.3 [M+H]+. ’ H NMR (400 MHz, DMSO-d6) 8 10.73 (br s. 1H), 10.12 (br s, 1H), 8.82 (s, 1H), 7.92 (br d, J = 5.1 Hz, 1H), 7.69 (br d, J = 8.1 Hz, 1H), 7.58 (br s, 2H), 6.92 (br d, J = 7.4 Hz, 4H), 6.56 (br d, J = 7.9 Hz, 2H), 5.75 - 5.59 (m, 1H), 5.37 (br s, 1H), 5.05 (s, 1H), 4.99 (br d, J = 10.3 Hz, 1H), 4.85 (br d, J = 17.1 Hz, 1H), 4.80 - 4.69 (m. 1H), 4.62 - 4.51 (m, 1H). 3.64 (br dd, J = 9.9, 4.4 Hz, 1H), 3.12 (br s, 6H), 3.04 - 2.89 (m, 2H), 2.83 - 2.72 (m, 1H), 2.58 (br s, 7H), 2.47 - 2.39 (m, 1H), 2.19 (br d, J = 5.6 Hz, 1H), 2.14 - 1.97 (m, 3H). 1.94 - 1.85 (m, 1H), 1.70 (br dd, J = 13.6,7.1 Hz, 1H), 0.87 (br t, 7 = 6.9 Hz, 3H).
Example 42: 3-(4-(3-(4-(4-((2-allyl-l-((R)-7-ethyl-7-hydroxy-6,7-dihydro-5H- cyclopenta[b]pyridin-2-yl)-3-oxo-2,3-dihydro-lH-pyrazolo[3,4-d]pyrimidin-6- yl)amino)phenyl)piperazin- 1 -yl)propyl)phenyl)piperidine-2, 6-dione (Compound 42)
[0335] Compound 42 (51 % yield) was synthesized from Intermediate 60 and 2- allyl- 1 - [(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl] -6-(4-piperazin- 1 - ylanilino)pyrazolo[3,4-d]pyrimidin-3-one (Intermediate 8) by following a similar procedure as described in Example 32 for the synthesis of Compound 32. LCMS (ESI+) m/z 742.3 [M+H]+. ’ H NMR (400 MHz, DMSO-d6) 5 10.81 (s. 1H), 10.22 - 9.99 (m, 1H), 8.82 (s. 1H), 7.93 (bi d, 7 - 7.1 Hz, 1H), 7.69 (d, 7- 8.1 Hz, 1H), 7.58 (br s, 2H), 7.21 - 7.16 (m, 2H), 7.15
- 7.10 (m, 2H), 6.92 (br d. J = 8.9 Hz, 2H), 5.74 - 5.59 (m, 1H), 5.04 (s, 1H), 4.99 (d, J = 9.9 Hz, 1H), 4.85 (br d, J = 17.0 Hz, 1H), 4.81 - 4.68 (m, 1H), 4.56 (br dd, J = 15.4, 5.4 Hz, 1H), 3.81 (dd, 7= 11.2, 4.9 Hz, 1H), 3.10 (br s, 4H), 3.03 - 2.90 (m, 1H), 2.84 - 2.73 (m, 1H), 2.71
- 2.56 (m, 3H), 2.55 - 2.51 (m. 4H), 2.47 - 2.43 (m, 1H), 2.35 (br t, 7 = 7.1 Hz, 2H). 2.25 - 2.11 (m, 2H), 2.09 - 1.97 (m, 2H), 1.95 - 1.83 (m, 1H), 1.83 - 1.65 (m, 3H), 0.87 (t, 7 = 7.4 Hz, 3H).
Example A
MOLT-4 and A-427 Cell Proliferation Assay
[0336] Cell proliferation was measured using the CellTiter-Glo® Luminescent Cell Viability Assay. The assay involved the addition of a single reagent (CellTiter-Glo® Reagent) directly to cells cultured in serum- supplemented medium. MOLT-4 cells (ATCC, CRL-1582) and A427 cells (ATCC, HTB-53) were cultured according to ATCC recommendations and were seeded at 6,000 cells for MOLT-4 and 3,000 cells for A427 per well.
[0337] Each compound evaluated was prepared as a DMSO stock solution (10 mM). Compounds were tested in duplicate on each plate, with a 10-point serial dilution
curve (1 :3 dilution). The highest compound concentration was 10 pM (final), with a 0.1 % final DMSO concentration. Plates were then incubated at 37 °C, 5% CO2 for 72 h, and then were equilibrated at rt for approximately 30 mins. An equi-volume amount of CellTiter-Glo® Reagent (100 pL) was added to each well. Plates were mixed for 2 mins on an orbital shaker to induce cell lysis and then incubated at rt for 10 mins to stabilize the luminescent signal. Luminescence was recorded using a Spectramax i3x (Molecular Devices) plate reader according to CellTiter-Glo protocol. IC50 determination was performed using a non-linear regression, variable slope (four parameter), inhibitor v. response equation (Prism 9.0). IC50 values are provided in Table 1. For comparison, Table 1 also includes IC50 value for compound ZN-c3.
For MOLT-4 and A427 CTG IC50: A = a single IC50 < 100 nM; B = a single IC50 >100 nM and < 200nM; C = a single IC50 >200 nM; ND = not determined
Example B
Protein degradation assay in MOLT-4 cells
[0338] 1 million MOLT-4 cells (ATCC, CRL-1582) were incubated with vehicle
(DMSO) or 10 pM, 1 pM, 0.1 pM or 0.01 pM concentrations of the indicated compounds for 5 h. After treatment, the cells were harvested in RIPA lysis buffer supplemented with 1% Phosphatase Inhibitor and Protease Inhibitor Cocktail and protein concentration was determined by BCA assay. An equal amount of protein (4.5 pg/lane) from each cell extract was loaded onto 12-230 kDa Separation 25 Capillary Cartridges from ProteinSimple and probed with WEE1 (1:200 dilution, final concentration of 1 pg/mL) and -Actin (1:500
dilution, final concentration of 0.6 pg/mL) antibodies on a ProteinSimple Jess system according to ProtcinSimplc/SimplcWcstcrn protocols. The area under the curve (AUC) from the resulting eletropherograms for each protein peak at the concentrations tested was used to calculate percent remaining for WEE1 using the equation percent remaining = lOO*(WEEl/0- Actin)/(WEElDMSo/p-ActinDMSo). For illustrative purposes, electopherograms were exported as virtual blots using Compass for SW v 6.0 (ProteinSimple). The WEE-1 antibody (sc-5285) was purchased from Santa Cruz Biotechnology and P-actin (MAB8929) was purchased from R&D Systems. Percent remaining of WEE1 after 5 hour treatment in MOLT-4 cells at the tested concentrations are provided in Table 2.
[0339] The ability for a heterobifunctional degrader to degrade a protein of interest (POI) is dependent upon the efficient formation of a ternary complex between a POI, the compound and the E3 ligase in a 1: 1: 1 ratio. At high compound concentrations, a phenomenon known as the “hook effect” occurs where POI and E3 binding sites are saturated, leading to POI and E3 proteins being bound by distinct degrader compounds, forming separate binary complexes. In this case, a 1:1:1 ternary complex cannot be formed efficiently between the POI and E3, and loss of degradation is observed. A “hook effect” was observed at higher concentrations with several compounds, however these results indicated that many of the exemplified compounds are potent degraders of WEE 1.
For MOLT-4 cells WEE1 degradation assay: A = <30%; B = 30-60%; C = >60%; ND = not determined.
Example C
HiBiT Assay to assess IKZF1 and GSPT1 neosubstrate degradation
[0340] Glutarimide-containing heterobifunctional degraders are known to engage additional proteins due to neomorphic interactions with the E3 ligase. Neosubstrate degradation is monitored, as degradation of these additional targets may increase efficacy or contribute to undesired off-target effects. The assessment of two well-documented neosubstrates, IKZF1 and GSPT1 , is described using the HiBiT Assay.
[0341] 5xl04 JURKAT-IKZFl-HiBiT (Promega CS3023169) or 5xl04 HEK-293-
GSPTl-HiBiT (Promega CS3O231O5) were seeded in a volume of 90 pL into wells of white, flat opaque bottom 96-well plates and incubated for 1 hour (IKFZ1) or overnight (GSPT1) at 37 °C and 5% CO2. RPMI-1640 + 10% FBS + 1% Pen/Strep + 200pg/mL Hygromycin (IKZF1) or DMEM + 10% FBS + 1% Pen/Strep + 200pg/mL Hygromycin (GSPT1) constituted complete medium. One hour before compound treatment, 90 pL of a 1:50 dilution of lOOx Vivazine substrate (Promega N2581) in media was added to each well. Cells were incubated for 1 hour at 37 °C and 5% CO2, and baseline luciferase levels were recorded using a SpectraMax M5e multi-mode microplate reader. Cells were then treated with compounds in
a 10-point half-log serial dilution format starting with a high dose of 10 pM using Pico8, with 0.1% DMSO normalization across all doses. 0.1% DMSO was included as a control. Total volume per well was 180 uL. Cells were incubated for 16 hours (IKZF1) or 24 hours (GSPT1) at 37 °C and 5% CO2. After the indicated incubation time, luciferase levels were read using SpectraMax M5e multi-mode microplate reader following the Cell-Titer Glo-luminescence protocol after each period of incubation. Data were corrected for background signal and initial seeding levels, and remaining IKZF1 or GSPT1 protein was expressed as % relative to DMSO. DC50 and Dmax were determined using GraphPad Prizm Software (v9.1).
[0342] Table 3 summarizes DC50 and Dmax for both IKZF 1 ( 16 h) and GSPT1 (24 h) protein degradation.
For GSPT1 and IKZF1 HiBiT protein degradation assay DC50: A = <100 nM; B = 100-500 nM; C = >500 nM; Dmax: A = >70%; B = 40-70%; C = <40%.
[0343] Furthermore, although the foregoing has been described in some detail by way of illustrations and examples for purposes of clarity and understanding, it will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present disclosure. Therefore, it should be clearly understood that the forms disclosed herein are illustrative only and are not intended to limit the scope of the present disclosure, but rather to also cover all modification and alternatives coming with the true scope and spirit of the disclosure.
Claims
1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
R1 is absent, a substituted or an unsubstituted 6 to 10 membered aryl, -NH-(a substituted or an unsubstituted 6 to 10 membered aryl)-, a substituted or an unsubstituted 6 to 10 membered heteroaryl, -NH-(a substituted or an unsubstituted 6 to 10 membered heteroaryl)- or -NH-(a substituted or an unsubstituted 6 to 10 membered cycloalkyl)-;
R2 is absent, a substituted or an unsubstituted 4 to 10 membered heterocyclyl or -O-(a substituted or an unsubstituted 4 to 10 membered heterocyclyl)-;
R3 is absent, a substituted or an unsubstituted Ci-Ce alkylene, -NH-, -NH-(a substituted or an unsubstituted C1-C6 alkylene)-, -O-(a substituted or an unsubstituted Ci-Ce alkylene )-NH- or -O-(a substituted or an unsubstituted CI-C alkylene)-NH- (a substituted or an unsubstituted Ci-Ce alkylene)-;
R4 is absent or a substituted or an unsubstituted 4 to 10 membered heterocyclyl; with the proviso that at least two of R1, R2, R3 and R4 are present;
RD is a substituted or an unsubstituted Ci-Ce alkyl; and
Y is -CH or N.
2. The compound of claim 1 , or pharmaceutical ly acceptable salt thereof, wherein R1 is absent.
3. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein
R1 is a substituted or an unsubstituted 6 to 10 membered aryl.
4. The compound of claim 3 , or pharmaceutical ly acceptable salt thereof, wherein R1 is an unsubstituted phenyl.
5. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R1 is -NH-(a substituted or an unsubstituted 6 to 10 membered aryl)-.
7. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R1 is a substituted or an unsubstituted 5 to 10 membered heteroaryl.
8. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R1 is -NH-(a substituted or an unsubstituted 5 to 10 membered heteroaryl)-.
9. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein R1 is -NH-(a substituted or an unsubstituted 6 to 10 membered cycloalkyl)-.
11. The compound of any one of claims 1 to 10, or pharmaceutically acceptable salt thereof, wherein R2 is absent.
12. The compound of any one of claims 1 to 10, or pharmaceutically acceptable salt thereof, wherein R2 is a substituted or an unsubstituted 4 to 10 membered heterocyclyl.
15. The compound of any one of claims 1 to 10, or pharmaceutically acceptable salt thereof, wherein R2 is a -O-(a substituted or an unsubstituted 4 to 10 membered heterocyclyl).
17. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is absent.
18. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is a substituted or an unsubstituted Ci-Ce alkylene.
19. The compound of claim 18, or pharmaceutically acceptable salt thereof, wherein R3 is -(CH2)-, -(CH2CH2)-, or -(CH2CH2CH2)-.
20. The compound of claim 18, or pharmaceutically acceptable salt thereof, wherein R3 is -(CH2CH(OH))-.
21. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is -NH-.
22. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is -NH-(a substituted or an unsubstituted Ci-Ce alkylene)-.
23. The compound of claim 22, or pharmaceutically acceptable salt thereof, wherein R3 is -NH-(CH2)-.
24. The compound of claim 22, or pharmaceutically acceptable salt thereof, wherein R3 is -NH-(CH2CH2)-, -NH-(CH2CH2CH2)- or -NH-(CH2CH2CH2CH2)-.
25. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH-.
26. The compound of claim 25, or pharmaceutically acceptable salt thereof, wherein R3 is -O-(CH2)4-NH-
27. The compound of any one of claims 1 to 16, or pharmaceutically acceptable salt thereof, wherein R3 is -O-(a substituted or an unsubstituted Ci-Ce alkylene)-NH-(a substituted or an unsubstituted Ci-Ce alkylene)-.
28. The compound of claim 27, or pharmaceutically acceptable salt thereof, wherein R3 is -O-(CH2)2-NH-(CH2)-.
29. The compound of any one of claims 1 to 28, or pharmaceutically acceptable salt thereof, wherein R4 is absent.
30. The compound of any one of claims 1 to 28, or pharmaceutically acceptable salt thereof, wherein R4 is a substituted or an unsubstituted 4 to 10 membered heterocyclyl.
34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is an unsubstituted Ci-Ce alkyl.
35. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is a substituted Ci-Ce alkyl.
36. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is a halogen-substituted Ci-Ce alkyl.
37. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is an ethyl.
38. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is a methyl.
39. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is a halogen-substituted ethyl.
40. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, wherein RD is a halogcn-substitutcd methyl.
41. The compound of any one of claims 1 to 40, or pharmaceutically acceptable salt thereof, wherein Y is -CH.
42. The compound of any one of claims 1 to 40, or pharmaceutically acceptable salt thereof, wherein Y is N.
43. The compound of any one of claims 1 to 42, or pharmaceutically acceptable salt thereof, wherein at least three of R1, R2, R3 and R4 are present.
44. The compound of any one of claims 1 to 43, or pharmaceutically acceptable salt thereof, wherein all four of R1, R2, R3 and R4 are present.
45. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure selected from those of Compound Nos. 1 to 42 as listed in Table A or a pharmaceutically acceptable salt thereof.
46. The compound of any one of claims 1 to 45, wherein one or more hydrogen atoms of the compound is replaced by deuterium.
47. A pharmaceutical composition comprising an effective amount of the compound of any one of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
48. Use of an effective amount of a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 47 in the manufacture of a medicament for ameliorating or treating a cancer, wherein the cancer is selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non- small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’s lymphoma.
49. Use of an effective amount of a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 47 in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a non-
small cell cancer, a breast cancer, a lung cancer, a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’s lymphoma.
50. Use of an effective amount of a compound of any one of claims 1 to 46, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 47 in the manufacture of a medicament for ameliorating or treating a malignant growth or tumor, wherein the malignant growth or tumor is due to a cancer selected from a brain cancer, a cervicocerebral cancer, an esophageal cancer, a thyroid cancer, a small cell cancer, a nonsmall cell cancer, a breast cancer, a lung cancer , a stomach cancer, a gallbladder/bile duct cancer, a liver cancer, a pancreatic cancer, a colon cancer, a rectal cancer, an ovarian cancer, a choriocarcinoma, an uterus body cancer, an uterocervical cancer, a renal pelvis/ureter cancer, a bladder cancer, a prostate cancer, a penis cancer, a testicular cancer, a fetal cancer, Wilms’ cancer, a skin cancer, malignant melanoma, a neuroblastoma, an osteosarcoma, an Ewing’s tumor, a soft part sarcoma, an acute leukemia, a chronic lymphatic leukemia, a chronic myelocytic leukemia, polycythemia vera, a malignant lymphoma, multiple myeloma, a Hodgkin’s lymphoma and a non-Hodgkin’s lymphoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263376024P | 2022-09-16 | 2022-09-16 | |
US63/376,024 | 2022-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024059808A1 true WO2024059808A1 (en) | 2024-03-21 |
Family
ID=90275830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/074329 WO2024059808A1 (en) | 2022-09-16 | 2023-09-15 | Wee1 inhibitors and methods for treating cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024059808A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019173082A1 (en) * | 2018-03-09 | 2019-09-12 | Zeno Royalties & Milestones, LLC | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
WO2022251224A1 (en) * | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
WO2023083194A1 (en) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1 protein kinase degradation agent and use thereof |
-
2023
- 2023-09-15 WO PCT/US2023/074329 patent/WO2024059808A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019173082A1 (en) * | 2018-03-09 | 2019-09-12 | Zeno Royalties & Milestones, LLC | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
WO2022251224A1 (en) * | 2021-05-28 | 2022-12-01 | Recurium Ip Holdings, Llc | Wee1 inhibitors and methods for treating cancer |
WO2023083194A1 (en) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1 protein kinase degradation agent and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7300460B2 (en) | Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones | |
US11014913B2 (en) | Pyridazinones as PARP7 inhibitors | |
ES2899196T3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as CDK inhibitors | |
EP3728252B1 (en) | 4-azaindole compounds | |
WO2023081209A1 (en) | Pi3k inhibitors and methods of treating cancer | |
JP2022534650A (en) | BTK inhibitor ring derivative, its preparation method and its pharmaceutical application | |
ES2950569T3 (en) | (S)-4-(8-amino-3-(1-(but-2-inoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n- (pyridin-2-yl)benzamide as a Btk inhibitor | |
WO2022251224A1 (en) | Wee1 inhibitors and methods for treating cancer | |
EA017144B1 (en) | N-containing bicyclic derivatives for use in treatment of androgen receptor associated conditions | |
EA010419B1 (en) | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | |
CN110621675A (en) | Tricyclic compounds for the treatment of proliferative diseases | |
KR20200006125A (en) | Kinase Inhibitors and Uses thereof | |
IL266312A (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
CA3201540A1 (en) | Aromatic heterocyclic compound, pharmaceutical composition and use thereof | |
CA3189873A1 (en) | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis | |
CA3235328A1 (en) | Covalent egfr inhibitors and methods of use thereof | |
CN116888108B (en) | Novel EGFR degradation agent | |
CA3190065A1 (en) | Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis | |
WO2022253309A1 (en) | Substituted heterocyclic compounds and application thereof | |
WO2024059808A1 (en) | Wee1 inhibitors and methods for treating cancer | |
JP2023540729A (en) | Novel PLK1 degradation-inducing compound | |
EP4069693B1 (en) | Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases | |
RU2796400C2 (en) | Pyrido[3,4-d]pyrimidine derivative and its pharmaceutically acceptable salt | |
WO2024044570A1 (en) | Compounds and methods for modulating her2 | |
WO2023154124A1 (en) | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |